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Preface and outline of the thesis
Background
Cancer is the most important cause of death and morbidity in Europe after 
cardiovascular diseases and has major impact on patients, families and society. 
Each year, more than 3 million new patients are diagnosed with cancer and 1.7 
million deaths occur as a result of this disease.1 Multiple therapeutic advances 
have been made the last decade, including the development of new targeted 
anticancer therapies. Targeted anticancer therapies are defined as ‘drugs or 
other substances that block the growth and spread of cancer by interfering 
with specific molecules (“targets”) that are involved in the growth, progression, 
and spread of cancer’.2 In contrast to traditional cytotoxic chemotherapy, 
which is incorporated in rapidly growing cells without selectivity for cancer 
cells versus normal healthy cells, targeted anticancer therapies take benefit of 
differences in malignant versus non-malignant cells, such as (over)expression 
or mutations in tumor driving molecules. 2 The oldest form is endocrine therapy, 
which blocks the hormone-receptor interaction in hormone driven tumors.2,3 
Rapid progress in our knowledge on cancer at molecular levels has led to 
an expansion of targeted anticancer drugs approved for use in daily clinical 
practice. Drugs that block specific intracellular signaling pathways (such as 
the EGFR inhibitor erlotinib), modulate the function of genes (e.g. the BCR-
ABL fusion protein inhibitor imatinib), or inhibit angiogenesis in the surrounding 
tumor microenvironment (like the VEGF inhibitor bevacizumab) are only a few 
examples.4
Remarkable enough, only half of the currently approved targeted anticancer 
therapies have predictive biomarkers available, while prediction of response 
or nonresponse is essential for all treated patients.5 In patients with breast 
cancer for example, the expression of hormone receptors, HER2 receptor 
amplification and recently mutations in PIC3CA are a prerequisite to support 
the use of endocrine therapy, HER2-blocking drugs or PI3Kα-specific inhibitors, 
respectively.6-8 However, even if biomarkers are available to support therapeutic 
decisions, these all have their limitations. Biomarkers are still mainly collected 
from tumor tissue with invasive biopsies, which are not always feasible or safe 
due to the location of the tumor, nor patient friendly.9 In addition, it has been 
reported that the expression of biomarkers can change over time between 
different tumor lesions within one patient and as a result a single tumor biopsy 
may give inadequate information for an individualized treatment plan.10-12 
Therefore, it is important to develop new methods for response prediction 
and treatment optimization strategies in oncology.
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Positron Emission Tomography (PET) is an imaging technique that allows 
visualization and quantification of the distribution of molecules labeled 
with positron-emitting isotopes.13 PET imaging has the advantage of being a 
non-invasive technique that can provide information on the different tumor 
lesions within a patient. For targeted therapies, PET can provide insight in 
target expression throughout the body or whether or not a radiolabeled drug 
reaches its target sites.14-17 Therefore, PET is an interesting technique to aid in 
the prediction and monitoring of targeted therapy effects.
Several promising PET techniques are emerging to visualize targets and targeted 
therapies in oncology, including hormone receptor imaging and imaging with 
radiolabeled drugs such as small molecule protein kinase inhibitors (e.g. 
[11C]erlotinib, [11C]afatinib and [11C]lapatinib PET), and monoclonal antibodies (e.g. 
[89Zr]trastuzumab, [89Zr]rituximab and [89Zr]atezolizumab PET).14,15,17-20 Eventually, 
these techniques could lead to personalized treatment strategies. The amount 
of tracer uptake in tumors may be predictive for treatment effects, guide the 
choice of therapy and provide insight in the optimal treatment dosage for a 
patient.21
Regarding the optimal treatment dosage of targeted anticancer therapies, 
further optimization is urgently needed in order to fully exploit their potential 
antitumor activity. Dose optimization strategies currently under investigation 
include drug monitoring to achieve a target plasma concentration of a drug, 
and alternative dosing schedules such as high-dose pulsatile/intermittent 
dosing of targeted drugs previously given in daily continuous schedules. For 
several small molecule protein kinase inhibitors, such as sunitinib, erlotinib and 
lapatinib, there is accumulating evidence that high-dose pulsatile schedules 
may improve antitumor effects or overcome resistance based on higher tumor 
accumulation and/or enhanced inhibition of drug targets.22-24 In addition, in 
multiple phase I studies, PET imaging is incorporated in the study design to 
determine the optimal drug dose until full target occupancy is reached.25-28 
Therefore, evaluation of the potential and limitations of PET imaging techniques 
is necessary to enable optimal use of targeted anticancer therapies in daily 
clinical practice.
Outline of the thesis
The aim of this thesis was to explore the value of different PET imaging 
techniques visualizing targets and targeted anticancer therapies for future 
treatment tailoring.
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As a general introduction, chapter 1 provides an overview of the available 
literature on molecular imaging with PET for the improvement of personalized 
cancer care.
Part I of this thesis focusses on visualizing targets: estrogen receptor (ER) and 
androgen receptor (AR) imaging in patients with breast cancer. Approximately 
75% of the patients with breast cancer have an ER-positive tumor. The success 
rate of endocrine therapy relies heavily on the ER expression of the tumor.8 
Recently, also AR expression emerged as a possible target of therapy, because 
it is present in 70–80% of the patients with breast cancer.29 In chapter 2, 
[18F]fluoroestradiol ([18F]FES) PET and [18F]fluorodihydrotestosterone 
([18F]FDHT) PET are evaluated to assess whether uptake correlates with the 
levels of ER and AR expression in simultaneous biopsied metastases. In 
chapter 3, the interobserver variability in visual and quantitative assessment of 
[18F]FES and [18F]FDHT PET are determined, because reliable, observer-
independent evaluation is necessary for application of these new techniques 
in clinical practice.
Part II concerns strategies to optimize treatment with the targeted anticancer 
drug sorafenib, a small molecule protein kinase inhibitor. Sorafenib has activity 
against multiple targets involved in the growth, angiogenesis and spread of 
cancer including C-RAF, B-RAF, mutant B-RAF, vascular endothelial growth 
factor receptors 1, 2 and 3, platelet-derived growth factor receptor β, FMS-like 
tyrosine kinase 3, c-Kit protein and RET receptor tyrosine kinase.30 Sorafenib has 
been approved for treatment of locally advanced and metastatic hepatocellular 
carcinoma, renal cell carcinoma and iodine-refractory differentiated thyroid 
carcinoma at a standard fixed dose of 400 mg twice daily in a continuous 
schedule.31-33 Currently, no biomarkers are available to predict response 
to sorafenib in an individual patient. In chapter 4, we examine whether 
[11C]sorafenib PET and [15O]H2O perfusion PET have the potential to predict the 
treatment efficacy of sorafenib. In chapter 5, the results of a phase I exposure 
escalation study are presented investigating an alternative high-dose, pulsatile 
schedule of sorafenib using drug monitoring in attempt to improve the efficacy 
of sorafenib.
Finally, chapter 6 summarizes the main results of this thesis, accompanied by 
a discussion and future perspectives. A Dutch summary of this dissertation is 
given in the Appendix.
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CHAPTER 1
Molecular imaging of targeted 
therapies with positron emission 
tomography: 
the visualization of personalized 
cancer care
Lemonitsa H. Mammatas, Henk M. W. Verheul, N. Harry 
Hendrikse, Maqsood Yaqub, Adriaan A. Lammertsma, C. 
Willemien Menke-van der Houven van Oordt




Molecular imaging has been defined as the visualization, characterization and 
measurement of biological processes at the molecular and cellular level in 
humans and other living systems. In oncology it enables to visualize (part of) 
the functional behaviour of tumour cells, in contrast to anatomical imaging 
that focuses on the size and location of malignant lesions. Available molecular 
imaging techniques include single photon emission computed tomography 
(SPECT), positron emission tomography (PET) and optical imaging. In PET, 
a radiotracer consisting of a positron emitting radionuclide attached to 
the biologically active molecule of interest is administrated to the patient. 
Several approaches have been undertaken to use PET for the improvement 
of personalized cancer care. For example, a variety of radiolabelled ligands 
have been investigated for intratumour target identification and radiolabelled 
drugs have been developed for direct visualization of the biodistribution in 
vivo, including intratumour therapy uptake. First indications of the clinical 
value of PET for target identification and response prediction in oncology 
have been reported. This new imaging approach is rapidly developing, but 
uniformity of scanning processes, standardized methods for outcome 
evaluation and implementation in daily clinical practice are still in progress. 
In this review we discuss the available literature on molecular imaging with 
PET for personalized targeted treatment strategies. In conclusion, molecular 
imaging with radiolabelled targeted anticancer drugs has great potential for the 
improvement of personalized cancer care. The non-invasive quantification of 
drug accumulation in tumours and normal tissues provides understanding of 
the biodistribution in relation to therapeutic and toxic effects.
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1. Introduction
In the last decade the U.S. Food and Drug Administration approved more than 
50 new targeted agents interfering with the underlying biology of the disease, 
especially for the treatment of solid and haematological malignancies [1]. In 
general, these drugs are only effective in a subgroup of patients, but upon 
treatment all patients are exposed to potential toxicity. Therefore, selection 
of patients for treatment with a targeted drug is important to improve cancer 
care. Several methods, including gene and protein profiling are in development 
and a few successes of treatment selection have reached daily clinical practice, 
e.g. BRAF mutation in patients with melanoma [2]. However, for many targeted 
agents no predictive biomarkers are available. Molecular imaging may provide an 
attractive alternative method for treatment selection. In this review we discuss 
the development of molecular imaging for personalized treatment strategies.
2. General principles of molecular imaging
Molecular imaging has been defined as the visualization, characterization and 
measurement of biological processes at the molecular and cellular level in 
humans and other living systems [3]. In oncology it permits the visualization 
of (part of) the functional behaviour of tumour cells, as opposed to anatomical 
imaging that focuses on the size and location of malignancies.
The development of several molecular imaging techniques has greatly advanced 
this field, including single photon emission computed tomography (SPECT), 
positron emission tomography (PET) and optical imaging. In PET a radiotracer 
consisting of a positron emitting radionuclide attached to the biologically 
active molecule of interest is administrated to the patient. As the radionuclide 
decays a positron is emitted in the body, which then annihilates with a nearby 
electron. This results in the production of two gamma-ray photons with 
energies of 511 keV that are ejected in opposite directions (Fig. 1). The PET 
scanner senses this pair of high-energy photons with crystal detectors placed 
in a ring around the patient. Thereby their source along the line of coincidence 
can be identified, enabling a three-dimensional reconstruction of the tracer 
concentration within the body [4]. The positron emitting radionuclides are 
produced in a cyclotron by bombarding target material with accelerated 
protons or deuterons. Each radionuclide will decay according to its own half-
life (Table 1). Radiolabelled ligands and radiolabelled drugs require significant 
biological evaluation before use in clinical trials is possible. This includes the 
determination of both affinity and selectivity for target proteins as well as 




are necessary before each administration, such as radiochemical purity, tracer 
integrity and apyrogenicity [5].
Figure 1. In PET the radiotracer emits a positron that annihilates with a nearby elec-
tron. This results in the production of two gamma ray photons with energies of 511 keV 
that are sensed with crystal detectors placed in a ring around the patient. Thereby, a 
three-dimensional reconstruction of the tracer concentration within the body can be 
made
PET has a superior sensitivity and spatial resolution compared with SPECT, 
in which the radionuclide only emits one single gamma ray photon that has 
to be detected by a gammacamara rotating around a patient [6]. In addition, 
the tissue penetration depth of PET is much higher compared with optical 
imaging, in which emitted light from a fluorescence or bioluminescence tracer 
is detected only up to several centimetres distance from the source [7]. Due to 
the higher sensitivity and superior spatial resolution, as well as the possibility 
to combine PET with CT yielding detailed anatomical information, PET has 
emerged as the preferred technique for clinical applications [8].
3. Radiolabelled ligands
3.1 Radioligands for imaging of cellular processes
In the clinical setting, PET has been most extensively used with the tracer 
[18F]-fluorodeoxyglucose ([18F]FDG), which makes it possible to measure 
glucose metabolism in cells. Due to the high rate of glycolysis in cancer cells, 
[18F]FDG PET is successfully used for detection and staging of malignancies 
and is being evaluated in the clinic as a method for response monitoring of for 
example oesophageal cancer, non-small cell lung cancer (NSCLC) and malignant 
lymphoma. In these malignancies it increased the sensitivity of CT-evaluation 
significantly, but its clinical impact is still under evaluation [9–11]. The most 
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important limitation of this tracer is the relatively low specificity since any 
process that leads to increased glucose metabolism, such as inflammation, 
may lead to increased [18F]FDG uptake [12]. Other tracers reflecting proliferation 
of tumour cells, tumour perfusion, apoptosis and hypoxia, have also been 
developed to image cellular processes important for prognosis, treatment 
decisions and response evaluation [13–16]. For example, [15O]H2O PET was shown 
to be a valuable tool for the measurement of tissue and tumour perfusion, with 
good reproducibility [14]. At this moment however, most of these tracers need 
further validation before clinical use is possible. In addition, more drug specific 
tracers have been developed.
Table 1. Commonly used PET radionuclides
Radionuclide Half-life Decay modes Maximum 
positron energy
Carbon-11 20,4 min 100 % positron emission 0,96 MeV
Nitrogen-13 10,0 min 100 % positron emission 1,20 MeV
Oxygen-15 2,0 min 100 % positron emission 1,74 MeV
Fluorine-18 109,8 min 97 % positron emission and 3 % 
electron capture
0,63 MeV
Copper-64 12,7 h 19 % positron emission, 41 % 
electron capture and 40 % β− decay
0,65 MeV
Bromine-76 16,1 h 57 % positron emission and 43 % 
electron capture
3,40 MeV
Yttrium-86 14,7 h 34 % positron emission and 78 % 
electron capture
3,10 MeV
Zirconium-89 78,4 h 25 % positron emission and 75 % 
electron capture
0,90 MeV
Iodine-124 4,2 days 25 % positron emission and 75 % 
electron capture
3,16 MeV
3.2 Radioligands for imaging of hormone receptors
Hormone receptors are important targets for anticancer therapies, particularly 
for patients with breast and prostate cancer. Radiolabelled ligands have been 
developed to image these target receptors and include 16α-[18F]-fluoro-17β-
oestradiol ([18F]FES) for oestrogen receptors, 21-[18F]fluoro-16 alphaethyl-19-
norprogesterone ([18F]FENP) for progesterone receptors and 16β-[18F]fluoro-
5α-dihydrotestosterone ([18F]FDHT) for androgen receptors [17–19]. Of these, 
[18F]FES has been most extensively studied.
[18F]FES is an analogue of oestradiol with similar binding characteristics [20]. 




compared to the ER expression in tumour biopsies. An overall sensitivity of 84 
% (95 % CI 73–91 %) and specificity of 98 % (95 % CI 90–100 %) are promising 
[21]. Its potential clinical value is discussed further on.
In contrast, imaging of the progesterone receptor (PR) is more difficult. The use 
of [18F]-FENP as a progesterone analogue in breast cancer was disappointing, 
which may be attributed to low receptor affinity and rapid metabolism [18, 22]. 
Further investigations with new PR radioligands are ongoing [23].
Evaluation of the androgen receptor (AR) using [18F]FDHT is also feasible [19]. 
[18F]FDHT PET detected 78 % of the lesions established with conventional 
imaging methods in patients with metastasized prostate cancer [24]. After 1 
day of treatment with the AR antagonist flutamide [18F]FDHT uptake decreased 
> 50 % indicating target site occupancy [19]. Expression levels of AR are known 
to be heterogeneous in prostate cancer [25] and [18F]FDHT may be able to 
quantify those levels before and during treatment which may improve response 
prediction and early response monitoring.
3.3 Radioligands for imaging of receptor tyrosine kinases
Inhibitors of receptor tyrosine kinases have been clinically approved for various 
malignancies. Because, in general, only a subgroup of patients will respond to 
these agents, different radiolabelled ligands have been developed for imaging 
receptor tyrosine kinases with PET to be potentially used for treatment 
selection. These include tracers made from natural ligands or their analogues, 
antibody fragments, affibodies and nanobodies [26–31].
Epidermal growth factor (EGF), the natural ligand of the epidermal growth factor 
receptor (EGFR), has been developed as a tracer, but its use was limited by rapid 
internalization and degradation after receptor binding and by high liver uptake 
[26]. Another drawback was uncertain binding activity associated with random 
radiolabelling of EGF. Based on EGF other compounds have been developed to 
improve image quality such as Cys-tagged EGF (cEGF). It provides site specific 
binding for labelling with N-[2-(4-[18F]fluorobenzamido)ethyl]maleimide to form 
the radioligand [18F]FBEM-cEGF, which retained the characteristics of the parent 
compound [27].
Antibody fragments have the advantage of a longer half-life than the natural 
ligand, though a much shorter half-life than the complete antibody. Antibody 
fragments facilitate repetitive PET scans in a short period of time. Also, their 
smaller size may theoretically result in better transport from
21
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blood to tissue and a higher tumour-to-background ratio [32]. Antibody 
fragments of the anti-HER2 antibody trastuzumab were labelled with 68Ga and 
allowed good sequential imaging of HER2 expression [28].
Affibodies are a type of scaffold proteins in which the framework of 58 amino 
acids is constant (the scaffold Z-domain), while amino acids in the binding site 
are individualized to the receptor of choice and optimized with a higher receptor 
affinity [33]. The EGFR based affibodies [64Cu]ZEGFR:1907 and [18F]ZEGFR:1907 
showed high and rapid tumour accumulation in animal studies. Tumours were 
well visualized 1 to 3 h after injection [29, 30]. In contrast, optimal visualization 
of EGFR-positive tumours with the labelled anti-EGFR-antibody [64Cu]cetuximab 
or [89Zr]cetuximab was achieved later at 24–72 h post injection [34, 35].
Finally, nanobodies are the smallest antigen binding fragments and consist 
of a single monomeric variable domain. The first nanobodies were derived 
from heavy-chain only antibodies found in species of Camelidae [36]. 
[68Ga]2Rs15dHis6 is a nanobody directed against the HER2 receptor. Intense 
tracer uptake was shown in HER2 expressing xenografts in comparison with 
nonexpressing tumours. No significant uptake in other tissues was shown, 
except for the kidneys [31]. Nanobodies bind to different epitopes of the 
tyrosine kinase receptor than monoclonal antibodies. Therefore, these may in 
the future be combined with therapy to directly study the effects on receptor 
expression [36]. Although these analogues of receptor ligands are promising 
imaging tracers, use of the original drug as a radiotracer offers the potential 




The high sensitivity of PET in combination with the high specific activity (i.e. the 
radioactivity per unit mass) of a radiolabelled drug make it possible to visualize 
extremely small amounts of the drug in the body, at concentrations in the 
lower femtomole range (10−15 mol) for which only a microdose of radiolabelled 
drug has to be administrated [37, 38]. Microdosing PET permits studying the 
kinetic behaviour of a drug without saturation of transporters and targets as 
well as avoiding toxic effects as long as such a low dose behaves identical to 
a therapeutic dose [39].
The development of clinically meaningful radiolabelled targeted drugs is a 
complex process requiring several considerations. First, attachment of the 




this may disturb its biochemical properties interfering with the functionality 
of the drug. In addition, the attachment has to be stable and the in vivo 
generation of radiolabelled metabolites as well as their affinity for the target 
of the drug should be known [40]. Second, the choice of radionuclide depends 
on expected pharmacokinetics of the drug. The half-life of the radionuclide 
should be compatible with the time it takes for the drug to achieve an optimal 
tumour-to-nontumour ratio. For small molecules a short-lived tracer will be 
appropriate. However, in case of a radionuclide with a short half-life, such as 
11C, onsite production using a cyclotron is required. Long-lived tracers, such as 
antibodies labelled with 89Zr, can be distributed over a larger distance making 
central synthesis for different hospitals possible. Third, the kinetic behaviour of 
the radiolabelled drug has to be determined with respect to optimal dose and 
ideal timing for PET imaging. Finally, the tumour uptake of a microdose should 
correlate with that of the therapeutic dose of the drug.
4.2 Radiolabelled monoclonal antibodies
Monoclonal antibodies have a large size of ~150 kDa. This large size makes 
it possible to use a bifunctional chelating agent for radionuclide binding. 
These chelators have two binding sites: one metal binding site for chelation 
to the radionuclide and one chemically reactive group for binding to the drug. 
Examples of frequently used chelators are diethylenetriamine pentaacetic acid 
(DTPA), 1,4,7,10-tetraazacylcododecane-N,N′,N″,N′′′-tetraacetic acid (DOTA) and 
desferrioxamine. Important factors to choose an appropriate chelator include 
charge, matching cavity size of the chelator compared to the ionic radius of 
the radionuclide as well as type and number of binding groups. In addition, the 
conjunction of the chelator to the monoclonal antibody should lead to a stable 
binding without altered immune reactivity [41].
The size of monoclonal antibodies results in slow distribution and target binding, 
which is dependent on diffusion and extravasation to the extracellular space. 
Due to these slow kinetics PET scans need to be performed several days after 
injection of the tracer. In addition, clearance is slow and this results in long 
biological half-lifes. For instance, the biological t½ of cetuximab is 70–100 h and 
therefore long-lived positron emitters such as 89Zr (t½ 78,4 h) are suitable for 
radiolabelling this drug [35]. Several monoclonal antibodies will be internalized 
after receptor binding [42]. This should be considered in the choice of the 
radionuclide. 76Br and 124I are rapidly degraded upon internalization and cleared 
from the target cells. In contrast, 64Cu, 86Y and 89Zr are trapped intracellularly 
in lysosomes upon internalisation. These accumulated radionuclides result in 
better visualization of drug targeting [43].
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4.3 Radiolabelled tyrosine kinase inhibitors and hormone receptor antagonists
Tyrosine kinase inhibitors (TKIs) and hormone receptor antagonists are 
molecules < 1 kDa. Both bind to their respective target receptors inhibiting signal 
transduction into the cell. The small structures of these drugs in combination 
with their lipophilicities provide an easy passage through the cell membrane.
To preserve the exact characteristics of these small molecule drugs in vivo, 
radionuclides are built in, rather than attached to the molecular structure. For 
TKIs often 11C is used to replace a cold carbon atom, such as in [11C]erlotinib and 
[11C]sorafenib [44, 45]. In principle all molecules can be labelled by replacing a 
carbon atom with 11C and the radiation dose is much lower than for longer lived 
radionuclides. However, 11C has a short half-life (t½ 20,4 min). This requires rapid 
tracer synthesis and direct PET imaging. In addition, the radiolabelled TKI should 
have a relatively fast tissue distribution to match the half-life of 11C for adequate 
visualization. The half-life of 18F is longer (t½ 109,8 min) and can sometimes 
be used if a cold fluorine atom is available in the molecular structure, like in 
[18F]gefitinib [46]. 18F has also been used to label tamoxifen and fulvestrant 
by adding a fluorine atom to the molecular structure. It was successful for 
tamoxifen, but the addition of 18F at the 16 α-position of fulvestrant dramatically 
decreased the binding affinity for the oestrogen receptor making it unsuitable 
for in vivo use [47, 48].
In contrast to the monoclonal antibodies that are metabolically fairly stable in 
the circulation, TKIs and hormone receptor antagonists may form radioactive 
metabolites which cannot be distinguished from the original drug during PET 
imaging. Direct measurements of the original drug and radiolabelled metabolites 
in blood samples taken during imaging are necessary for all new radiolabelled 
drugs, in order to accurately quantify drug biodistribution with PET. In addition, 
different positions of the radionuclide in the molecular structure of the drug 
should be considered, as this may influence the formation of radioactive 
metabolites.
5. Biodistribution of drugs
5.1 Biodistribution
Molecular imaging of radiolabelled drugs with PET provides direct insight into 
the biodistribution of the drug over time in tumours and normal tissues, which 
is preferably investigated with a dynamic scan, rather than a static scan. 
A dynamic scan generates continuous images in a selected period of time. 
However, as a consequence it is limited to the relatively small field of view of 




body by moving the scanner bed over multiple positions, but it only captures 
one moment in time [49].
A region of interest (ROI) can be drawn onto the acquired dynamic PET images 
in which the radioactivity is measured over time resulting in a time-activity 
curve (TAC). Kinetic modelling can be applied to describe the tissue uptake of 
a drug within the ROI over time. A directly measured blood curve is used as 
an input function and the output function is the TAC of the tissue of interest 
corrected for the intravascular background contribution to the signal. With 
computer modelling an appropriate compartment model is then chosen to 
accurately describe the kinetic behaviour of the drug over time. The most 
frequently applied compartment models are the single tissue model, the 
reversible two tissue model and the irreversible two tissue model (Fig. 2) [50–52]. 
With an appropriate compartment model several parameters of interest can 
be derived, such as the total volume of distribution (VT), the binding potential 
(BPND) for the receptor or, if irreversible binding is the case, the net rate of drug 
accumulation (Ki) [50, 53].
This type of kinetic analysis is not possible with monoclonal antibodies, since a 
dynamic PET is not feasible due to the long biological half-lifes of up to several 
weeks. As an alternative, serial static scans are made in a period of 1–2 weeks 
from which TACs are derived. The biodistribution of monoclonal antibodies has 
been described using a single tissue compartment model with K1 reflecting 
extravasation and k2 washout of the large molecules [54]. However, limitations 
are the lack of time points as in practice a maximum of 4–6 static scans can 
be performed. In addition, for monoclonal antibodies it is frequently required 
to co-administer unlabelled antibody for saturation of ‘sink’ tissue, i.e. normal 
tissue in which the relatively low tracer dose sequestrates, which may interfere 
with the accurate quantification of binding to target sites.
Figure 2 (right). Kinetic modelling with radiolabelled drugs. a. The plasma TAC is used 
as an input function derived from the blood sampler. b. The tumour TAC is used as an 
output function measured with PET. c. In the single tissue model the drug concentration 
in a certain tissue (Ctissue) depends on the drug concentration in the plasma (Cplasma), the 
drug transport from plasma to tissue (K1) and the drug transport from tissue to plasma 
(k2). d. In the two tissue model the radiolabelled drug concentrations are divided over 
two tissue compartments: a free and a bound fraction. In this model the kinetics of 
the radiolabelled drug not only depend on Cplasma, K1 and k2, but also on k3 and k4 that 
describe exchange between the free and bound tissue fraction, respectively. e. In the 
irreversible two tissue model k4 is 0
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Once an appropriate compartment model is determined, it can be used as a 
‘gold standard’ for the validation of simplified outcome measures to facilitate 
clinical use. The simplest tool for identifying tracer uptake is of course visual 
inspection: is there tumour targeting or not? For comparison of results however, 
simplified standardized quantification methods such as the standardized 
uptake value (SUV) have been investigated. The SUV is the tracer uptake within 
a ROI, measured at a certain time after administration and normalized to the 
injected dose and to a factor accounting for body mass (e.g. body weight, 
body surface area or lean body weight). The accumulation of a radiolabelled 
drug within a ROI may be reported as SUVmean, SUVmax or SUVpeak. SUVmean is 
the average SUV of all voxels within a ROI, SUVmax is the highest voxel within 
a ROI and SUVpeak is the average SUV in a small defined area surrounding the 
voxel with the highest activity. Each method has its own benefits, but an 
unequivocal outcome measure is important for comparison of patients [55]. 
Using methods such as the SUV, a threshold may be defined that correlates 
with treatment response or toxicity in normal tissues. In addition, changes in 
SUV after treatment may be useful for early response evaluation. However, the 
SUV needs to be validated as in some instances different results are obtained 
when compared with the gold standard, i.e. full kinetic analysis [56]. Finally, one 
static Pet at a single optimal time point has to be selected from the TAC data 
to make it feasible for daily clinical practice.
5.2 Pharmacokinetic and pharmacodynamic insight with molecular imaging
The insight in drug behaviour has led to the incorporation of microdosing PET 
in early clinical drug development [57]. PET can help to select an appropriate 
starting dose in clinical trials by identifying the lowest dose needed for 
intratumoral target occupancy in a small number of patients. In these dose 
finding studies reduced radioactivity in the ROI after an increasing amount of 
unlabelled drug indirectly implies target site occupancy [37]. On the contrary, 
an extra unlabelled drug dose may also induce tracer uptake in the ROI, thereby 
suggesting saturation of sink tissue. The accumulation of radiolabelled drugs will 
depend on the affinity of the drug for its target in the tumour in combination 
with (nonspecific) binding in other tissues and pharmacokinetics.
In addition, the biodistribution of a new drug may provide some insight in its 
efficacy. For example, it has been demonstrated in brain tumours that PET can 
non-invasively determine the capacity of a drug to cross the blood–brain barrier 
[58]. Prediction of toxicity at sites of drug accumulation, such as the heart and 
bone marrow, is another potential advantage of molecular imaging.
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Molecular imaging of targeted therapies with positron emission tomography
It should be noted that most tracers are administered intravenously, while many 
targeted agents are available in oral form. Pharmacokinetics may differ between 
oral and intravenous variants of a drug due to factors as absorption and first 
pass effect. Although oral tracer administration can be considered, it is often 
cumbersome due to formulation issues and radiation exposure with the need 
for longer-lived isotopes as a result of the slow gastrointestinal absorption. In 
addition, a first-pass effect may lead to higher non-specific accumulation in 
the liver resulting in less image quality [59].
6. Response prediction
6.1 Tracer uptake in tumours
In order for anticancer agents to be effective, the fundamental hypothesis 
is that adequate concentrations of the drug have to reach the tumour and 
the target has to be biologically active in that particular tumour. PET with 
radiolabelled ligands provides insight in the presence of the target. In addition, 
PET with radiolabelled anticancer drugs provides insight in intratumoral drug 
accumulation as well as target expression (Table 2 shows an overview of targeted 
anticancer drugs used in daily clinical practice that have been investigated as 
PET tracers). Both approaches may potentially predict response.
6.1.1 Uptake of [18F]FES
Several studies investigated the sensitivity and specificity of [18F]FES PET 
compared to the ER expression in tumour biopsies. Overall, there was a 
correlation with a pooled sensitivity of 84 % (95 % CI 73-91 %) and a specificity 
of 98 % (95 % CI 90–100 %) [21]. Moreover, [18F]FES uptake in the tumour lesions 
showed predictive value. Tumours of patients with response to endocrine 
therapy revealed significantly more uptake at baseline, with a mean uptake 
about two times higher, compared with non-responders [60, 61]. Quantitative 
thresholds for [18F]FES uptake have been defined in small studies resulting in a 
negative predictive value of up to 88 % and a corresponding positive predictive 
value of 65 % [21]. A high negative predictive value is of importance to correctly 
exclude patients from endocrine therapy and select alternative therapies. On 
the other hand, [18F]FES PET may also identify susceptibility for endocrine 
therapy in patients with an ER negative biopsy and yet concurrent lesions 
with [18F]FES uptake. It is well known that ER discrepancy between primary 
breast cancer and its metastases can be found in up to 40 % of patients [62–
64]. With [18F]FES PET non-invasive evaluation of ER expression in all tumour 
localizations can be performed thus identifying patients who potentially 
benefit from hormonal therapy (Fig. 3). In the future it could be possible that 
heterogeneous [18F]FES uptake may lead to multimodal treatment strategies 




for [18F]FES negative lesions. In addition, the absence of [18F]FES uptake may 
guide the start of cytotoxic chemotherapy. In a Dutch multicentre trial, we are 
currently prospectively studying the value of [18F]FES PET for selection of the 
first line treatment in patients with metastatic breast cancer (clinical trials.
gov; NCT01957332).
Figure 3. Oestrogen receptor-positive metastases on [18F]FES PET. Oestrogen recep-
tor-positive bone, liver, and nodal metastases are visible. Physiological [18F]FES uptake 
can be seen in the liver, bile duct, intestinal tract, and bladder. [18F]FES = 16α-[18F]-flu-
oro-17β-oestradiol. Reprinted from The Lancet Oncology, volume 14, M. van Kruchten 
et al., PET imaging of oestrogen receptors in patients with breast cancer, e465-475, 
Copyright 2013, with permission from Elsevier [21]
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6.1.2 Uptake of radiolabelled monoclonal antibodies
The feasibility of radiolabelled trastuzumab for molecular imaging with 
static PET was demonstrated in three human studies. Two studies used 
[64Cu]trastuzumab in a dose of ~130 MBq per 90 μg and ~450 MBq per 5 
mg, respectively [65, 66]. PET scans were performed from 1 up to 48 h after 
injection and the best assessment of tumour uptake was 48 h after injection. 
Of the previously identified lesions with CT or MRI, 81–89 % showed uptake of 
[64Cu]trastuzumab. In addition, new skeletal hot spots were detected which 
were too small to be identified on CT. The uptake in normal tissues was low, with 
exception of the heart wall, liver, spleen and kidneys. Combined infusion with 
45 mg unlabelled trastuzumab increased the visualization of liver metastases 
presumably by saturation of the sink in normal liver tissue.
Trastuzumab has also been coupled to 89Zr, which has a longer half-life 
compared with 64Cu, to improve PET imaging as it is a relatively slow distributing 
agent. Indeed, the optimal imaging time point was 4–5 days after injection, with 
a lower blood pool activity and higher tumour uptake compared to earlier time 
points [67]. Similar to the results with [64Cu]trastuzumab, the majority of lesions 
previously shown with conventional imaging methods were also identified with 
[89Zr]trastuzumab PET and co-infusion of unlabelled trastuzumab improved 
detection of the lesions.
Recently, we performed a [89Zr]cetuximab PET feasibility study in patients with 
KRAS wild type metastasized colorectal cancer prior to start of treatment with 
cetuximab. A dose of ~37 MBq per 10 mg [89Zr]cetuximab was co-administrated 
with the first therapeutic dose cetuximab. The optimal visualization of non-
hepatic tumour lesions was achieved 6 days after injection (Fig. 4). The SUVpeak 
in patients with tumour uptake ranged from 2.3 to 7.5. Due to high accumulation 
of cetuximab in healthy liver tissue, hepatic metastases could not be evaluated. 
Preliminary results in this feasibility study indicated that patients with tumour 
uptake have a higher chance of response [68].
The amount of uptake depends on expression/accessibility of the drug target, as 
well as binding characteristics such as receptor affinity and internalization. Most 
studies up to date assume a correlation between tracer uptake and therapeutic 
tumour concentrations, but factors like radiolabelled metabolites, dissociation 
of the label from the drug, as well competing unlabelled drug can interfere 
with the capacity of the PET scan to predict actual drug concentrations in the 
tumour tissue. Therefore, the quantitative correlation between radiolabelled 
drug uptake determined with PET and the actual drug targeting measured in 




Figure 4. Representative [89Zr]cetuximab PET images of a patient with metastasized 
colorectal cancer. a. The CT scan shows a pulmonary metastatic lesion in the left lower 
lobe. b. The [89Zr]cetuximab PET scan made 1 day post injection (p.i.) shows high vascular 
uptake in for example the arcus aorta (A) and lung vessels (V), sequestration in liver (L) 
and spleen (S), as well as intestinal uptake (I) due to secretion of 89Zr in feces. c. The 
[89Zr]cetuximab PET scan made 3 days p.i. shows less vascular and splenic uptake and 
some tumour uptake in the pulmonary lesion. d. The [89Zr]cetuximab PET scan made 
6 days p.i. shows the best uptake in the pulmonary lesion as is indicated with the color 
code, with a SUVpeak of 3.0
[89Zr]bevacizumab, a radiolabelled monoclonal antibody against the circulating 
growth factor VEGF, has been studied in 23 patients with 26 resectable 
breast tumours before surgery [69]. Patients received ~37MBq per 5 mg 
[89Zr]bevacizumab and a PET scan after 4 days showed a 3-fold higher SUV in 
tumours than in normal breast tissue in 25 out of 26 breast tumours. Expression 
of VEGF-A in breast tumours even exceeded that of normal breast tissue 
10–20 fold, possibly due to the fact that tissue quantification also measured 
intracellular VEGF, whereas [89Zr]bevacizumab only binds to extracellular VEGF.
These studies and other preliminary data indicate that for every new tracer the 
biodistribution has to be investigated and optimal conditions with respect to 
the amount of radiolabelled and unlabelled drug together with imaging time 
point have to be determined. At this moment, several studies have included 
analysis comparing drug uptake predicted with PET to target expression 
confirmed in tumour tissue. In addition, we are currently performing several trials 
comparing drug uptake predicted with PET with the actual drug concentrations 
measured in tumour biopsies, for radiolabelled monoclonal antibodies and TKIs 
(clinicaltrials.gov; NCT01691391 and NCT02111889). Thereby, the value of PET to 
predict therapeutic concentrations in the tumour will be established directly.
33
Molecular imaging of targeted therapies with positron emission tomography
6.2 Tumour uptake predictive for response
One of the ultimate goals of PET imaging with radiolabelled targeted drugs is 
of course response prediction at the level of the patient as well as the separate 
tumour lesions. Several studies have shown association of tumour uptake and 
response. In the past, different chemotherapy agents have been labelled with 
PET tracers to study tumour uptake in relation to response prediction [70, 71]. 
Before start of therapy, [11C]docetaxel PET revealed a significant correlation 
between tumour uptake and percentage decrease in longest tumour diameter 
in patients with NSCLC [72]. Similarly, in a small group of patients with 
metastasized colorectal cancer the SUVmean of [
18F]5-FU PET prior to treatment 
with 5-FU was not only correlated with treatment response, but also with 
survival [73].
Regarding targeted therapy the predictive value of [18F]tamoxifen PET was 
investigated in 10 patients with ER-positive breast cancer with 23 primary or 
metastatic lesions [74]. Three patients, each with a suspected lesion without 
[18F]tamoxifen uptake, appeared to be truly negative for breast cancer based on 
tumour biopsies and clinical course. Six patients were evaluable for the response 
to tamoxifen. Three out of six patients with clinical benefit of tamoxifen had 
positive lesions on [18F]tamoxifen PET. In contrast, two of the three patients 
with a poor outcome had negative lesions and one showed mixed uptake. 
However, high non-specific uptake in lungs, heart and liver have limited the 
further development of [18F]tamoxifen as a tracer, in contrast to [18F]FES.
A study in ten patients with NSCLC investigated the uptake of [11C]erlotinib 
in relation to EGFR mutations such as exon 19 deletion and exon 21 point 
mutations, which are positively correlated with the antitumour activity of 
erlotinib [56]. Compared with wild type EGFR, these mutations result in a 
2–3 fold higher TKI binding activity for both test and retest [11C]erlotinib PET, 
p = 0,009 (Fig. 5). Tumour uptake in patients treated with erlotinib correlated 
well with treatment effect. Interestingly, one patient developed resistance to 
erlotinib shortly before the study. Although this patient demonstrated higher 
[11C]erlotinib uptake than patients with wild type tumours, the uptake was 
the lowest of the mutated group. Eventually, this patient appeared to have a 
T790Mmutation in EGFR, which is known to cause resistance to erlotinib [75]. 
Another study in 13 patients with NSCLC reported uptake of [11C]erlotinib in four 
out of 13 patients prior to start of treatment with erlotinib [76]. Three out of 
four patients with uptake had benefit of treatment with erlotinib, compared to 




Figure 5. Representative [11C]erlotinib PET images of two different patients with NSCLC. 
a. Patient with an EGFR exon 19 deletion, tumour in the right upper lobe (black arrow) 
and mediastinal lymph nodes (black arrowhead). b. Patient with wild-type EGFR, tumour 
located at the left hilum (white arrow). Patient a (with mean tumour VT of 1.30) shows 
higher tumour uptake than patient b (with mean tumour VT of 0.67) as indicated by the 
color code. The liver (#) shows physiologic uptake of metabolized and nonmetabolized 
[11C]erlotinib. Notice artifacts caused by mediastinal blood vessels (*). Coronal images 
are shown of CT-fused parametric [11C]erlotinib uptake (a1 and b1), CT (a2 and b2), and 
[18F]FDG uptake (a3 and a3). High FDG uptake is seen in the heart (H). Reprinted from 
Clinical Cancer Research, volume 19, I. Bahce et al., Development of [11C]erlotinib pos-
itron emission tomography for in vivo evaluation of EGF receptor mutational status, 
183–193, Copyright 2013, with permission from the American Association for Cancer 
Research (AACR) publishers [56]
There are also ongoing studies regarding response prediction using radiolabelled 
therapeutic antibodies. For example, a study in patients with HER2-positive 
breast cancer evaluates the clinical utility of [89Zr]trastuzumab for the 
identification of patients, who are unlikely to respond to TDM-1 (clinicaltrials.
gov; NCT01565200). And yet another study investigates the clinical utility of 
[18F]FES PET and [89Zr]trastuzumab PET for the identification of patients with 
metastasized breast cancer who are likely to respond to first-line endocrine 
therapy and/or trastuzumab compared to standard treatment selection based 
on a tumour biopsy (clinicaltrials.gov; NCT01957332). These forthcoming 
studies will help to identify the possibilities and clinical utility of these types 
of imaging for treatment selection, response prediction and understanding 
tumour heterogeneity.
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7. New clinical developments with PET
7.1 Early response evaluation with radiolabelled targeted drugs
Various animal studies have been performed to evaluate the early effects of 
targeted therapies on the expression of HER2, EGFR and VEGF together with 
vessel density using radiolabelled trastuzumab, cetuximab or bevacizumab 
PET, respectively (Table 2). Afatinib, an irreversible TKI of EGFR, HER2 and HER4, 
decreased [89Zr]trastuzumab uptake > 80% after 1 week of treatment in HER2-
positive NCI-N87 gastric cancer xenografted mice compared to mice injected 
with a control vehicle. Tumour biopsies showed HER2 downregulation and 
tumour size was reduced. In contrast, [18F]FDG PET showed no differences in 
tumour uptake during treatment [77].
Another example is the effect of Heat Shock Protein 90 (Hsp90) inhibitors on 
EGFR, HER2 and VEGF expression. Hsp90 is a chaperone protein involved in the 
expression, conformation and activity of various oncological target proteins, 
including protein kinases and steroid hormone receptors. This novel group of 
anticancer drugs inhibits Hsp 90 at the ATP-binding site and they are currently 
being investigated in clinical trials [78]. In mice with various human tumour 
xenografts the Hsp90 inhibitors showed a 40–50 % decrease in tumour uptake 
of [64Cu]cetuximab [79], [64Cu]trastuzumab [80], [89Zr]trastuzumab [81] as well as 
[89Zr]bevacizumab [82] within 1 week of treatment compared to pre-treatment 
uptake and/or controls. This correlated well with the difference in EGFR, HER2 
and VEGF expression and vessel density measured histologically, which was 
significantly decreased in the animals treated with the Hsp90 inhibitors. A 
simultaneously reduced proliferation rate was measured with Ki67 staining in 
mice with reduced PET uptake.
The early effect of everolimus on tumour vascularization was explored with 
radiolabelled bevacizumab in animal models. Everolimus, an inhibitor of 
mammalian target of rapamycin (mTOR), also inhibits the production of VEGF. 
It has shown clinical benefit in the treatment of patients with metastasized 
renal cell cancer and breast cancer. [64Cu]bevacizumab or [89Zr]bevacizumab 
PET was performed after treatment with everolimus in 786-O renal cancer and 
A2780luc+ ovarian cancer xenografted mice, respectively. Everolimus decreased 
the tumour uptake of radiolabelled bevacizumab about 50 % in comparison 
to mice treated with a control vehicle. This was in accordance with reduced 
VEGF-A levels, mean vascular density and tumour growth in mice treated with 
bevacizumab in contrast to controls [83,84].
Finally, one human study has been performed to study the effect of sunitinib 




during treatment in patients with metastatic renal cell carcinoma [85]. A total 
of 26 patients were included of which 22 patient were evaluable. Treatment 
with bevacizumab and interferon resulted in a significant, nearly 50 % drop 
in mean SUVmax of [
89Zr]bevacizumab uptake at 2 weeks with an additional 10 
% decrease at 6 weeks. Whether these observations may correlate with early 
response remains to be evaluated in new clinical trials.
7.2 The value of PET for drug combination strategies
Besides response prediction and early response evaluation, molecular 
imaging provides insight in the interaction between anticancer therapies. It 
can take years to find effective drug combinations in clinical trials, as drug 
schedules have shown a profound effect on interaction between the different 
components. Only during clinical trials it became apparent that combining the 
anti-VEGF antibody bevacizumab with cetuximab or panitumumab reduced 
their efficacy significantly [86, 87]. Studying drug distribution with molecular 
imaging in combination treatment can provide a rationale to avoid possible 
detrimental drug combinations and select the potentially successful ones. The 
effect of bevacizumab on drug uptake in tumours has been investigated in 
animal as well human studies. Mice with SKOV-3 ovarian or OE19 oesophageal 
cancer xenografts were injected before treatment with [89Zr]trastuzumab, 
[89Zr]bevacizumab or [89Zr]IgG on day zero [88]. On days 13, 16 and 19 the mice 
received 5 mg/kg unlabelled bevacizumab. A second tracer dose was injected on 
day 14 and PET was performed 1 and 6 days after each injection. Bevacizumab 
reduced the tumour uptake of all radiolabelled antibodies compared to baseline 
with a 40–50 % decrease in [89Zr]trastuzumab, [89Zr]bevacizumab and [89Zr]IgG 
SUVmean. The similar decrease in [
89Zr]IgG illustrates that the reduced antibody 
uptake is a general result of treatment with bevacizumab, possibly due to 
reduced leakage into the tumour tissue and diminished tumour perfusion.
Comparable results were obtained in human trials combining bevacizumab 
with cytotoxic chemotherapy. [18F]5-fluorouracil PET showed a 20 % decrease 
in tumour uptake in patients with colorectal cancer after treatment with 
bevacizumab [89]. Another study in patients with NSCLC showed a significant 
decline in tumour [11C]docetaxel uptake after the administration of bevacizumab. 
This decrease in [11C]docetaxel uptake correlated with a reduction in tumour 
perfusion evaluated with [15O]H2O PET [90].
Other compounds can also interfere with blood flow and tumour uptake. 
Interferon-α was shown to increase tumour blood flow and tumour uptake 
of [18F]5-FU in patients with various malignancies [91]. Pre-treatment with 
dexamethasone reduced tumour uptake of [11C]docetaxel in patients with 
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NSCLC, possibly due to increased drug efflux activity by transporters, such as 
P-glycoprotein and breast cancer resistance protein [92, 93].
These studies illustrate the potential value of molecular imaging to design novel 
treatment combinations and dosage schedules as well as to understand and 
predict the combined efficacy and toxicity.
7.3 Dose titration
Traditionally, dose finding for anticancer agents in phase I trials has been directed 
to find the maximum tolerated dose assuming that the maximum dose will 
provide the maximum benefit. In contrast to cytotoxic chemotherapy, for many 
targeted anticancer agents dose limiting toxicity and a maximum tolerated 
dosage are not reached in phase I trials, e.g. for bevacizumab, trastuzumab 
and cetuximab [94–96]. Therefore, other criteria such as pharmacokinetics/
dynamics as well as (in)activation of downstream targets are used to determine 
the optimal dose. For example, the dosage schedule of cetuximab is based on a 
plateau of clearance reached with increasing dosage and the associated nearly 
complete saturation of EGFRs [96]. Still, there is a large variation in through 
levels and AUC exposition between patients, suggesting pharmacokinetic 
differences between patients leading to potentially suboptimal therapeutic 
effects. Measurement of the intratumour concentrations of radiolabelled 
drugs with PET may help to predict the best dosage for an individual patient. 
Currently, we are recruiting patients to investigate image guided treatment 
optimization for patients with metastasized RAS wild type colorectal cancer 
with [89Zr]cetuximab (clinicaltrials.gov; NCT01691391). Dosages of cetuximab will 
be adapted according to tumour uptake seen on the [89Zr]cetuximab PET with 
the objective to improve clinical benefit in these patients.
Another example of potential dose titration with PET is radiation dosimetry for 
radioimmunotherapy. In general, a higher radiation dose is associated with more 
clinical benefit. However, toxicity of normal tissues must be prevented. 90Yttrium 
emits high energy beta arrays suitable for radiation and bound to the anti-
CD20 monoclonal antibody ibritumomab tiuxetan. [90Y]ibritumomab tiuxetan 
is used as radioimmunotherapy in the treatment of relapsed or refractory non-
Hodgkin lymphomas. Instead of a fixed dose/kg, individual dosing has been 
investigated using [89Zr]ibritumomab tiuxetan to predict radiation dosimetry of 
[90Y]ibritumomab tiuxetan [97]. In a human study, seven patients with relapsed 
B-cell non-Hodgkin lymphoma underwent PET 1, 72 and 144 h after the injection 
of 70 MBq [89Zr]ibritumomab tiuxetan as well as 2 weeks later after injection of 
15 or 30 MBq/kg [90Y]ibritumomab tiuxetan [98]. Based on [89Zr]ibritumomab 
tiuxetan PET the predicted doses correlated well with the absorbed organ doses 




highest absorbed dose of [90Y]ibritumomab tiuxetan was the liver, SUVmean 3,2 ± 
1,8 mGy/MBq. In comparison, tumour absorbed doses ranged from 8,6 to 28,6 
mGy/MBq. Although it should be confirmed in a larger study, the SUVmean of 
[89Zr]ibritumomab tiuxetan in the liver at 72 or 144 h appears a good predictor 
for dose optimization with therapeutic [90Y]ibritumomab tiuxetan.
8. Discussion and conclusions
With the growing amount of therapeutic options, the selection of the optimal 
treatment for an individual patient is increasingly important. Analysis of 
tumour material regarding pathological characteristics, mutational status 
and expression levels of target proteins is essential for treatment selection. 
However, repeated biopsies of multiple sites to characterize the individual 
metastases over time are limited by the accessibility of the lesions and the 
acceptable burden for the patient. ‘Liquid biopsies’ to investigate circulating 
tumour cells, circulating tumour DNA and other tumour related factors can 
support minimally invasive characterization of the evolving tumour. However, 
none of these techniques are able to appreciate tumour heterogeneity of all 
different lesions non-invasively within a single patient over time. Recent studies 
have suggested that intra- and intertumour heterogeneity for multiple different 
tumour types may be important [99, 100] in addition to changes in receptor 
expression and mutational status during the course of treatment [101]. PET using 
radiolabelled drugs or ligands identifying drug targets is a promising tool that 
may fill this gap, as it may be used to accurately quantify tumour heterogeneity 
and drug biodistribution over time non-invasively. We envision that molecular 
imaging may contribute to response prediction and early response evaluation 
of targeted drugs in patients with malignancies.
Integration of molecular imaging with PET in daily clinical practice has several 
challenges:
1. Uniformity of the scanning process and standardized methods for outcome 
evaluation are necessary for reproducibility and comparison of results. The 
main issue here is to determine the optimal trade-off between accuracy and 
simplicity. For [18F]FDG scanning procedures have been harmonized [102] and 
recommendations have been made for standardization of response criteria 
[103].
2. There are potential confounding factors using PET. The question is whether 
the behaviour of a microdose of the radiolabelled drug is the same as that of 
a therapeutic dose. The microdose may not be enough to reach tumour sites 
because of a ‘sink effect’, i.e. the microdose binds to (non-specific) targets 
outside the tumour leaving not enough tracer for tumour accumulation, 
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which especially is a challenge for antibody-tracers. Addition of a cold dose 
of the drug may overcome this as has been shown for [89Zr]trastuzumab [66].
3. A drug may also have a more general effect outside the tumour, for instance 
by activating immune cells like the monoclonal antibody ipilimumab, which 
binds to the cytotoxic T-lymphocyte associated antigen 4 and causes T-cell 
immune responses against tumours [104]. In this case, tumour uptake of the 
drug is not the issue.
4. Causes for false-positive results may include high background levels in 
tissues adjacent to the tumour and nonspecific vascular leakage due to 
abnormal tumour vasculature in the absence of adequate drug-target 
binding. False-negative uptake of the tracer may be caused by reduced 
vascular perfusion and tumour necrosis. These are typical problems using 
static measurements, with dynamic scans one can separate non-specific 
vascular leakage from specific uptake.
In conclusion, molecular imaging with radiolabelled targeted anticancer drugs 
has great potential for improvement of personalized cancer care. The non-
invasive quantification of drug accumulation in tumour and normal tissues 
provides understanding of the biodistribution in relation to therapeutic 
and toxic effects. Although only a limited number of clinical studies with 
radiolabelled targeted anticancer drugs are available, the results indicate that 
there is value in response prediction, early response evaluation and optimization 
of dosing schedules. Larger studies are necessary to determine the exact role in 
daily clinical practice. Standardized methods regarding tracer production, PET 
procedures and outcome analysis are required to obtain meaningful results 
from these future trials in order to make individual treatment decisions for 
better patient outcome.
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In addition to the well-known estrogen receptor (ER) and human epidermal 
growth factor receptor 2, the androgen receptor (AR) is also a potential drug 
target in breast cancer treatment. Whole-body imaging can provide information 
across lesions within a patient. ER expression in tumor lesions can be visualized 
by 18F-fluoroestradiol (18F-FES) PET, and AR expression has been visualized in 
prostate cancer patients with 18F-fluorodihydrotestosterone (18F-FDHT) PET. 
Our aim was to assess the concordance between 18F-FDHT and 18F-FES PET 
and tumor AR and ER expression measured immunohistochemically in patients 
with metastatic breast cancer. Methods: Patients with ER-positive metastatic 
breast cancer were eligible for the study, irrespective of tumor AR status. The 
concordance of 18F-FDHT and 18F-FES uptake on PET with immunohistochemical 
expression of AR and ER in biopsies of corresponding metastases was analyzed. 
Patients underwent 18F-FDHT PET and 18F-FES PET. A metastasis was biopsied 
within 8 wk of the PET procedures. Tumor samples with more than 10% and 1% 
nuclear tumor cell staining were considered, respectively, AR- and ER-positive. 
Correlations between PET uptake and semiquantitative immunohistochemical 
scoring (percentage positive cells × intensity) were calculated. The optimum 
threshold of SUV to discriminate positive and negative lesions for both AR and 
ER was determined by receiver-operating-characteristic analysis. Results: In the 
13 evaluable patients, correlation (R2) between semiquantitative AR expression 
and 18F-FDHT uptake was 0.47 (P = 0.01) and between semiquantitative ER 
expression and 18F-FES uptake 0.78 (P = 0.01). The optimal cutoff for AR-positive 
lesions was an SUVmax of 1.94 for 
18F-FDHT PET, yielding a sensitivity of 91% 
and a specificity of 100%; the optimal cutoff was an SUVmax of 1.54 for 
18F-
FES PET, resulting in a sensitivity and specificity of 100% for ER. Conclusion: 
18F-FDHT and 18F-FES uptake correlate well with AR and ER expression levels 
in representative biopsies. These results show the potential use of whole-
body imaging for receptor status assessment, particularly in view of biopsy-
associated sampling errors and heterogeneous receptor expression in breast 
cancer metastases.
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INTRODUCTION
The estrogen receptor (ER) is expressed in 75% of the breast carcinomas, which 
makes patients with such tumors eligible for ER-targeted therapy (1). Although 
the ER, human epidermal growth factor receptor 2, and progesterone receptor 
are routinely determined in breast cancer for prognosis and treatment decision 
making, this is not the case for the androgen receptor (AR). Nevertheless, 
several studies have shown that the AR is also present in 70%–80% of the 
breast carcinomas, which offers a potential new treatment strategy with AR-
affecting drugs (2).
Patients with metastatic breast cancer received androgens in the first half of 
the 20th century, with response rates of 19%–36% (3,4). However, side effects of 
androgens, including hirsutism and lowering of voice, combined with awareness 
of the conversion of androgens into estrogens resulted in the discontinuation 
of androgen therapy in breast cancer patients. With several emerging, less toxic 
AR-targeted therapies for patients with prostate cancer, and the development 
of resistance to current breast cancer treatment options, AR-targeted therapies 
in breast cancer have reentered clinical trials.
A challenge in this era of rapidly emerging drug targets and treatment options 
is to administer the right drug to the right patient. It is well recognized that only 
those patients with ER-expressing tumors can benefit from endocrine therapies 
(1). Because the ER is functionally and structurally highly comparable to the AR, 
response to AR-targeting drugs may also rely on AR expression in the tumor.
Standard immunohistochemical staining of the primary tumor is inexpensive, 
easy to apply, and well established in decision making for adjuvant therapies. 
However, discordant ER expression between the primary breast tumor and 
metastases has been observed in 18%–40% of the patients (5–8). Molecular 
imaging offers the possibility to noninvasively determine the presence of 
relevant drug targets in all metastases within an individual patient. Tumor ER 
expression can be visualized by 18F-fluoroestradiol (18F-FES) PET in breast cancer 
patients (9). AR expression in prostate cancer patients has been evaluated using 
18F-fluorodihydrotestosterone (18F-FDHT) PET (10,11). If 18F-FDHT PET is also able 
to determine the AR status in metastatic breast cancer patients, this technique 
has the potential to select patients eligible for AR-targeted therapies. The aim 
of the present study was to assess whether uptake on 18F-FES and 18F-FDHT 







Postmenopausal patients with metastatic breast cancer with previous ER-
positive primary tumor were eligible if they had a metastasis outside the liver 
that was safe to biopsy. Patients were staged with full-body bone scintigraphy 
(bone scan) and a contrast-enhanced CT scan (chest/abdomen) within 6 wk 
before the PET examinations. A tumor biopsy was performed within 8 wk of the 
PET examinations. Exclusion criteria for the study were the use of ER ligands less 
than 6 wk before entering the study, and a life expectancy of less than 3 mo. 
Aromatase inhibitors and chemotherapy were allowed. All patients gave written 
informed consent before study participation, according to the Declaration 
of Helsinki, and the protocol was approved by the local Ethical Committee 
(EudraCT no., 2012-003981-42)
Study Design
We performed a prospective, 2-center feasibility trial (NCT01988324). The 
primary endpoint was the concordance of 18F-FDHT and 18F-FES uptake with, 
respectively, AR and ER expression in a newly obtained biopsy of a metastasis 
measured by immunohistochemistry. Secondary endpoints were the optimum 
threshold to discriminate positive and negative lesions for both AR and ER on 
PET, inter- and intrapatient 18F-FDHT and 18F-FES heterogeneity, and correlation 
between tracer uptake and serum hormone levels at the time of scanning. 
Venous blood was collected before 18F-FES tracer injection to evaluate serum 
estradiol (luminescence immune assay), luteinizing hormone, follicle-stimulating 
hormone (both fluorescence immune assay), and sex hormone–binding globulin 
(chemiluminescence microparticle immune assay). These have been reported 
to affect tumor 18F-FES uptake in breast cancer studies (12). Before 18F-FDHT 
injection, blood was collected for serum testosterone and dihydrotestosterone 
levels (both liquid chromatography-mass spectrometry assay).
Tumor histology
All patients underwent a biopsy of a metastasis, detectable by conventional 
imaging, within 8 wk of the PET procedures. Biopsies were formalin-fixed and 
paraffin-embedded. Biopsies were centrally revised by a dedicated breast 
pathologist. ER (CONFIRM anti-Estrogen Receptor [SP1] Rabbit Monoclonal 
Primary Antibody; Ventana) and AR (anti-Androgen Receptor [SP107] Rabbit 
Monoclonal Primary Antibody; Ventana) were stained with a Benchmark 
automated stainer (Ventana) at the Department of Pathology of the University 
Medical Center Groningen. Antibodies were prediluted by the supplier. ER 
was scored according to the guideline of the American Society of Clinical 
Oncologypathologists (13) and semiquantitatively: the percentage of positive 
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tumor nuclei was multiplied by the intensity of staining (0, negative; 1, weak; 
2, moderate; and 3, strong). This led to a score of 0–300 (14). Because AR is 
not a routine staining in breast cancer, a threshold of more than 10% positive 
nuclear staining was used as a discriminator for AR positivity, based on current 
use in literature (2).
Imaging
CT scans were evaluated by a radiologist. Bone scans were evaluated by 2 
nuclear physicians. All tumor lesions visible on CT (>1 cm) and bone scans 
were documented. Patients underwent 18F-FDHT PET and 18F-FES PET on 
separate days within 14 d. 18F-FES and 18F-FDHT were produced as described 
previously (15,16). Patients received approximately 200 MBq of 18F-FDHT and 
18F-FES. Whole-body PET/CT was performed 60 min after tracer injection with 
a Siemens 64-slice mCT (PET/CT) (University Medical Center Groningen) or a 
Philips Gemini 64 TF PET/CT camera (VU University Medical Center) using the 
European Association of Nuclear Medicine Research Limited (EARL)–approved 
protocols (17). Low-dose CT (for attenuation and scatter correction) and PET 
imaging were performed within 1 procedure. All images were reconstructed 
according to the specifications of the EARL accreditation program (17).
Tumor 18F-FES uptake was quantified for all lesions seen on CT and bone scans, 
as well as for nonphysiologic uptake visible above background with an SUVmax of 
greater than 1.5 based on previous studies (18,19). All lesions detected on bone, 
CT, and 18F-FES PET scans were also quantified on the 18F-FDHT PET scan. In 
line with previous studies, we used the SUVmax to calculate tumor 
18F-FDHT and 
18F-FES uptake (18,19). We also measured the SUVmean using a 50% isocontour of 
the hottest pixel to assess the average SUV computed in the volume of interest. 
The SUVpeak was used to calculate uptake in a 1-cm
3 spheric volume of interest 
surrounding the voxel with the highest activity. Background correction was 
applied using a volume of interest at the unaffected contralateral site whenever 
available, or at the surrounding tissue of the same origin and deducted from 
the SUV of the tumor (i.e., lesion SUVmax/mean/peak minus background SUVmax/mean/
peak, resulting in background corrected SUVmax/mean/peak.
Statistical analysis
18F-FDHT PET/CT and 18F-FES PET/CT findings were compared with 
immunohistochemical findings for AR and ER expression, respectively. The 
optimum threshold of SUV to discriminate positive and negative lesions for 
both AR and ER was determined by receiver-operating-characteristic analysis. 
Correlations between semiquantitative receptor analysis and SUV were 







Twenty-one patients were included between September 2014 and August 2015 
(Table 1), and 13 were evaluable for the primary study endpoint. Nonevaluable 
were 5 patients with a nonvital tumor biopsy (24%), and 3 patients (14%) with 
biopsied lesions not visible on conventional imaging or PET (n = 2 skin lesions, 
n = 1 intestinal lesion). All evaluable patients had an ER-positive and AR-positive 
primary breast cancer based on immunohistochemistry. Three patients (23%) 
showed conversion between the primary tumor and the metastasis of either 
ER (8%), AR (8%), or both (8%) measured with immunohistochemistry.
Concordance between SUV and immunohistochemistry of same tumor lesion
Figure 1 shows 2 representative examples of AR immunohistochemical staining 
results and corresponding 18F-FDHT PET scans. Mean 18F-FDHT SUVmax of the 
biopsies in AR-positive lesions was 3.1 (SD, 0.90) versus a mean 18F-FDHT SUVmax 
in AR-negative lesions of 1.9 (SD, 0.01). Mean 18F-FES SUVmax of the biopsied 
ER-positive lesions was 4.3 (SD, 2.4) versus a mean 18F-FES SUVmax in biopsied 
ER-negative lesions of 1.1 (SD, 0.4). The correlation between semiquantitative 
AR expression and 18F-FDHT uptake was R2 = 0.47 (P = 0.01), and between 
semiquantitative ER expression and 18F-FES uptake it was R2 = 0.78 (P = 0.01) 
(Fig. 2). The correction for background uptake did not improve the correlation 
between semiquantitative AR and ER expression and 18F-FDHT and 18F-FES 
uptake, because background correction resulted in a correlation of R2 = 0.39 
and 0.78, respectively. The correlations between immunohistochemistry and 
SUVpeak, SUVmean, and background-corrected SUVpeak and SUVmean did not differ 
from the correlations observed between immunohistochemistry and SUVmax 
(Supplemental Table 1; supplemental materials are available at http://jnm.
snmjournals.org).
The optimal SUVmax cutoff for 
18F-FDHT PET was 1.9, leading to a sensitivity 
of 91% and a specificity of 100% (area under the curve, 0.91; 95% confidence 
interval, 0.74–1.0). Receiver-operating-characteristic analysis showed an optimal 
cutoff value for 18F-FES PET to be SUVmax 1.5, resulting in a sensitivity and 
specificity of 100%. The correction of tracer uptake for background or using 
SUVmean or SUVpeak instead of SUVmax did not improve the results (Supplemental 
Table 2).
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Table 1. Patient characteristics
Characteristic n %
Mean age (y) 64
Sex
 Female 11 85
 Male 2 15
Primary tumor characteristics IHC





 T1N0M0 4 31
 T1N1M0 1 8
 T2N0M0 4 31
 T2N1M0 1 8
 T3N2M0 3 23
Metastatic tumor characteristics IHC
 ER+/AR+ 10 77
 ER+/AR− 1 8
 ER−/AR+ 1 8
 ER−/AR− 1 8
Treatment at time of 18F-FES and 18F-FDHT PET scans
 Aromatase inhibitor 5 38
 Chemotherapy 4 31
 None 4 31
ER+ = ER-positive; AR+ = AR-positive; ER− = ER-negative; AR− = AR-negative;
IHC = immunohistochemistry.
Heterogeneity in uptake
Heterogeneity in lesion uptake was seen between patients and across lesions 
within individual patients for both 18F-FES and 18F-FDHT uptake. An example of 
a typical 18F-FDHT and 18F-FES PET is shown in Figure 3. With the cutoff at 1.9 
for 18F-FDHT PET, all patients had both 18F-FDHT–positive and 18F-FDHT–negative 
lesions. SUVmax on 
18F-FDHT for tumor lesions varied within patients (median, 2.8; 
range, 0.8–6.5) and between patients (median, 2.7; range, 1.7–3.7). Eleven of 13 




on 18F-FES PET varied widely between lesions (median, 3.2; range, 0.6–12.2) and 
patients (median, 2.4; range, 1.3–6.0).
Figure 1. Comparison of immunohistochemistry staining of AR between an AR-negative 
(0% AR staining) lesion (A, top) and AR-positive (100% staining) lesion (B, top). (Bottom) 
Horizontal 18F-FDHT PET/CT fusion images. (A, bottom) Physiologic uptake in small intes-
tines and kidneys. Arrow indicates biopsied lesion (rib) with no visual enhanced uptake. 
(B, bottom) Physiologic uptake in small intestines and high uptake throughout pelvic 
bones. Arrow indicates biopsied lesion in iliac bone with visually enhanced uptake.
Figure 2. Correlation plot of semiquantitative analysis of receptor status and SUVmax as 
measured by PET scan for AR (left) and ER (right).
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Figure 3. Example of typical 18F-FES (A–C) and 18F-FDHT (D–F) distribution in same pa-
tient with multiple bone metastases. (A) Sagittal 18F-FES PET/CT fusion image with 
physiologic uptake in liver, small intestine, and urinary tract and pathologic uptake in 
multiple vertebrae. (B) 18F-FES PET maximum-intensity-pixel format to allow visualiza-
tion of biodistribution of 18F-FES tracer. (C) Horizontal 18F-FES PET/CT fusion image with 
physiologic uptake in small intestine and pathologic uptake throughout pelvic bones. 
(D) Maximum-intensity-pixel format of 18F-FDHT PET scan, with physiologic uptake in 
blood pool of heart and liver and excretion via bile to small intestine, and urinary tract. 
(E) Sagittal 18F-FDHT PET/CT fusion image with physiologic uptake and pathologic uptake 
in multiple vertebrae. (F) Horizontal 18F-FES PET/CT fusion image with physiologic uptake 
in large vessels and small intestines and pathologic uptake throughout pelvic bones.
A total of 298 lesions were detected with CT scans (n = 95), bone scans 
(n = 126), or 18F-FES PET scans (n = 239). Most lesions (81%) showed uptake 
above background on 18F-FES PET. CT or bone scan identified 59 lesions that 
showed no 18F-FES uptake above background. 18F-FES PET identified 48 lesions 
not visible on conventional imaging. In total, 278 lesions could be used for 
18F-FES PET analysis. Because of the high physiologic background uptake near 
the lesion such as in the liver and intestines, 20 lesions could not be reliably 
quantified. Most of the lesions were in the bone (n = 219); 34 lesions were in the 




Figure 4. Distribution of SUVmax per lesion per patient measured by 
18F-FES PET. Lesions 
are divided into bone (blue), lymph nodes (red), lung (green), and others (purple). Orange 
circles are biopsied lesions. Blue boxes indicate ER-positive biopsies (>1% staining); num-
bers indicate score of biopsy (i.e., intensity times percentage positive cells). Dashed 
line indicates threshold set based on receiver-operating-characteristic analysis. White 
boxes indicate negative biopsies (<1% staining).
On 18F-FDHT PET scans, 196 lesions (66%) were visible above background, of 
which 42 lesions could not be reliably quantified because of high physiologic 
background uptake near the lesion (e.g., the liver, blood vessels, and intestines). 
One hundred two lesions were not visible above background but were visible 
on either CT scan, bone scan, or 18F-FES PET scan. In total, 256 lesions were 
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included for 18F-FDHT PET analysis. Most of the lesions were bone lesions 
(n = 222), 14 lesions were lymph nodes, and the remaining 20 lesions were 
visceral lesions (Fig. 5).
Figure 5. Distribution of SUVmax per lesion per patient measured by 
18F-FDHT PET. Le-
sions are divided into bone (blue), lymph nodes (red), lung (green), and others (purple). 
Orange circles are biopsied lesions. Orange boxes indicate AR-positive biopsies (i.e., >10% 
staining); white boxes indicate negative biopsies. Numbers in boxes indicate score of 
biopsy (i.e., intensity times percentage positive cells). Dashed line indicates threshold 




Uptake in healthy liver tissue was high on both 18F-FDHT PET and 18F-FES PET 
scans, rendering analysis of liver metastases impossible. The mean liver uptake 
on 18F-FDHT SUVmean was 4.4 (range, 3.6–5.8) versus the mean liver uptake on 
18F-FES SUVmean of 12.8 (range, 8.2–19.6). Several lesions were nonquantifiable 
due to high blood-pool accumulation on the 18F-FDHT PET. The blood-pool 
accumulation measured in the descending thoracic artery was higher on 18F-
FDHT PET than 18F-FES PET: SUVmean of 4.6 (range, 3.8–6.2) versus SUVmean of 1.3 
(range, 0.9–2.1), respectively.
Correlation between PET uptake and serum hormone levels and sex 
hormone–binding globulin
18F-FDHT tumor uptake did not correlate with serum sex hormone–binding 
globulin, DHT, or testosterone levels (Supplemental Tables 3–5). Serum estradiol 
levels correlated positively with18F-FES tumor uptake (R2 = 0.52; P = 0.01). 18F-FES 
tumor uptake did not correlate with sex hormone–binding globulin, luteinizing 
hormone, or follicle-stimulating hormone serum levels.
DISCUSSION
This is the first study in which the 18F-FDHT uptake is evaluated in breast 
cancer patents and in which 18F-FDHT tracer uptake was correlated with 
semiquantitative AR analysis in a biopsy of the corresponding metastasis. 18F-
FDHT uptake shows a moderate correlation with AR expression, and 18F-FES 
uptake shows a strong correlation with ER expression.
In this study, we showed that 18F-FDHT can identify AR-positive metastases 
in breast cancer patients. 18F-FDHT PET may therefore be an interesting 
tool to select patients eligible for clinical trials with AR antagonists and to 
analyze the receptor occupancy of these drugs. AR-targeted therapy is not 
yet standard in breast cancer patients, but preliminary results of phase II trials 
are promising, with stable disease in 35% of metastatic breast cancer patients 
(20,21). More clinical studies exploring the efficacy of AR-targeted therapy in 
AR-positive metastatic breast cancer are currently ongoing (e.g., NCT00468715, 
NCT00755885). Even combined AR- and ER-targeted therapies are currently 
under way (NCT02910050, NCT02953860).
To date 18F-FDHT PET has been used only in trials with metastatic prostate 
cancer patients. A comparison of 59 metastatic prostate cancer lesions visible 
on conventional imaging showed that 97% were also visible on the 18F-FDHT 
PET (10). Here, conventional imaging also included 18F-FDG PET. In our study, 
we found that 66% of the lesions visible on conventional imaging were visible 
on 18F-FDHT PET.
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With serial 18F-FES PET scans in patients treated with ER modulators such as 
fulvestrant, we were able to visualize residual ER availability during therapy, 
which was associated with early progression (22). For other ER modulators 
such as GDC0810 and Z-endoxifen, 18F-FES PET provided information about ER 
occupancy and guided dose selection for phase II trials (23,24). 18F-FDHT uptake 
in tumor lesions of patients with prostate cancer diminished in 3 patients after 
treatment with a high dose of testosterone. Treatment with the AR blocker 
enzalutamide also resulted in a reduced uptake on 18F-FDHT PET in prostate 
cancer patients (10). We are currently investigating the effect of the AR blocker 
bicalutamide on residual AR availability assessed by 18F-FDHT PET in patients 
with metastatic breast cancer. Secondary endpoints are the relation between 
percentage decreased uptake on 18F-FDHT PET and response to treatment 
measured by RECIST in the case of measurable disease (NCT02697032).
This study enforces the earlier observed correlation between 18F-FES uptake 
and ER expression. Correlations between the 18F-FES PET uptake parameters 
and immunohistochemistry on the metastatic biopsy using an SUVmax of greater 
than 1.5 showed a 100% sensitivity and specificity similar to previously published 
results (9,18,19). The parameters SUVmax, SUVmean, and SUVpeak did not differ, and 
correction for background did not influence the correlation. Therefore, for 18F-
FES PET analysis in the diagnostic setting SUVmax can be used, and correction 
for background is not required. The correlation between uptake on 18F-FDHT 
PET scans and immunohistochemical staining was lower than on 18F-FES PET 
and immunohistochemical staining. The kinetic properties and metabolism 
of 18F-FES and 18F-FDHT are similar (25,26). But 18F-FDHT has a lower relative 
binding affinity of 0.43 for AR than FES, which has a binding affinity of 0.83 for 
ER (21). Furthermore, SUV might not be the best quantification method for 18F-
FDHT uptake. In a small study with 4 metastatic prostate cancer patients, SUV 
corrected for plasma 18F-FDHT concentration showed a better correlation (27).
We analyzed factors that potentially could influence tracer uptake such as 
circulating hormone levels. We found only estradiol levels to be correlated 
with higher uptake on 18F-FES PET scans, which might be related to higher ER 
expressions in tumor lesions in postmenopausal patients with higher residual 
estradiol levels. In fact, we found a correlation of R2 of 0.42 (P = 0.02) between 
serum estradiol levels and ER expression determined by immunohistochemical 
staining on a metastasis biopsy. There was no correlation between other serum 
hormone levels and 18F-FES or 18F-FDHT tumor uptake. These data indicate 
that physiologic circulating hormone levels are too low to directly affect tracer 
uptake in the tumor. Tracer uptake can be influenced by volume, that is, partial-




(28). However, in our study there was no correlation found between the volumes 
of interest of the lesions and 18F-FES or 18F-FDHT uptake.
Because of the feasibility setting of this study, only a limited number of patients 
were evaluable for primary endpoint. Therefore, larger studies should confirm 
the optimal cutoff value for 18F-FDHT PET. In our study, 5 of the 21 entered 
patients did not have vital tumor tissue in their metastatic biopsies. CT may 
have also shown bone lesions that were no longer active, as patients were 
heavily pretreated. This might have resulted in an overestimation of 18F-FES– and 
18F-FDHT–negative sites. Others have used 18F-FDG PET to visualize hormone 
receptor–negative lesions. We refrained from doing so, because 18F-FDG PET 
can also be negative in hormone receptor–positive breast cancer lesions (29). 
PET imaging of hormone receptors also has some restrictions. Liver lesions 
are nonevaluable by 18F-FES and 18F-FDHT PET because of high uptake of both 
tracers in the liver. In addition, 18F-FDHT PET has the disadvantage of high 
accumulation in the blood pool, rendering it difficult to analyze lesions near 
large veins. This has also been described in a 18F-FDHT PET study in prostate 
cancer patients (9). If the 18F-FDHT PET would be used as a diagnostic tool, this 
would be complementary to the current conventional imaging.
CONCLUSION
In our heavily pretreated patient population, hormone receptor conversion 
in the metastasis, when compared with the primary tumor, occurred in 23% 
of the patients. This is similar to previously reported conversion rates (7,8). 
Heterogeneous uptake in tumor lesions on both 18F-FES and 18F-FDHT PET was 
seen in most patients, suggesting that both receptor-positive and -negative 
lesions are present in 1 patient. Current guidelines advise on a biopsy being 
performed when metastatic disease presents. This may not always be feasible. 
However, when omitted, changes in receptor status over time might lead to 
suboptimal therapy choices. 18F-FDHT and 18F-FES PET have the potential to 
serve as a surrogate for metastasis biopsy, especially when lesions are difficult 
to access or sampling errors are prone to occur.
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Purpose: Correct identification of tumour receptor status is important for 
treatment decisions in breast cancer. [18F]FES PET and [18F]FDHT PET allow non-
invasive assessment of the oestrogen (ER) and androgen receptor (AR) status 
of individual lesions within a patient. Despite standardized analysis techniques 
interobserver variability can significantly affect the interpretation of PET results 
and thus clinical applicability. The purpose of this study was to determine visual 
and quantitative interobserver variability of [18F]FES PET and [18F]FDHT PET 
interpretation in patients with metastatic breast cancer.
Methods: In this prospective, two-centre study, patients with ER-positive 
metastatic breast cancer underwent both [18F]FES and [18F]FDHT PET/CT. In 
total, 120 lesions were identified in 10 patients with either conventional imaging 
(bone scan or lesions > 1 cm on high-resolution CT, n = 69) or only with [18F]FES 
and [18F]FDHT PET (n = 51). All lesions were scored visually and quantitatively 
by two independent observers. Visually PET-positive lesions were defined as 
uptake above background. For quantification, we used standardised uptake 
values (SUV): SUVmax, SUVpeak and SUVmean.
Results: Visual analysis showed an absolute positive and negative interobserver 
agreement for [18F]FES PET of 84% and 83%, respectively (kappa = 0.67, 95% 
CI 0.48-0.87), and 49% and 74% for [18F]FDHT PET, respectively (kappa = 0.23, 
95% CI -0.04-0.49). Intraclass correlation coefficients (ICC) for quantification 
of SUVmax, SUVpeak and SUVmean were 0.98 (95% CI 0.96-0.98), 0.97 (95% CI 0.96-
0.98) and 0.89 (95% CI 0.83-0.92) for [18F]FES, and 0.78 (95% CI 0.66-0.85), 
0.76 (95% CI 0.63-0.84) and 0.75 (95% CI 0.62-0.84) for [18F]FDHT, respectively.
Conclusion: Visual and quantitative evaluation of [18F]FES PET showed high 
interobserver agreement. These results support the use of [18F]FES PET in 
clinical practice. In contrast, visual agreement for [18F]FDHT PET was relatively 
low due to low tumour to background ratios, but quantitative agreement was 
good. This underscores the relevance of quantitative analysis of [18F]FDHT PET 
in breast cancer.
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INTRODUCTION
Breast cancer is the most common malignancy in women in the Western 
World. The majority of breast tumours express the oestrogen receptor (ER), 
which is the main indicator of potential response to anti-oestrogen therapies 
[1, 2]. Therefore, it is mandatory to determine ER expression in breast cancer. 
Recently, the androgen receptor (AR) emerged as a possible target for breast 
cancer therapy. The AR is present in 70-80% of patients with breast cancer and 
AR antagonists are under investigation in clinical trials [3-6].
A tumour biopsy is the gold standard to determine receptor expression. 
However, this is an invasive procedure, is not always feasible in case of 
inaccessible tumour sites, and is subject to sampling errors [7]. The 16α- 
[18F]fluoro-17β-oestradiol ([18F]FES) and 16β-[18F]fluoro-5α-dihydrotestosterone 
([18F]FDHT) PET/CT have been developed to non-invasively visualise, respectively, 
the ER and AR status in the tumour lesions within a patient. Previously, it has 
been shown that [18F]FES and [18F]FDHT uptake correlate well with ER and AR 
expression levels in representative breast cancer biopsies [8-10]. As a diagnostic 
tool, [18F]FES PET leads to better diagnostic understanding in 88% and to a 
change of therapy in 48% of the patients presenting with a clinical dilemma 
[11]. To predict treatment effects, [18F]FES PET can be used to assess residual ER 
availability during treatment with e.g. fulvestrant, a selective ER down regulator. 
Inadequate reduction of the [18F]FES PET signal (< 75%) by fulvestrant treatment 
was associated with early progression [12]. Similarly, in patients with prostate 
cancer, [18F]FDHT PET was used to determine the optimal dose of the AR blocker 
enzalutamide in a phase 1 trial [13]. Lastly, patients with ER-positive breast 
cancer and high [18F]FDG uptake showed a worse progression free survival if 
[18F]FES uptake was low in comparison to high [18F]FES uptake (3 versus 8 
months, respectively) [14].
For all these potential applications, reliable, observer-independent identification 
and quantification of [18F]FES and [18F]FDHT uptake in tumour lesions is 
essential for translation to daily clinical practice. Up till now, there are no data 
on the interobserver variability of [18F]FES and [18F]FDHT PET in breast cancer. 
Therefore, the primary objective of this study was to examine interobserver 
variability in visual and quantitative assessment of [18F]FES and [18F]FDHT PET. 
Secondary objectives included the effect of tumour to background ratio (TBR), 
tracer accumulation, tumour size and the use of different SUV parameters 
(SUVmax, SUVpeak or SUVmean) on interobserver agreement. Also, the added value 
of quantitative assessment in comparison to visual assessment was examined 




with those detected on conventional imaging methods (contrast enhanced CT 
scan and bone scan).
MATERIALS AND METHODS
Patient population
This prospective two-centre interobserver variability study was part of a study 
investigating the correlation between [18F]FES and [18F]FDHT uptake and ER- and 
AR-expression in simultaneously biopsied metastases, of which the results have 
been published elsewhere [8]. Patients were recruited from September 2014 to 
August 2015 at the CCA-VUmc University Medical Center Amsterdam and the 
University Medical Center Groningen in the Netherlands.
Eligibility criteria included metastatic breast cancer and an ER-positive primary 
tumour, ≥ 1 extrahepatic tumour lesion, ECOG performance status of ≤ 2 and 
a postmenopausal status or use of LHRH-agonists. Patients were excluded if 
they had used ER- or AR-binding drugs during the 6 weeks before study entry, 
because these ligands compete with tracer binding.
 All patients had to give written informed consent before study participation. 
The study was conducted in compliance with the ethical principles originating 
in or derived from the Declaration of Helsinki and in compliance with all 
International Conference on Harmonization Good Clinical Practice guidelines. 
The local medical ethics committee approved the study (NCT01988324).
Imaging protocols
[18F]FES and [18F]FDHT were produced as described previously [15, 16]. On 
separate days ≤ 14 days apart, 200 MBq (± 10%) of each tracer was injected. 
After 60 minutes (± 5 minutes) a low-dose CT was performed during tidal 
breathing for attenuation correction, followed by a whole-body PET scan (skull 
vertex to mid-thigh, 2 minutes per bed position). PET/CT scans were made 
using a Philips Gemini TF-64 PET/CT (Amsterdam) or Siemens 64 slice mCT 
PET/CT (Groningen). Acquisition and reconstruction protocols used on both 
scanners were according to the recommendations of the European Association 
of Nuclear Medicine (EARL) [17].
In addition, a high-resolution, contrast-enhanced CT chest-abdomen and bone 
scan were performed within 6 weeks of the PET scans for comparison.
Image analyses
Contrast enhanced CT scans were examined by experienced radiologists and 
bone scans by experienced nuclear medicine physicians, respectively, masked 
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for the [18F]FES and [18F]FDHT PET results. Two independent observers from 
each centre (LM and CV) trained and supervised by two experienced nuclear 
medicine physicians, performed visual and quantitative analyses. The observers 
had knowledge of conventional imaging results (contrast enhanced CT and 
bone scans).
A visually PET-positive lesion was defined as focal uptake above local 
background incompatible with physiological uptake. Liver metastases were 
excluded from all analyses in this study because of high physiological [18F]FES 
and [18F]FDHT uptake in healthy liver tissue, making reliable identification of 
metastases difficult. In addition, if visual interpretation of uptake in a (potential) 
lesion was impossible, e.g. due to overlap with adjacent organs with high 
physiological tracer, the readers independently reported it as ‘not evaluable’ 
in the visual ratings and these were excluded from further analyses. For each 
patient the observers made a list that consisted of all lesions already detected 
on conventional imaging, followed by additional lesions discovered on [18F]FES 
or [18F]FDHT PET. An anatomical description of all the lesions was reported in 
order to match the results. In case a lesions was not reported by one of the two 
observers it was scored as not visible for that observer. All visually PET-positive 
lesions were quantified, as well as PET-negative lesions that were identified on 
conventional imaging (i.e. lesions on bone scintigraphy and/or high resolution 
CT > 1 cm).
Each observer manually drew volumes of interest (VOI) on the tumour contours, 
using PET images for PET-positive lesions and low dose CT images for PET-
negative lesions (lesions only seen on bone scan or high resolution CT were 
visually matched on the low dose CT). Lesions were separately analysed based 
on visibility on either PET or conventional imaging alone to investigate the 
influence of visibility on imaging techniques on interobserver agreement.
 For every VOI the standardised uptake values (SUV), i.e. the tracer uptake 
within a VOI normalised to the injected dose and body weight, were calculated 
using the software programs accurate (in-house build using IDL, observer 1) and 
syngo.via version VB10B, Siemens (observer 2). Both programs yielded identical 
results on test images. Three types of SUV were compared in this study: SUVmax 
(voxel with highest SUV within the VOI), SUVpeak (average SUV of a 1 cm
3 sphere 
containing the hottest voxels of the VOI) and SUVmean with isocontour 50% of 
SUVmax (average SUV of all voxels with uptake ≥ 50% of SUVmax).
Based on previous studies an SUVmax [
18F]FES cut-off ≥ 1.5 was used to define 
ER-positivity (corresponding with a IHC cut-off of ≥ 1%) and an SUVmax [
18F]FDHT 




For [18F]FES and [18F]FDHT, the SUVmax tumour-background ratio (TBR) was 
defined as the ratio of the SUVmax of a tumour lesion and the SUVmean of healthy 
background tissue. To determine the SUVmean of healthy background tissue a VOI 
was drawn on reference tissue in the unaffected contralateral site whenever 
available or in the unaffected surrounding tissue of the same origin [18].
Statistical analyses
For visual assessments, agreement was calculated with absolute and relative 
measures of interobserver agreement. Absolute agreement is the probability 
that if one observer would score a lesion as visible (positive agreement) or not 
visible (negative agreement) on the PET scan, the other observer would do 
the same. It is calculated by the following formulas: positive agreement = 2 x 
lesions visible to both observers/(2 x lesions visible to both observers + lesions 
only visible to observer 1 + lesions only visible to observer 2) and negative 
agreement = 2 x lesions not visible to both observers/ (2x lesions not visible 
to both observers + lesions only not visible to observer 1 + lesions only not 
visible to observer 2) [19]. In order to compare results with previous studies, 
also reliability (relative agreement) was calculated according to Cohen’s kappa 
and results were interpreted as follows: kappa 0.01-0.20 as slight, 0.21-0.40 as 
fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial and 0.81-1.00 as almost 
perfect interobserver agreement [20]. To account for potential within-person 
correlation in visual assessments, a Chi square test was performed to examine 
whether the percentage visual agreement differed per patient.
For quantitative assessments, parameters are presented as mean ± SD, and 
reliability was calculated with intraclass correlation coefficients (ICC) using a 
two-way random effect model with absolute agreement. For the interpretation 
of the ICCs, the following guideline was used: ≥ 0.90 as excellent, ≥ 0.75 as good, 
≥ 0.50 as moderate and < 0.50 as poor [21].
Absolute agreement on quantitative assessments were analysed with Bland-
Altman plots (differences between observers showed a normal distribution). 
For each lesion it graphically shows the average SUV of observers 1 and 2 on 
the x-axes and on the y-axes the difference between observers for each lesion, 
expressed as percentage of the average SUV value. Percentage differences were 
used instead of absolute differences to achieve independence of magnitude 
of differences from magnitude of SUV values and it facilitates comparisons 
between the SUV parameters SUVmax, SUVmean and SUVpeak, which may show 
large differences in absolute values.
To investigate the effect of TBRs on interobserver variability, differences 
between TBRs of [18F]FES and [18F]FDHT PETs were tested with Wilcoxon 
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matched pairs signed rank tests. In addition, correlations between tracer uptake 
or tumour size and percentage interobserver differences were determined using 
the Spearman correlation coefficient (r). Finally, linear regression was performed 
to find the linear function between SUVmax, SUVpeak and SUVmean for [
18F]FES 
and [18F]FDHT PET and Cochran’s Q and McNemar tests were used to analyse 
differences between visibility and quantitative uptake above or below cut-
off for SUVmax, SUVpeak and SUVmean. P value < 0.05 was considered significant. 




A total of 120 lesions were identified in 10 patients using the different imaging 
modalities (Table 1). Most lesions were skeletal (66%), followed by lymph node 
(25%) and visceral metastases (9%). The median number of lesions per patient 
was 9 (range 2-32).
Comparison of lesion detection on different imaging modalities
Of the 120 lesions in total (Table 1), most were identified on [18F]FES PET (n = 64 
[53%] and n = 69 [58%] by observer 1 and 2, respectively), followed by high 
resolution CT (n = 54 [45%]), bone scintigraphy (n = 40 [33%]) and [18F]FDHT 
PET (n = 36 [30%] and n = 37 [31%]). Fifty and 42% of the lesions identified 
on [18F]FES PET by observer 1 and 2, respectively, were also detected on high 
resolution CT or bone scintigraphy (Figure 1). For [18F]FDHT PET, 55% and 49% 
of the identified lesions were seen with conventional imaging. Conversely, 
46 and 42% of the lesions identified on conventional imaging were visible on 
[18F]FES PET by, respectively, observer 1 and 2, and 29% and 26% were seen 
on [18F]FDHT PET. In particular, more lymph node lesions were detected on 
[18F]FES PET and [18F]FDHT PET compared to conventional imaging: 97% and 
53% versus 27% of all detected lymph node lesions, respectively.
Visual analysis of [18F]FES and [18F]FDHT PET images
Out of 120 lesions, a total of 87 and 74 on [18F]FES and [18F]FDHT PET, respectively, 
were analysed for visual interobserver agreement. The other lesions were 
excluded because one or both observers reported these as ‘not evaluable’ due 








Age in years, mean (range) 67 (48-79)



















Visible lesions: total; median per patient (range)
Conventional imaging (CT; bone scan)
Visible on PET alone ([18F]FES or [18F]FDHT PET)
Total visible on [18F]FES PET (observer 1; 2)











Bone (conventional imaging; [18F]FES;  
[18F]FDHT PET)
Lymph node (conventional imaging; [18F]FES; 
[18F]FDHT PET)
Visceral* (conventional imaging; [18F]FES;  
[18F]FDHT PET)
79 (55; 45; 
37)
30 (8; 29; 16)
11 (6; 9; 5)
66% (80%; 54%; 
64%)
25% (12%; 35%; 
28%)
9% (9%; 11%; 9%)
*Excluding liver
For lesions visible on conventional imaging, [18F]FES PET readings (Table 2) had 
substantial positive and negative agreement of 84% (95% CI 72-92%) and 83% 
(95% CI 70-91%), respectively (kappa = 0.67, 95% CI 0.48-0.87). By including 
lesions that were only visible on [18F]FES PET, the positive agreement improved 
to 88% (95% CI 80-93%) for all lesions scored on [18F]FES PET (negative 
agreement remained the same). [18F]FDHT PET showed lower positive agreement 
of 49% (95% CI 32-65%) for lesions visible on conventional imaging, while 
negative agreement was 74% (95% CI 62-83%) (kappa = 0.23, 95% CI -0.04-
0.49). Positive agreement for all lesions scored on [18F]FDHT PET was 58% (95% 
CI 43-71%). By looking at lesions only visible on PET and not on conventional 
imaging, the positive agreement rate was the highest: 91% (95% CI 81-96%) for 
[18F]FES PET and 80% (95% CI 55-93%) for [18F]FDHT PET. Visual interobserver 
agreement was not significantly different between the 10 different patients in 
this study: P = 0.159 for [18F]FES PET and P = 0.387 for [18F]FDHT PET.
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An important aspect in the identification of tumour lesions is how well tracer 
uptake can be distinguished from background uptake in normal reference 
tissue. The TBR of [18F]FDHT was significantly lower than that of [18F]FES (Figure 
2). In bone lesions, the mean TBR of [18F]FDHT was 2.0 (± SD 0.6) versus 3.3 (± 
SD 2.2) for [18F]FES (P = 0.003). In addition, in lymph node lesions, the mean 
[18F]FDHT TBR was 4.6 (± SD 1.9) compared to 10.7 (± SD 8.4) for [18F]FES (P < 
0.0001).
Figure 1. Tumour lesions detected with conventional imaging, [18F]FES and [18F]FDHT PET.
Quantitative analyses of [18]FES and [18F]FDHT PET images
Out of 120 lesions, a total of 94 and 95 were quantified by both observers on 
[18F]FES and [18F]FDHT PET, respectively. The other lesions were not quantified 
by one or both of the observers as a result of overlap with adjacent organs with 
high physiological tracer uptake, unless there was a clear anatomical substrate 




Table 2. Visual interobserver agreement for lesions visible (A, C) and not visible on 
conventional imaging (B, D) on [18F]FES and [18F]FDHT PET, respectively.
A Visual interobserver agreement on [18F]FES PET for lesions visible on conventional imaging
OBSERVER 1
OBSERVER 2 VISIBLE NOT VISIBLE NOT EVALUABLE§ TOTAL
VISIBLE 24 3 2 29
NOT VISIBLE 6 22 4 32
NOT EVALUABLE§ 2 6 0 8
TOTAL 32 31 6 69
B Visual interobserver agreement on [18F]FES PET for lesions not visible on 
conventional imaging
OBSERVER 1
OBSERVER 2 VISIBLE NOT VISIBLE NOT EVALUABLE§ TOTAL
VISIBLE 26 3 11 40
NOT VISIBLE 2 1* 3 6
NOT EVALUABLE§ 4 1 0 5
TOTAL 32 5 14 51
C Visual interobserver agreement on [18F]FDHT PET for lesions visible on conventional 
imaging
OBSERVER 1
OBSERVER 2 VISIBLE NOT VISIBLE NOT EVALUABLE§ TOTAL
VISIBLE 9 8 1 18
NOT VISIBLE 11 27 1 39
NOT EVALUABLE§ 0 11 1 12
TOTAL 20 46 3 69
D Visual interobserver agreement on [18F]FDHT PET for lesions not visible on 
conventional imaging
OBSERVER 1
OBSERVER 2 VISIBLE NOT VISIBLE NOT EVALUABLE§ TOTAL
VISIBLE 6 2 11 19
NOT VISIBLE 1 10# 6 17
NOT EVALUABLE§ 9 4 2 15
TOTAL 16 16 19 51
§Not evaluable lesions due to overlap with adjacent organs with high physiological tracer 
uptake. *Lesions identified on [18F]FDHT PET, #Lesions identified on [18F]FES PET.
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In general, interobserver agreement was excellent for PET quantification (Figure 
3) of all lesions combined (i.e. visible on PET or seen on conventional imaging). 
The ICCs for quantification of SUVmax, SUVpeak and SUVmean on [
18F]FES PET were 
0.98 (95% CI 0.96-0.98), 0.97 (95% CI 0.96-0.98) and 0.89 (95% CI 0.83-0.92). 
For [18F]FDHT PET the ICCs were lower with 0.78 (95% CI 0.66-0.85), 0.76 (95% 
CI 0.63-0.84) and 0.75 (95% CI 0.62-0.84), respectively.
In addition, [18F]FES (Figure 4) and [18F]FDHT PET (Figure 5) quantification was 
analysed separately with Bland Altman plots for all lesions visible on PET or 
lesions only visible on conventional imaging (hence, PET-negative lesions). For 
[18F]FES PET, PET-positive lesions showed excellent quantitative interobserver 
agreement with mean differences < 2% and 95% limits of agreement (LOA95%) 
being narrower for SUVmax (LOA95% -31.3% to 34.3%) and SUVpeak (LOA95% -31.1% 
to 28.4%), compared to SUVmean (LOA95% -46.5% to 44.3%). More differences 
were shown for PET-negative lesions with mean interobserver differences < 14% 
and larger LOA95% (within ± 75%), but note that absolute differences between 
observers were generally low due to a low SUV. Similarly, for [18F]FDHT PET 
interobserver agreement was better for PET-positive (mean interobserver 
differences < 7%, LOA95% within ± 45 %) compared to PET-negative lesions 
(mean interobserver differences < 12%, LOA95% within ± 76%). SUVmax and SUVpeak 
showed a better interobserver agreement in comparison to SUVmean for the 
quantification of lesions visible on [18F]FES PET, while on [18F]FDHT PET the 
different SUV parameters were comparable.
Higher levels of tracer accumulation in PET positive lesions were not associated 
with improved interobserver agreement (for [18F]FES PET: Spearman r = 0.04, 
0.26 and 0.14 for SUVmax, SUVpeak and SUVmean, respectively and for [
18F]FDHT PET: 
Spearman r = 0.00, r = 0.03 and r = -0.17, respectively). In addition, there was 
no correlation between tumour size and interobserver agreement (for [18F]FES 
PET: Spearman r = 0.10, r = 0.08 and r = 0.06, for SUVmax, SUVpeak and SUVmean, 
respectively and for [18F]FDHT PET: Spearman r = -0.07, r = -0.16 and r = -0.42, 
respectively).
The added value of quantitative assessment in comparison to visual assessment
Based on previous studies, [18F]FES and [18F]FDHT SUVmax cut-off levels of 1.5 
and 1.9, respectively, have been identified. There are however limited data 
on quantitative thresholds and corresponding cut-off values for SUVpeak and 
SUVmean. Based on linear regression of all lesions quantified in this study, an 
SUVmax cut-off of 1.5 on [
18F]FES PET corresponded with an SUVpeak of 1.2 and an 
SUVmean of 1.1 (Supplementary figure S1), and for [
18F]FDHT PET, an SUVmax cut-off 




Figure 2. The difference in tumour to background ratio between [18F]FES and [18F]FDHT 
PET shown visually (A) and quantitatively (mean ± SD) for bone and lymph node lesions (B).
The arrows in Fig 2A show a bone lesion in the right os ilium visible on [18F]FES PET 
which is only subtly visible on [18F]FDHT PET. Note there is physiological tracer uptake of 
[18F]FES in liver, gallbladder, intestine, bladder and for [18F]FDHT also in the blood pool.
Figure 3. Intraclass correlation coefficients for all quantified tumour lesions on [18F]FES 
(n = 94) using SUVmax, SUVpeak and SUVmean (A, B and C) and [
18F]FDHT PET ( n = 95) (D, E 
and F). Note: not quantifiable lesions by one or both of the observers were excluded as 
a result of overlap with adjacent organs with high physiological tracer uptake.
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Figure 4. Bland Altman plots showing the % differences in SUVmax, SUVpeak and SUVmean 
between observers for lesions visible on [18F]FES PET (A, B, C) or only visible on con-
ventional imaging (D, E, F). The dashed lines represent the mean difference between 
observers ± 95% limits of agreement (LOA95%).
Figure 5. Bland Altman plots showing the % differences in SUVmax, SUVpeak and SUVmean 
between observers for lesions visible on [18F]FDHT PET (A, B, C) or only visible on con-




For diagnostic purposes it is important to identify all receptor positive tumour 
lesions. Therefore, we compared visual and quantitative tracer uptake above/
below cut-off levels (Table 3). In 3% and 1% of the lesions scored visually positive 
on [18F]FES PET by observer 1 and 2 respectively, SUVmax was below the threshold 
of 1.5. For [18F]FDHT PET, 14% of the visually positive lesions scored by observer 
1 as well as observer 2 had an SUVmax below the threshold of 1.9. There were 
no structural differences between observer 1 and 2. The discrepancies were 
mostly seen in lesions located in tissue with low background uptake such as 
skin and lung metastases (Supplementary table S1). Conversely, in 44% and 
39% of the lesions scored visually negative on [18F]FES PET by observer 1 and 2, 
respectively, SUVmax was ≥ 1.5. Similarly, respectively 31% and 52% of the visually 
negative lesions had an SUVmax ≥ 1.9 on [
18F]FDHT PET, respectively. However, in 
most cases (60%) we observed overlap with organs having high physiological 
tracer accumulation such as liver and bowel, followed by lesions that were 
determined to be visually positive at second glance (32%). After correction for 
these effects, ≤ 4% of the visually negative lesions had an SUVmax above cut-
off for both tracers.
Table 3. Discrepancies between visual and quantitative assessments (above/below 
cut-off values for receptor positivity) for [18F]FES (A) and [18F]FDHT PET (B). Note: not 
evaluable lesions were excluded









SUVMAX ≥ 1.5 62 (97%) 16 (44%) 68 (99%) 15 (39%)
SUVMAX < 1.5 2 (3%) 20 (56%) 1 (1%) 23 (61%)
SUVPEAK ≥ 1.2 54 (84%) 19 (53%) 67 (97%) 16 (42%)
SUVPEAK < 1.2 10 (16%) 17 (47%) 2 (3%) 22 (58%)
SUVMEAN ≥ 1.1 57 (89%) 8 (22%) 67 (97%) 11 (29%)
SUVMEAN < 1.1 7 (11%) 28 (78%) 2 (3%) 27 (71%)









SUVMAX ≥ 1.9 31 (86%) 19 (31%) 32 (86%) 29 (52%)
SUVMAX < 1.9 5 (14%) 43 (69%) 5 (14%) 27 (48%)
SUVPEAK ≥ 1.6 30 (83%) 25 (40% 33 (89%) 30 (54%)
SUVPEAK < 1.6 6 (17%) 37 (60%) 4 (11%) 26 (46%)
SUVMEAN ≥ 1.3 31 (86%) 20 (32%) 33 (89%) 30 (54%)
SUVMEAN < 1.3 5 (14%) 42 (68%) 4 (11%) 26 (46%)
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Comparing the impact of the different SUV parameters on discrepancies 
between visual and quantitative assessments, showed no significant differences 
with the only exception that SUVmean showed less visually negative lesions 
above cut-off on [18FES]PET than SUVmax or SUVpeak for observer 1 (P = 0.008 
and P = 0.001, respectively), but not for observer 2 (P = 0.125 and P = 0.063, 
respectively).
DISCUSSION
Interobserver variability is an important step in the clinical application of 
diagnostic tools. Here, we showed that both visual and quantitative evaluation 
were highly reproducible between independent observers evaluating [18F]FES 
PET at separate centres using different scanners and software. Visual positive 
and negative absolute agreement was > 80%, with a kappa of 0.67. Also, the 
interobserver reliability of quantitative metrics was excellent for SUVmax and 
SUVpeak (ICC of 0.98 and 0.97, respectively) and good for SUVmean (ICC of 0.89). 
In comparison, staging patients with breast cancer showed similar results for 
bone scintigraphy (kappa 0.62-0.78) and [18F]FDG PET (kappa 0.65 and an ICC 
of 0.93 for the quantification of [18F]FDG uptake) [22-26].
[18F]FDHT PET also showed good interobserver reliability for quantitative 
assessments with ICCs ≥ 0.75. These values are slightly lower than those of 
[18F]FES PET, and this was probably due to the lower lesional [18F]FDHT uptake, 
because quantitative agreement according to Bland Altman analyses were 
comparable for both tracers. The TBR of [18F]FDHT was considerably lower 
compared to [18F]FES. This probably explains the higher variability in visual 
interpretation (kappa = 0.23), mainly caused by a low visual positive agreement 
(49%) in lesions already identified by conventional imaging modalities, while 
positive agreement in lesions not identified by conventional imaging was much 
higher (80%), as well as negative visual agreement between observers (74%). 
An important impeding factor was the significantly lower TBR of [18F]FDHT in 
bone and lymph node lesions compared to [18F]FES PET. The TBR of [18F]FDHT 
in the current study (2.0 for bone and 4.6 for lymph nodes) was also lower than 
in prostate cancer metastases (3.3 for bone and 5.7 for soft tissue metastases) 
with an SUVmax three times higher in prostate cancer (7.1-9.1 versus 2.0 in the 
present breast cancer study) [27, 28]. This suggests that higher AR expression 
likely results in better interobserver reliability.
Our study had some limitations. There were only a limited number of patients 
included in this study. However, receptor expression between lesions within 
a single patient can be heterogeneous [29], which was confirmed in the 




[8]. In addition, we showed there was no within-patient correlation in visual 
assessments. A second limitation is a substantial number of ‘not evaluable’ 
lesions, due to overlap with adjacent organs with high physiological background. 
The decision for evaluability was left to each observer individually, which 
may have contributed to the low agreement (≤ 6%) on these ‘not evaluable 
lesions’. For future studies we recommend that all lesions with physiological 
background overlap from liver, gallbladder, intestine, bladder and for [18F]FDHT 
also from bloodpool are regarded as not evaluable. A third limitation is the 
lack of robust [18F]FES and [18F]FDHT thresholds for test positivity. We used an 
SUVmax cut-off of 1.5 for [
18F]FES and 1.9 for [18F]FDHT PET based on previous 
data corresponding with ER and AR positivity in biopsies and so far showing 
the best predictive value for response to endocrine therapy [8, 9, 30, 31]. Some 
studies suggested an SUVmax cut-off of 2.0 for [
18F]FES PET, taking into account 
the background [18F]FES uptake in normal tissues which can exceed the cut-off 
of 1.5 [29-31]. Tissue specific cut-off values may indeed be more appropriate as 
there are responders to endocrine therapy with a tumour SUVmax < 2.0. In the 
current study, up to 20% of the visually positive lesions had an SUVmax < 2.0, 
while < 3% had an SUVmax < 1.5 (Supplementary table S2).
For diagnostic purposes simple visual assessment of [18F]FES uptake may 
suffice to determine the receptor status of a tumour lesion (agreement was 
high between visual assessment and the applied SUVmax cut-off value of 1.5 for 
ER-positivity). True discrepancies between visibility and corresponding uptake 
above or below cut-off were low (< 4%), making quantification of visually negative 
lesions not only cumbersome, but also unnecessary. Also, quantification of 
lesions without visual [18F]FES uptake leads to higher interobserver variability 
due to differences in VOI definition. However, quantification remains a helpful 
tool for nuclear medicine physicians in ‘equivocal [18F]FES lesions’. In addition, 
quantification is useful to measure receptor availability over time for the 
evaluation of treatment effects. In contrast, quantification of [18F]FDHT uptake 
is still required in future breast cancer studies, as we have shown relatively low 
visual agreement.
The role of [18F]FES and [18F]FDHT PET in addition to conventional imaging 
modalities needs to be defined further. It has to be taken into account that 
besides partial volume effects and constraints due to background tracer 
uptake limiting their detection, receptor expression can be heterogeneous and 
variable during the course of the disease [11, 32]. In addition, treatment may 
induce changes in receptor expression, but also eradicated tumour cells can 
leave a visible lesion on conventional imaging (e.g. sclerotic bone lesions), in 
absence of viable tumour cells. In the current study with heavily pretreated 
patients, 42-46% and 26-29% of the lesions identified by conventional imaging 
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were detected on [18F]FES and [18F]FDHT PET, respectively. Vice versa, only 
approximately 50% of the lesions observed on [18F]FES PET and [18F]FDHT PET, 
were identified by conventional imaging.
Therefore, a potential role for [18F]FES PET may be in staging of early ER-positive 
breast cancer as an addition to existing imaging techniques. Standard staging 
with [18F]FDG PET can miss low-intermediate grade ER-positive lesions due to 
their low metabolic activity [33]. We are currently investigating [18F]FES PET in 
staging patients with low grade, ER-positive locally advanced or recurrent breast 
cancer versus [18F]FDG PET (NCT03726931), and in metastatic breast cancer 
versus addition to conventional diagnostics (NCT01957332). The non-invasive 
visualisation of receptor status in metastatic lesions with PET offers a number 
potential clinical advantages. For example, in case conventional diagnostics 
cannot establish a final diagnosis of suspected metastatic breast cancer 
lesions (e.g. as a result of inaccessible biopsy sites or repeated biopsy sampling 
errors). Also, PET imaging may help to determine the hormone receptor status 
of different tumour sites within a patient and guide treatment decisions. For 
instance, to decide on the origin of a metastatic lesion in case of multiple 
primary tumours or to determine whether receptor conversion occurred in 
metastases from a single primary tumour [11]. If validated, this may help with 
multimodality treatment strategies for heterogeneous tumour sites of breast 
cancer, such as endocrine therapy for [18F]FES positive lesions combined with a 
local modality such as radiotherapy for concurrent [18F]FES negative lesions [34].
CONCLUSION
In conclusion, our findings demonstrate that visual and quantitative evaluation 
of [18F]FES PET has a high interobserver concordance and support the use in 
clinical practice. Although [18F]FDHT PET showed relatively low visual agreement, 
presumably a result of the low AR expression and consequently low TBR in 
patients with breast cancer, there was good quantitative agreement between 
observers, acceptable for further [18F]FDHT PET imaging studies in breast 
cancer.
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SUPPLEMENTAY MATERIAL
Supplementary table S1. Biodistribution of [18F]FES and [18F]FDHT in various organs 
(n = 10)
ORGAN [18F]FES SUVMEAN [
18F]FDHT SUVMEAN
Mean (± SD) Mean (± SD)
Galbladder 49.7 (± 28.3) 30.4 (± 26.6)
Bladder 14.5 (± 7.3) 14.1 (± 6.7)
Liver 12.0 (± 4.0) 3.9 (± 0.4)
Intestine 4.1 (± 1.9) 2.9 (± 1.0)
Kideney 2.3 (± 0.5) 3.2 (± 0.4)
Uterus 1.7 (± 0.6) 2.0 (± 0.3)
Pancreas 1.4 (± 0.3) 1.6 (± 0.5)
Bloodpool 1.3 (± 0.6) 3.9 (± 0.7)
Adrenal Gland 1.2 (± 0.1) 1.9 (± 0.4)
Spleen 1.0 (± 0.3) 2.1 (± 0.3)
Lung 0.9 (± 0.3) 1.0 (± 0.1)
Bone 0.9 (± 0.3) 1.1 (± 0.1)
Ovary 0.8 (± 0.2) 1.3 (± 0.3)
Stomach 0.6 (± 0.4) 0.9 (± 0.6)
Breast 0.6 (± 0.3) 0.8 (± 0.2)
Muscle 0.6 (± 0.1) 0.8 (± 0.1)
Brain 0.5 (± 0.1) 0.4 (± 0.1)
Fat 0.5 (± 0.2) 0.6 (± 0.1)
Supplementary table S2. Discrepancies between visual and quantitative assessments 
(above/below cut-off values for receptor positivity) for [18F]FES using higher cut-off 
values









SUVmax ≥ 2.0 51 (80%) 7 (19%) 64 (93%) 6 (16%)
SUVmax < 2.0 13 (20%) 29 (80%) 5 (7%) 32 (84%)
SUVpeak ≥ 1.6 45 (70%) 9 (25%) 57 (83%) 7 (18%)
SUVpeak < 1.6 19 (30%) 27 (75%) 12 (17%) 31 (82%)
SUVmean ≥ 1.5 45 (70%) 6 (17%) 57 (83%) 6 (16%)




Supplementary figure S1. Linear regression showing the relationship between SUVmax, 
SUVpeak and SUVmean for [





Supplementary figure S1. Linear regression showing the relationship between SUVmax, SUVpeak and 
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Purpose: Sorafenib leads to clinical benefit in a subgroup of patients, while 
all are exposed to potential toxicity. Currently, no predictive biomarkers are 
available. The purpose of this study was to evaluate whether 11C-sorafenib and 
15O-H2O PET have potential to predict treatment efficacy.
Methods: In this prospective exploratory study, 8 patients with advanced 
solid malignancies and an indication for sorafenib treatment were included. 
Microdose 11C-sorafenib and perfusion 15O-H2O dynamic PET scans were 
performed before and after two weeks of sorafenib therapy. The main 
objective was to assess whether tumor 11C-sorafenib uptake predicts sorafenib 
concentrations during therapy in corresponding tumor biopsies measured with 
liquid chromatography tandem mass spectrometry (LC-MS/MS). Secondary 
objectives included the association of 11C-sorafenib PET, perfusion 15O-H2O PET 
and sorafenib concentrations after therapeutic dosing with response.
Results: 11C-sorafenib PET did not predict sorafenib concentrations in 
tumor biopsies during therapy. In addition, sorafenib plasma and tumor 
concentrations, were not associated with clinical outcome in this exploratory 
study. Higher 11C-sorafenib accumulation in tumors at baseline and day 14 
of treatment showed association with poorer prognosis and was correlated 
with tumor perfusion (rs = 0.671, P = 0.020). Interestingly, a decrease in tumor 
perfusion measured with 15O-H2O PET after only 14 days of therapy showed an 
association with response, with a decrease in tumor perfusion of 56% ± 23% 
(mean ± SD) versus 18% ± 32% in patients with stable and progressive disease, 
respectively.
Conclusion: Microdose 11C-sorafenib PET did not predict intratumoral sorafenib 
concentrations after therapeutic dosing, but the association between a 
decrease in tumor perfusion and clinical benefit warrants further investigation.
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INTRODUCTION
Since the discovery of Rapidly Accelerated Fibrosarcoma (RAF) kinases in 
1983 as oncoproteins involved in cancer proliferation, migration and survival, 
protein kinase inhibitors have been developed in an attempt to inhibit these 
RAF kinases (1). Sorafenib was the first clinically successful RAF inhibitor (2). 
The molecular properties of sorafenib (~ 637 Daltons) enable diffusion and 
transporter mediated uptake into the cell. Sorafenib competes with adenosine 
triphosphate in order to occupy the hydrophobic pocket directly adjacent to its 
binding site, thereby trapping protein kinases in an inactive state (3). Apart from 
RAF kinases, sorafenib has shown affinity for multiple other protein kinases, 
thereby suppressing angiogenesis and inducing apoptosis (4). Sorafenib has 
been approved for treatment of locally advanced and metastatic hepatocellular 
carcinoma, renal cell carcinoma and iodine-refractory differentiated thyroid 
carcinoma (5-7). However, response to sorafenib is variable, resulting in clinical 
benefit for only a subgroup of patients, while all are exposed to potential toxicity 
(5-7). Most common side effects include gastrointestinal symptoms, fatigue, 
and (hand-foot) skin reactions (5-7). Currently, no biomarkers are available to 
identify which patients are likely to benefit from sorafenib.
The response to sorafenib is thought to be directly related to drug 
concentrations in tumor tissue (8). Non-invasive quantification of drug uptake 
in tumors and normal tissues at different time points using positron emission 
tomography (PET) imaging may provide insight in tissue pharmacokinetics in 
relation to therapeutic effects. For some protein kinase inhibitors, such as 
[11C]erlotinib PET, this approach already has shown clinical relevance (9). PET is 
a highly sensitive method to detect tracer concentrations in the body at the 
lower picomolar range (10-12 mol/L) (10). This enables the use of a microdose 
drug tracer, i.e. a drug dose < 1% of the expected pharmacologically active 
concentration, avoiding toxicity of the studied drug (11). The tracer 11C-sorafenib 
has been developed without changing the molecular structure of the drug itself 
(12). In mice, 11C-sorafenib PET showed tumor uptake in the RAF-expressing 
human renal cell carcinoma xenograft RXF393 (12).
The purpose of the present study was to explore whether 11C-sorafenib uptake 
in tumors can be used as a potential biomarker for treatment efficacy. The 
primary objective was to assess whether microdose 11C-sorafenib PET at 
baseline or a change in uptake after 14 days of treatment (steady state), could 
predict sorafenib concentrations after therapeutic dosing as measured in 
corresponding tumor biopsies. Secondary objectives were to investigate the 
effect of tumor perfusion on 11C-sorafenib delivery and to assess the anti-




uptake and sorafenib concentrations in tumors, together with tumor perfusion 
(changes), were related to patient outcome.
MATERIALS AND METHODS
Study Design
This prospective exploratory study, with a planned sample size of n = 8, was 
conducted at the Amsterdam UMC, location VUmc, The Netherlands. Patients 
underwent dynamic microdose 11C-sorafenib PET scans before (‘baseline’) and 
after two weeks of treatment with sorafenib 400 mg twice daily (‘on treatment’) 
when steady state levels of sorafenib were reached (13). Within 2 hours of the on 
treatment 11C-sorafenib PET scan, a tumor biopsy and a venous blood sample 
were taken to measure (unlabeled) steady state sorafenib concentrations during 
therapy. Prior to each 11C-sorafenib PET scan, a dynamic 15O-H2O PET scan was 
performed to measure tumor perfusion (Figure 1). For all patients, sorafenib 
treatment was continued until progressive disease, severe toxicity, or refusal 
by the patient.
Figure 1. Study design.
Patient Population
Adult patients with a histologically confirmed, metastatic solid malignancy 
accessible for tumor biopsy, who were eligible for standard palliative treatment 
with sorafenib, were included i.e. hepatocellular carcinoma, renal cell carcinoma 
and iodine-refractory differentiated thyroid carcinoma (other in- and exclusion 
criteria are shown in Supplement Table 1).
The study was approved by the Medical Ethics Review Committee of Amsterdam 
UMC, location VUmc (NCT02111889) and all subjects signed a written informed 
consent.
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Tracer Synthesis
11C-sorafenib and 15O-H2O were produced according to good manufacturing 
practice guidelines, as described previously (12,14). Carbon-11 was incorporated 
in the molecular structure of sorafenib at the terminal methylamide position.
PET Scanning
Scans were performed using a Gemini TF-64 PET-CT scanner (Philips Medical 
Systems, Best, The Netherlands) with an 18.4 cm axial field of view, divided 
into 45 contiguous planes. Patients received two venous catheters (for tracer 
injection and manual venous sampling, respectively) and an indwelling catheter 
in the radial artery for continuous arterial blood sampling during PET/CT. 
Patients were positioned supine on the scanner bed. Elastic body-restraining 
bandages were used to minimize movement during PET-CT scanning. A CT 
based topogram was performed to determine that both tumor and left ventricle 
were within the field of view of the scanner. Next, a 10 minutes dynamic scan 
was performed, starting at the time of an intravenous injection of ~370 MBq 
15O-H2O (5 mL at a rate of 0.8 mL∙sec
-1, followed by a 35 mL saline flush at a 
rate of 2.0 mL∙sec-1). Finally, a 60 minutes dynamic scan was acquired, starting 
at the time of an intravenous injection of ~370 MBq 11C-sorafenib (5 mL at a 
rate of 0.8 mL∙sec-1, followed by a 35 mL saline flush at a rate of 2.0 mL∙sec-1). A 
30 mAs low-dose CT scan was performed between 11C-sorafenib and 15O-H2O 
dynamic PET scans for attenuation correction and segmentation purposes.
Using the three-dimensional row action maximum likelihood reconstruction 
algorithm (3D RAMLA), 15O-H2O scans were reconstructed into 26 frames with 
increasing duration (1 x 10, 8 x 5, 4 x 10, 2 x 15, 3 x 20, 2 x 30 and 6 x 60 s). 
11C-sorafenib scans were reconstructed into 36 frames (1 x 10, 8 x 5, 4 x 10, 3 x 
20, 5 x 30, 5 x 60, 4 x 150, 4 x 300 and 2 x 600 sec). All data were normalized and 
corrected for dead time, decay, randoms, scatter and attenuation. Resulting 
PET images consisted of 128 x 128 x 90 isotropic voxels, with 4 x 4 x 4 mm3 voxel 
size, and a final resolution of 5 mm FWHM.
Blood Sampling
During 15O-H2O and 
11C-sorafenib scans, arterial blood was withdrawn 
continuously at a rate of 300 mL∙h-1 for the first five minutes and 150 mL∙h-1 
thereafter until the end of the scan, using an online detection system (Comecer, 
Joure, The Netherlands) (15). In addition, 7 mL arterial and venous samples 
were collected manually in lithium heparine containing tubes at 5, 7 and 9 
minutes after injection of 15O-H2O and at 5, 10, 20, 30, 40 and 60 minutes 
after injection of 11C-sorafenib. After each sample the line was flushed with 2 
mL saline. These venous samples were used for measuring plasma-to-whole 




radiolabeled metabolites. The arterial samples were used for calibration of 
the continuous arterial input curve. Because of the invasive character of an 
arterial catheter, a non-invasive image derived input function (IDIF) was also 
investigated (Supplement Figure S1).
Blood Radioactivity Concentrations of Tracer and Metabolites
Whole blood and plasma radioactivity concentrations of the parent drug and 
its radiolabeled metabolites were determined in the blood samples using a 
well-counter, cross-calibrated against the PET scanner (Supplement Table S2).
Volume of Interest Definition
Volume of interests (VOIs) of tumor lesions were defined manually on low dose 
CT scans, avoiding large blood vessels and normal liver tissue. In addition to the 
complete tumor volume, a separate VOI was defined for the rim of each tumor 
lesion using 2 voxels from the outer border of the tumor contour for comparison 
with tracer uptake in the whole tumor VOI, as central tumor necrosis may affect 
tracer uptake. Next, low-dose CT VOIs were projected onto corresponding 
dynamic PET images to generate time-activity curves (TAC) for 11C-sorafenib 
and 15O-H2O. In addition, VOIs were defined on normal organs for 
11C-sorafenib 
biodistribution (16).
Analysis of Tumor Perfusion
Tumor perfusion (F in mL/cm3/min) was obtained by fitting each 15O-H2O TAC 
to the single-tissue compartment model in combination with the arterial input 
function, as described previously (17). This model was implemented in Matlab 
R2017B software (MathWorks, Natick, USA).
Biodistribution of 11C-sorafenib in Healthy Tissues
The biodistribution of 11C-sorafenib in healthy tissues was measured during the 
40-60 minutes interval of the dynamic PET scan and expressed as the mean 
standardized uptake value (SUVmean), which is routinely used for evaluating the 
biodistribution in normal tissues (18).
11C-sorafenib Pharmacokinetics in Tumors
Tumor TACs derived from 11C-sorafenib scans at baseline and after 14 days 
therapy were fitted to three different compartment models (i.e. 1-tissue, 
irreversible 2-tissue and reversible 2-tissue models) using the arterial plasma 
input function, corrected for radiolabeled metabolites. All models included 
a blood volume parameter to account for intravascular activity. The optimal 
model for describing the TAC data was selected based on Akaike Information 
and Schwartz Criteria (19,20).
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Sorafenib Concentrations in Tumor and Plasma during Therapy
Using 14-16 Gauge biopsy needles, experienced intervention radiologists 
obtained tumor biopsies. In case of central necrosis, as seen on CT, samples were 
taken from the rim of the tumor. Samples were snap frozen within 1 minute of 
the biopsy, followed by storage under -80 °C conditions. Both plasma and tumor 
tissue samples were obtained within 2 hours of the on treatment 11C-sorafenib 
PET scan. Liquid chromatography tandem mass spectrometry (LC-MS/MS) was 
used as a reference method to measure sorafenib concentrations, as described 
previously (21).
Safety and Response Evaluation
Safety evaluations were performed in all patients with grading of adverse events 
according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events, version 4.0. Tumor response evaluation was performed every 
2 months during sorafenib therapy according to Response Evaluation Criteria 
in Solid Tumors (RECIST) version 1.1 (22).
Statistical Analysis
Statistical analyses were performed using SPSS software for Windows version 
22.0 (SPSS Inc. Chicago, USA). Tumor uptake of 11C-sorafenib (both at baseline 
and on treatment PET scan) was compared with corresponding tumor and 
plasma sorafenib concentrations and with the calculated tumor-to-plasma 
concentration ratio of sorafenib after therapeutic dosing. PET measures 
are presented as mean ± SD. Correlations were explored using Spearman’s 
correlation coefficient (rs). The Wilcoxon signed rank test was used to compare 
PET measures before and after 14 days of sorafenib treatment, and to compare 




Eight patients were included (Table 1) between September 2013 and November 
2015. There were no side effects during tracer injection or imaging procedures. 
Patients received 100% of the therapeutic dose during sorafenib treatment, 
except for patient 4. This patient had to end study participation within 2 weeks 
of treatment as a result of unexpected rapid clinical progression. In the other 
patients at least one contrast-enhanced CT scan was obtained for response 
evaluation. Five patients had progressive disease at first evaluation and two 
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Figure 2. Biodistribution of 11C-sorafenib in different healthy tissues and tumor tissue. 
PRE = baseline, POST = after 14 days of sorafenib therapy.
Biodistribution of 11C-sorafenib
The highest 11C-sorafenib accumulation was in the liver (SUVmean 10.4 ± 3.3 at 
baseline and 6.4 ± 1.6 on treatment), whereas concentrations in skin were lowest 
(SUVmean 0.3 ± 0.1 at baseline and 0.01 ± 0.01 on treatment) (Figure 2).
Comparison of 11C-sorafenib uptake at baseline with that on treatment showed 
the largest differences in the liver with an SUVmean decrease from 10.4 to 6.4 
(P = 0.018) and in blood with an SUVmean increase from 2.3 to 3.6 (P = 0.018).
No association was seen between the biodistribution of 11C-sorafenib and 
treatment related toxicities.
Quantitative Analysis of 11C-sorafenib Uptake in Tumors
A total of 15 lesions could be evaluated. Tumor volumes were highly variable, 
with a median size of 10 cm3 and range of 4-2527 cm3. Patient 4 only had a 




A PET tracer dose of 347 ± 66 MBq (mean ± SD) 11C-sorafenib was given with 
a specific activity of 35350 ± 9929 MBq/μmol sorafenib. As the molecular 
weight of sorafenib is 464.8 µg/µmol this corresponded with 4.9 ± 1.6 µg of 
unlabeled sorafenib. After injection, 11C-sorafenib was quite stable, with only 
< 5% labeled metabolites formed during the 60 minutes scan. The reversible 
2-tissue compartment model with four rate constants and additional blood 
volume parameter best described 11C-sorafenib tumor kinetics (Supplement 
Figure S2). Therefore, the total volume of distribution (VT) = K1/k2*(1+k3/k4) was 
used as outcome parameter, which represents the tumor-to-plasma ratio of 
11C-sorafenib at equilibrium.
At baseline, 3/8 patients had a tumor VT > 1, i.e. 
11C-sorafenib accumulation in 
the tumor was higher than in plasma (Figure 3). After 14 days of treatment, no 
patients were left with a tumor VT > 1. Overall, tumor VT values of 
11C-sorafenib 
were higher at baseline than at day 14 of treatment (0.68 ± 0.55 versus 0.29 ± 
0.20, P = 0.007).
Figure 3. Fusion 11C-sorafenib PET/CT (sum 40-60 min), low-dose CT and PET images 
from three patients showing 11C-sorafenib uptake in tumor lesions (red arrows)). Patient 
A with hepatocellular carcinoma has a metastasis in the left costa 4, patient B with 
renal cell carcinoma has a metastasis in the left adrenal gland, and patient C with he-
patocellular carcinoma has a large intra-abdominal metastasis. Physiologic uptake can 
be seen in the liver (white *) and kidneys (yellow Δ).
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Figure 4. Tumor 11C-sorafenib VT on days 0 (A) and 14 (B) in lesions of patients with pro-
gressive (PD) and stable (SD) disease.
No significant differences in 11C-sorafenib VT were established between whole 
tumor and outer tumor rim (P = 0.944 at baseline and P = 0.138 at day 14). In 
addition, total tumor volume was not correlated with the amount of tracer 
uptake (rs = 0.196, P = 0.483 at baseline and rs = -0.134, P = 0.713 at day 14). 
Surprisingly, patients with clinical benefit had a lower tumor 11C-sorafenib VT 
in comparison to patients with progressive disease at baseline (0.34 ± 0.08 
versus 0.92 ± 0.61) as well as after 14 days of treatment (0.13 ± 0.05 versus 0.37 
± 0.18) (Figure 4 A and 4B). In contrast, the percentage decrease in 11C-sorafenib 
VT between baseline and on treatment scans was not associated with clinical 
outcome (stable disease -58% ± 26% versus progressive disease -34% ± 55%).
Comparison of LC-MS/MS and 11C-sorafenib PET Results
Sorafenib concentrations in tumor biopsies and plasma after two weeks of 
treatment as measured using LC-MS/MS are presented in Table 1. In plasma, 
the median sorafenib concentration was 6680 µg∙L-1 (range: 4860-9610 µg∙L-1). 
The median sorafenib concentration in tumor biopsies was 5700 µg∙L-1 (range: 
3000-13400 µg∙L-1), which was lower than in plasma in 4 out of 8 patients. 
There was no correlation between plasma and tumor sorafenib concentrations 
(rs = 0.607, P = 0.148). PET derived tumor 
11C-sorafenib VT both at baseline and 
during therapy were not correlated with corresponding LC-MS/MS measured 
sorafenib concentrations in tumor biopsies (rs = -0.429, P = 0.337 at baseline 
and rs = -0.250, P = 0.589 at day 14) (Figure 5A). In addition, the calculated 
tumor-to-plasma concentration ratio of sorafenib after therapeutic dosing 
was not related to 11C-sorafenib VT (baseline as well as day 14 rs = -0.357, 




and on treatment PET were not correlated with sorafenib concentrations 
in tumor biopsies (rs = -0.500, P = 0.267), nor with the calculated tumor-to-
plasma concentration ratio of sorafenib after therapeutic dosing (rs = -0.321, 
P = 0.498). Moreover, plasma and tumor concentrations of sorafenib measured 
with LC-MS/MS during treatment were not associated with treatment outcome 
(plasma concentrations: 8245 µg/L ± 1930 µg/L versus 6807 µg/L ± 1483 µg/L 
and tumor concentrations: 8725 µg/L ± 4278 µg/L versus 7294 µg/L ± 5486 
µg/L for stable versus progressive disease, respectively).
Tumor Perfusion Effects Measured using 15O-H2O PET
Tumor perfusion, measured using 15O-H2O PET, at baseline could be compared 
with that after 14 days of treatment in five out of eight patients. In the other 
patients only one 15O-H2O PET scan was performed as a result of technical 
problems (n = 2) or early study dropout (n = 1). Higher perfusion of the tumor 
rim at baseline and after 14 days of treatment was associated with higher 
11C-sorafenib VT in the tumor (baseline rs = 0.671, P = 0.020 and day 14 rs = 0.641, 
P = 0.025), (Figure 6A). However, no significant correlation between 11C-sorafenib 
uptake and total tumor perfusion at baseline and after 14 days of treatment 
was observed (baseline rs = 0.574, P = 0.056 and day 14 rs = 0.485, P = 0.058).
Analysis of tumor perfusion and clinical response revealed that patients with 
stable disease had larger decrease in total tumor perfusion (56% ± 23%) after 
14 days of sorafenib treatment than patients with progressive disease (18% ± 
32%) (Figure 6B).
Figure 5. Correlation between tumor 11C-sorafenib VT values and the tumor sorafenib 
concentrations (A) and sorafenib tumor-to-plasma ratio (B) measured with LC-MS/MS.
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Figure 6. Correlation between tumor VT values of 
11C-sorafenib and perfusion of the 
tumor rim (A). Tumor perfusion difference after 14 days of sorafenib treatment in pa-
tients with PD and SD (B).
DISCUSSION
To the best of our knowledge, this is the first clinical study directly comparing 
tracer uptake with drug concentrations after therapeutic dosing measured 
with LC-MS/MS in corresponding tumor biopsies. In contrast to expectations, 
this study showed that sorafenib concentrations in tumors during treatment 
could not be predicted by microdose 11C-sorafenib PET. Both LC-MS/MS and PET 
are very accurate for the quantification of drug concentrations, with low test-
retest variability in the range of 5-10% (10,21,23,24). However, there are biopsy 
and tracer dependent factors that may explain the observed discrepancies 
between LC-MS/MS and PET.
Biopsies only provide one sample of the tumor lesion. In case of intratumor 
heterogeneity this may lead to an under- or overestimation of sorafenib 
concentrations in the whole tumor. Overall, no significant intralesional 
heterogeneity of 11C-sorafenib uptake between the whole tumor and its outer 
rim was established in this study. However, in larger tumors, regional differences 
in 11C-sorafenib uptake were seen (Figure 3), supporting sample effects as a 
potential contributing factor to the discrepancies observed between LC-MS/
MS and PET.
Another reason for discrepancies between LS/MS-MS and PET may be 
tracer dependent. Linearity in tumor pharmacokinetics, in other words dose 




therapy was not observed in this study (Table 1). Non-linearity has been reported 
in 27% of the ascending drug dose studies by comparison of plasma drug 
concentrations, which can be due to the levels of drug transporters, metabolic 
enzymes and drug-target occupation (25,26).
First, drug transporting systems may become (partially) saturated after 
(prolonged) exposure to therapy in comparison to the tracer dose. Sorafenib 
is a substrate for organic anion and cation transporters, but uptake mostly 
depends on passive diffusion into cells (27,28). In addition, sorafenib is a 
substrate for efflux transporters, in particular breast cancer resistance protein 
(BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1). Sorafenib has demonstrated 
capacity to inhibit BCRP and P-gp in a dose-dependent manner (29,30). This 
could potentially result in less tumor efflux of higher concentrations sorafenib. 
However, the affinity of sorafenib for these efflux transporters has shown to be 
weak and therefore tumor accumulation is not likely influenced by transporter-
mediated alterations (27 ). The 11C-sorafenib VT in this study, which did not 
increase after 14 days of treatment, was consistent with this (Table 1).
Second, sorafenib is metabolized in the liver by uridine diphosphoglucose-
glucuronosyltransferase 1A9 (UGT1A9) to sorafenib glucuronide and by CYP3A4 
to the active metabolite sorafenib N-oxide (31). Saturation of these enzymes 
could add to the non-linearity. 11C-sorafenib accumulated predominantly in 
the liver, however metabolite release to the bloodstream was very low (< 5%) 
as a result of rapid biliary excretion (31). Although therapeutic administration 
of sorafenib significantly reduced tracer uptake in the liver (P = 0.018) and 
increased available 11C-sorafenib in the blood pool (P = 0.018), this did not result 
in increased tumor accumulation of 11C-sorafenib after 14 days. In fact, tracer 
uptake decreased in most tumor lesions at day 14 (P = 0.007), most probably 
caused by competition of the microdose with the much higher concentrations 
of unlabeled sorafenib after therapeutic dosing.
Finally, another potential cause for the different results between tracer uptake 
and sorafenib concentrations after therapy may consist of the complex drug-
target binding characteristics of this multikinase inhibitor with fast reversible 
as well as slow (ir)reversible target binding sites. Previously, the target binding 
kinetics of sorafenib have shown to be slower than for sunitinib and lenvatinib 
for example and therefore the 1 hour scanning time may have been too short to 
reflect drug-target occupation after 14 days of continuous sorafenib treatment 
(32,33). Overall, sorafenib showed low accumulation in tumors. A recent study 
in mice also demonstrated that sorafenib had significantly less intratumoral 
drug accumulation in comparison with other anti-angiogenic drugs (8), which 
may in part be attributed to sorafenib ’s higher protein bound fraction in blood 
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(> 99%) and its strong binding affinity for albumin, as it is assumed that only 
the free (unbound) drug can induce a pharmacologic effect (34,35). In only 3 of 
the 8 patients 11C-sorafenib accumulation was higher in tumors than in plasma, 
which was correlated with increased perfusion of the tumor rim (for the whole 
tumor this was only borderline significant, presumably a result of central tumor 
necrosis).
Higher 11C-sorafenib accumulation in tumors at baseline or after 14 days of 
sorafenib treatment was not related with treatment benefit. On the contrary, 
clinical benefit was associated with lower 11C-sorafenib uptake in tumors, which 
may be a result of the lower tumor perfusion observed in these patients. This is 
a prognostic rather than a predictive imaging finding and in line with previous 
studies showing that higher expression of pro-angiogenic factors such as VEGF 
and VEGFR 1-3 and increased tumor vascularity were associated with poorer 
prognosis in patients with hepatocellular carcinoma, renal cell carcinoma and 
follicular thyroid carcinoma (36-39). Some other microdose drug tracers, such 
as 11C-erlotinib and 11C-docetaxel, showed that higher tracer accumulation in 
tumors was in fact correlated with treatment benefit (9,40). The tracer signal of 
11C-sorafenib is more complex as it binds to multiple pharmacological targets 
with different affinity and the signal may be dominated by some targets, while 
other targets with less affinity may lead to stronger anti-tumor effects and 
these target effects may also differ between different tumor types (41,42). In 
addition, neither LC-MS/MS measured sorafenib concentrations in plasma nor 
tumor biopsies during therapy were useful predictors of clinical response in this 
exploratory study. Possibly, because the current tumor concentrations achieved 
with sorafenib therapy already induce sufficient protein kinase inhibition (42). 
However, another explanation may be that tumor concentrations reached 
with the current therapeutic schedule are in fact too low, resulting in overall 
marginal clinical activity. Consequently, even higher tumor concentrations may 
be necessary to improve the anti-cancer effects of sorafenib. Preclinical and 
clinical studies have indeed shown that higher levels of sorafenib exposure, 
in comparison with the levels reached with standard sorafenib dosing, are 
associated with improved anti-tumor activity, but dose escalation is limited 
by the toxicity of sorafenib (43-45).
The current exploratory study showed preliminary evidence for the value of 
15O-H2O PET in early response prediction to sorafenib treatment. After only 2 
weeks of treatment, tumor blood flow decreased more in patients with clinical 
benefit as compared with patients with progressive disease (56 versus 18%). 
Although these results are limited by the small cohort size of this study, it is in 
line with other angiogenesis inhibitors. For example, early reduction in tumor 




patients treated with bevacizumab and sunitinib (46,47). Thus, early decrease in 
tumor perfusion may have predictive value for outcome of sorafenib treatment. 
Given the potential benefit for patients of early response prediction, this finding 
warrants further investigation.
CONCLUSION
In conclusion, microdose 11C-sorafenib PET was not useful for the prediction 
of intratumoral sorafenib concentrations during treatment measured with 
LC-MS/MS. However, there was preliminary evidence for an association between 
a decrease in tumor perfusion after only 2 weeks of sorafenib therapy and 
clinical benefit. This warrants further investigation to assess its value as an 
early biomarker for sorafenib efficacy.
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SUPPLEMENTAL MATERIAL
Supplement table S1. In- and exclusion criteria
Inclusion Criteria Exclusion Criteria
- Eastern Cooperative Oncology Group performance 
status 0-2
- One or more extrahepatic tumor lesion(s) 
measurable according to RECIST version 1.1 (19)
- Hemoglobin > 6.0 mmol/L
- Absolute neutrophil count (ANC) > 1.5 x 10*9/L
- Platelet count ≥ 100 x 10*9/L
- Total bilirubin < 2 times the upper limit of normal 
(ULN)
- Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) < 2.5 x ULN or < 5x ULN 
in case of liver metastases (except for patients 
with hepatocellular carcinoma, then Child Pugh 
classification A-B)
- Serum creatinine eGFR ≥ 50 mL/min
- Evidence of serious 
uncontrolled 
concomitant disease 
(such as infections, 
cardiovascular, 
pulmonary, skin and 
central nervous system 
diseases)
- Major surgery < 28
- Thromboembolic events 
< 3 months
Supplement table S2. Method to measure blood 11C-sorafenib concentrations and 
metabolites
Method
- For 11C-sorafenib, whole blood (0.5 mL) was weighed in duplicate and after 
centrifuging (5 minutes; 7°C; 4000 rpm)
- Plasma was collected and 0.5 mL was weighed in duplicate
- Solid phase extraction and high performance liquid chromatography (HPLC) were 
used to separate parent compound and radiolabeled metabolites and determine 
their fractions in the samples. Therefore, 1 mL plasma was diluted with 2 mL 0.15M 
HCl and transferred to a Waters Sep-Pak tC18 SPE column. The cartridge was 
washed with 5 mL of water and eluted with 1.5 mL of methanol
- This eluate was injected onto a Phenomenex Luna C18 5 µm 250 x 10 mm with a 
flow of 4 mL∙min-1. The gradient system was a mixture of acetonitrile (A) and 0.1% 
trifluoroacetic acid (B) and was programmed as follows: t = 0 min 90% B, t = 9 min 
20% B, t = 12 min 20% B, t = 15 min 90% B
- Fractions were collected and measured for radioactivity with a gamma-counter to 




Supplement figure S1. Correlation between tumor VT values of 
11C-sorafenib derived 
from the arterial blood sampler input function (BSIF) and those obtained using the less 
invasive image derived input function (IDIF). A VOI of 12 voxels in 3 planes was drawn 
in the left ventricle of the heart to measure 11C-sorafenib concentrations in the blood 
pool to serve as IDIF. IDIFs were corrected for calibration, plasma to whole blood ratios 
and metabolites using the manual venous samples similarly to BSIF with arterial sam-
ples as described above. The non-invasive IDIF showed excellent correlation with the 
arterial BSIF, therefore IDIF can be used as a non-invasive alternative of BSIF to measure 
11C-sorafenib VT in tumor lesions.
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Supplement figure S2. Schematic diagram of the most frequently used compartment 
models: the single tissue compartment model (A), the irreversible two tissue compart-
ment model (B) and the reversible two tissue compartment model (C). K1 represents 
transport from plasma to tissue and k2 from tissue to plasma and; k3 and k4 describe 
the exchange between free and bound tissue fractions. Typical 11C-sorafenib tumor 
time-activity curves (blue circles) are fitted to plasma input (red line) according to these 
three models (green lines) and are shown for the peaks (0-8 minutes) and the complete 
time-activity curves (0-60 minutes). Akaike and Schwartz criteria showed preference for 
the reversible two tissue compartment model in 68% of the tumor lesions, as compared 
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Background: (Pre)clinical evidence is accumulating that intermittent exposure 
to increased doses of protein kinase inhibitors may improve their treatment 
benefit. In this phase I trial, the safety of high-dose, pulsatile sorafenib was 
studied.
Patients and Methods: High-dose sorafenib was administered once weekly in 
exposure escalation cohorts according to a 3+3 design. Drug monitoring was 
performed in weeks 1-3 and doses were adjusted to achieve a predefined target 
plasma Area Under the Curve (AUC)(0-12h). The effect of low gastric pH on 
improving sorafenib exposure was investigated by intake of the acidic beverage 
cola.
Results: Seventeen patients with advanced malignancies without standard 
treatment options were included. Once weekly, high-dose sorafenib exposure 
was escalated up to a target AUC(0-12h) of 125-150 mg/L/h, achieving a ~2-
fold higher Cmax compared to standard continuous dosing. Dose limiting 
toxicity was observed in 3 patients: grade 3 duodenal perforation (2800 mg 
sorafenib), grade 5 multiorgan failure (2800 mg sorafenib) and grade 5 biliary 
tract perforation (3600 mg sorafenib). The mean difference between observed 
and target AUC(0-12h) was 45% (SD±56%) in week 1 using a fixed starting dose 
of sorafenib compared to 2% (SD±32%) in week 3 as a result of drug monitoring 
(P=0.06). Dissolving sorafenib in cola, instead of water, did not improve sorafenib 
exposure. Clinical benefit with stable disease as best response was observed 
in two patients.
Conclusion: Treatment with high-dose, once weekly sorafenib administration 
resulted in dose limiting toxicity precluding dose escalation above the exposure 
cohort of 125-150 mg/L/h. Drug monitoring was a successful strategy to pursue 
a target exposure.
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INTRODUCTION
Sorafenib is an oral multikinase inhibitor, originally developed as an inhibitor 
of RAF kinases [1]. Besides activity against C-RAF, B-RAF and mutant B-RAF, it 
also inhibits vascular endothelial growth factor receptors 1, 2 and 3, platelet 
derived growth factor receptor β, FMS-like tyrosine kinase 3, c-Kit protein and 
RET receptor tyrosine kinase at low concentrations [2]. At high intracellular 
concentrations, sorafenib has affinity for multiple other kinases [3]. Sorafenib 
is currently approved for the treatment of renal cell carcinoma, hepatocellular 
carcinoma and iodine refractory thyroid cancer at a standard fixed dose of 400 
mg twice daily in a continuous schedule [4-7]. However, at this standard fixed 
dose large interpatient variability in drug exposure was demonstrated after 
both single and multiple doses [8].
Increased sorafenib exposure is associated with improved efficacy [9, 10]. Dose-
escalation of sorafenib to 600 mg twice daily after failure of standard dosing 
in patients with progressive renal cell carcinoma resulted in tumor reduction 
in 42% of the patients [9]. In addition, intrapatient dose-escalation in patients 
without substantial toxicity showed that a higher area under the concentration-
time curve (AUCmax > 100 mg/L/h) of sorafenib was associated with longer 
progression free survival (PFS) [10]. Unfortunately, toxicity limits further dose 
escalation of the continuous schedule [8].
An alternative approach to achieve high exposure, with less toxicity, may be 
high-dose, pulsatile administration of protein kinase inhibitors [11, 12]. Recently 
we showed promising preclinical and clinical benefit of an alternative high-
dose treatment regimen of sunitinib [13]. Also, promising preclinical results for 
high-dose sorafenib were reported. In mice bearing 789-O renal cell carcinoma 
xenografts such a schedule exhibited increased reduction of tumor perfusion 
and microvessel density as well as slower tumor growth in comparison to 
continuous conventional dosing [14].
An important challenge for optimizing high-dose sorafenib administration is the 
amount of drug absorption in the gastro-intestinal tract. Sorafenib absorption is 
saturable > 800 mg/day in a daily continuous schedule. However, a moderate fat 
meal (in comparison to a high fat meal of ≥ 50% fat) and multiple divided doses 
per day have shown to improve the absorption of sorafenib by 30% and 50%, 
respectively [15, 16]. The influence of gastric pH on the absorption of sorafenib is 
less clear, although the solubility of sorafenib increases with decreasing pH and 
ranges from 0.034 mg/100 mL at pH 1.0 to 0.013 mg/100 mL at pH 4.5 [17-19]. 
Thus, the administration of an acidic beverage such as classic cola, with a pH of 




Based on these considerations we initiated a clinical phase I study with high-
dose, pulsatile sorafenib. Weekly pulses of high sorafenib exposure over a 12 hour 
window (AUC(0-12h) were pursued in an attempt to improve clinical efficacy. 
To overcome saturation of absorption we applied dose fractioning (portions 
of 200-400 mg administered at 2 hour intervals), a standardized moderate fat 
diet, and investigated the effect of cola on sorafenib bioavailability. Sorafenib 
exposure was determined during 12 hours following ingestion of the last dose 
fraction. Finally, administration of the same dose was anticipated to result in 
large variability in sorafenib plasma AUC(0-12h) per patient [8]. Therefore, drug 
monitoring was performed during week 1-3 to titrate the patients individual dose 




Eligible were patients with a pathologically confirmed solid malignancy 
refractory to standard therapy or for whom no standard therapy existed. 
Patients had to be ≥ 18 years of age with an Eastern Cooperative Oncology 
Group Performance of ≤ 1. Required laboratory values at entry included 
hemoglobin ≥ 5.6 mmol/L, absolute neutrophil count ≥ 1.5 x 10*9/l, platelet 
count ≥ 100 x 10*9/l, total bilirubin ≤ 1.5 times the upper limit of normal (ULN), 
ALT and AST ≤ 2.5 x ULN (in case of liver metastases: ≤ 5 times ULN), serum 
creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 ml/min (based on MDRD), 
albumin > 25 g/L, PT-INR/PTT < 1.5 x ULN (unless coumarin derivatives were 
used), activated partial thromboplastin time < 1.25 x ULN.
The main exclusion criteria were other anticancer therapies within 4 weeks (6 
weeks for nitrosoureas and mitomycin C); evidence of serious uncontrolled 
concomitant disease (such as cardiovascular disease, nervous system disease, 
pulmonary disease, gastrointestinal disorders or active bacterial, viral, fungal 
or mycobacterial infections); uncontrollable hypertension (> 160/95 mmHg), 
prior radiotherapy on the abdominal or thoracic area or on > 3 vertebrae; major 
surgery within 4 weeks; pregnancy or breast feeding. If applicable, patients 
were required to take contraceptive precautions while on the trial and for 6 
months afterwards.
All patients gave written informed consent before study entry and the 
local medical ethics committee of the Amsterdam UMC, location VUmc 
(Medisch Ethische Toetsingscommissie VUmc), approved the study. The study 
(NCT02636426) was conducted in accordance with the Declaration of Helsinki 
and Good Clinical Practice guidelines.
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Study design and treatment plan
This single center phase I study was conducted at the Amsterdam UMC, 
location VUmc, the Netherlands. High-dose sorafenib was administered once 
weekly in exposure escalation cohorts that consisted of 3-6 patients using a 
standard 3 + 3 design. Drug monitoring was performed in weeks 1-3 and doses 
were adjusted a maximum of 2 times if necessary, to achieve the predefined 
target plasma AUC(0-12h) of the cohort. The starting exposure level was 25-50 
mg/L/h, analogous to the continuous schedule [23], and was escalated in 
subsequent cohorts with increments of 25 mg/L/h.
The primary objective was to investigate the maximum tolerated plasma AUC(0-
12h) of high-dose, pulsatile sorafenib and its safety and tolerability. Secondary 
objectives were (1) the pharmacokinetic behavior, (2) the influence of cola on 
sorafenib exposure, (3) the feasibility of drug monitoring to achieve the target 
plasma AUC(0-12h) and (4) preliminary evidence of improved anticancer activity 
with high-dose pulsatile sorafenib treatment of this alternative sorafenib 
treatment strategy.
The total weekly dose sorafenib was divided in portions of 200-400 mg and 
given every 2 hours to prevent saturation of absorption and to result in a high 
plasma peak concentration at the end of all ingested portions. Each dose was 
dissolved in either a large glass of water or classic Coca-Cola (the Coca-Cola 
Company, Atlanta GA) (~240 ml). Furthermore, patients used a standard low-
fat diet (± 14 g fats, 100 g proteins, 1800 kcal) with as well as between doses 
on the day of administration to optimize the absorption and bioavailability of 
sorafenib.
Patients continued study treatment until unacceptable toxicity, disease 
progression or the patient’s request to stop. Evaluable patients had to be 
treated for a minimum of 2 weeks or would otherwise be replaced by an 
additional patient.
Safety assessment
Safety and tolerability assessments, including physical examination, ECG and 
blood hematology and chemistry, were performed weekly during the first 8 
weeks and once every 4 weeks thereafter. Adverse events (AEs) were graded 
according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 4.0.
Dose (/exposure) limiting toxicity (DLT) was defined as any grade 3 toxicity 




study drug. The maximum tolerated exposure (MTE) was defined at the highest 
exposure level at which ≤ 33% of patients experienced DLTs.
Tumor response measurements
Tumor response was assessed by computed tomography or magnetic resonance 
imaging at baseline and every 8 weeks thereafter using RECIST version 1.1 [24].
Pharmacokinetic analysis
During the first 3 weeks of study treatment, blood samples for measurement of 
sorafenib and its active metabolite sorafenib N-oxide were taken prior to each 
dose (i.e. prior to each portion of the total weekly dose given every 2 hours) and 
1, 2, 3, 4, 8, 12 and 60-96 hours after the last dose.
The plasma concentrations of sorafenib and sorafenib N-oxide were determined 
using a validated liquid chromatography-tandem mass spectrometry method 
[25]. The sorafenib and sorafenib N-oxide plasma AUC(0-12h) were determined 
from the time of the last sorafenib tablet ingestion until 12 hours afterwards with 
a non-compartmental method. Within 72 hours after ingestion, the sorafenib 
AUC(0-12h) was established by our department of Clinical Pharmacology and 
Pharmacy and if necessary, the dose was adjusted accordingly to achieve the 
target AUC(0-12h) of the exposure cohort. Per patient a maximum of 2 dose 
adjustments were permitted. In addition, the maximum concentration (Cmax) 
and time of maximum concentration (Tmax) were determined.
Statistical considerations
Descriptive statistics were used to describe patient characteristics, treatment 
administration, safety, efficacy and pharmacokinetic data. Progression-free 
survival (PFS) was defined as the time from first treatment until progression 
of disease or death as a result of any cause. Fisher’s exact tests were used to 
assess correlations between exposure level or dose and frequency of AEs. A 
paired t-test was used to investigate the effect of personalized dose titration 
on achieving the target sorafenib AUC(0-12h). Last, a Mann Whitney test was 
used to investigate the effect of cola on dose normalized (to a standard dose 
of 800 mg sorafenib) plasma sorafenib Cmax and AUC(0-12h) levels. Data were 
considered significant at P < 0.05.
RESULTS
Patients and treatment
Seventeen patients with progressive metastatic malignancies were enrolled 
between November 2015 and December 2017. Patient characteristics are shown 
in Table 1. A total number of 114 weekly cycles sorafenib were administered with 
a median of 7 cycles per patient (range 1-24).
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Table 1. Patient Characteristics
Characteristic Number of patients, N = 17
Age (years)






































3 (1 patient prior used standard dose sorafenib)
Number of prior systemic regimens
Median (range) 2 (0-6)
Patients were treated at target AUC(0-12h) levels from 25-50 to 125-150 mg/L/h. 
Because the first exposure cohort (AUC(0-12h) 25-50 mg/L/h) already resulted 
in higher sorafenib exposure than expected (median AUC(0-12h) 71, range 61-103 
mg/L/h), the second exposure cohort was set at 75-100 mg/L/h. In subsequent 
cohorts, target exposure levels were increased with steps of 25 mg/L/h (Table 2).
Reasons for treatment discontinuation were disease progression (N = 11), 
treatment related toxicity (N = 3), completion of the study protocol i.e. 
treatment discontinuation because ≥ 33% of patients experienced DLTs in 
that cohort (N = 1), patient withdrawal (N = 1) and a pathological bone fracture 
(N = 1). The latter two patients were considered non-evaluable as described in 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adverse events which were at least possibly related to high-dose sorafenib are 
summarized in Table 3. Most common clinical toxicities were fatigue (67%), 
nausea (67%), vomiting (53%) and diarrhea (27%). These grades 1-2 toxicities 
typically started 1-2 days after sorafenib administration and were manageable 
with standard supportive care measures.
Serious adverse events were predominantly observed in the gastro-intestinal 
tract. At the target exposure level of 75-100 mg/L/h, 1 patient developed grade 
5 biliary tract perforation after 3 cycles of treatment (sorafenib dose was 3600 
mg with an observed AUC(0-12h) of 182 mg/L/h). The cohort was expanded to 
6 evaluable patients, but no further DLT occurred. At the subsequent 100-125 
mg/L/h target exposure level, 3 patients were treated without DLT. However, a 
DLT occurred in 2 out of 3 patients in the 125-150 mg/L/h cohort. One patient 
developed grade 3 duodenal perforation after 2 cycles of treatment (sorafenib 
dose was 2800 mg with an observed AUC(0-12h) of 54 mg/L/h). The other 
patient suffered from grade 5 multiorgan failure after 2 cycles of treatment 
(sorafenib dose was 2800 mg with an observed AUC(0-12h) of 47 mg/L/h) and 
died. At that point the phase I study was preliminary terminated because 
these serious toxicities precluded further dose escalation and investigation of 
a potential benefit of a high-dose, pulsatile approach.
Overall, the frequency and rate of grade ≥ 3 AEs increased with a higher dose 
of sorafenib (P = 0.003 and P = 0.008, respectively) but did not increase with 
higher exposure (P = 0.43 and P = 0.70, respectively). Grade ≥ 3 AEs developed 
from doses ≥ 2800 mg/week. Dose interruptions were required in 5 (33%) 
patients, of which 3 (20%) were due to the previously reported DLTs leading to 
permanent study discontinuation.
Pharmacokinetics
Plasma samples for pharmacokinetic analyses were available from all 17 
included patients and results are summarized in Table 3. Mean exposure 
increased with higher sorafenib doses up to 2400 mg per week, after which 
no additional increases were seen. This is possibly related to a saturation of 
uptake in the gastro-intestinal tract. The increases were similar for AUC(0-
12h) as well as Cmax throughout the escalating exposure cohorts. In the current 
phase I study, highest exposure levels were up to 204 mg/L/h (SD ± 113 mg/L/h) 
with a Cmax up to 21.0 mg/L (SD ± 11 mg/L), reached at median 7 hours after 
ingestion (range 1-12 hours). The plasma concentration time curves of sorafenib 
showed a biphasic pattern, which has been described previously, and is most 
likely caused by biliary excretion and the enterohepatic cycle (Figure 1). No 
accumulation of sorafenib was seen a week after each ingestion. The major 
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metabolite of sorafenib, sorafenib N-oxide, comprised approximately 4% of 
the parent drug and showed similar Cmax and AUC(0-12h) patterns compared to 
sorafenib (Supplementary Figure S1).
Figure 1. A High-dose, pulsatile sorafenib plasma concentrations (mean ± SD) in week 
1 using a standard fixed dose for each cohort (N = 17, black dots are time points of 
sorafenib ingestion) and B shows the effect of drug monitoring (N = 12, each colored 
symbol represents an individual patient followed in weeks 1-3).
At start of treatment, with a pulsatile fixed high-dose, sorafenib exposure 
showed large interpatient variability with a mean difference between observed 
and target AUC(0-12h) of 45% (SD ± 56%) in week 1 (Figure 1). Personalized dose 
titration resulted in a mean difference between observed and target AUC(0-12h) 
of 2% (SD ± 32%) in week 3. The difference between week 1 and week 3 showed 
a trend towards an improved prediction of exposure (P = 0.06).
All patients in this phase I study used proton pump inhibitors (PPI) for various 
reasons, which could decrease sorafenib absorption as a result of an increasing 
gastric pH. In order to lower the pH, sorafenib was dissolved in cola, but this 
did not lead to an increase in sorafenib AUC(0-12h) or Cmax compared to patients 




Figure 2. Effect of cola on sorafenib absorption. Cola did not affect sorafenib AUC(0-
12h) (A) or Cmax (B) Black and red dots represent sorafenib dissolved in water and cola, 
respectively.
Treatment efficacy
Thirteen patients were evaluable for response. As best response, 2 patients 
(15%) had stable disease: a patient with cholangiocarcinoma for a duration of 
3 months and treated at the target exposure level of 75-100 mg/L/h (sorafenib 
dose was 2400 mg/week and observed AUC(0-12h) was 100 mg/L/h in week 3) 
and another patient with hepatocellular carcinoma for a duration of 5.5 months, 
who was treated at the target exposure level of 100-125 mg/L/h (sorafenib dose 
was 4800 mg/week and observed AUC(0-12h) was 94 mg/L/h in week 3). The 
latter patient was previously progressive during treatment with sorafenib at the 
standard continuously dosed schedule. Eleven patients (85%) had progressive 
disease. No complete or partial responses were observed.
Discussion
In this phase 1 study, a high-dose, intermittent sorafenib schedule was 
investigated and dose escalation was performed according to a novel 
concept, i.e. based on escalating sorafenib plasma AUC(0-12h) levels, instead 
of conventional dose escalating cohorts. The aim was to reach the highest 
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tolerable plasma sorafenib peak concentration supposed necessary for the 
highest intratumoral concentration to improve blockade of tumor kinase 
targets. With the standard continuous sorafenib schedule of 400 mg twice 
daily, mean sorafenib exposure varied from 21.8-107 mg/L/h on day 1 and 47.8-
71.7 mg/L/h at steady state, while mean Cmax values ranged from 2.9-3-4 mg/L 
on day 1 to 5.4-9.4 mg/L at steady state, which was reached approximately 3 
hours after ingestion (range 0-24 hours) [8, 26]. High-dose pulsatile sorafenib 
resulted in a Cmax up to 21.0 mg/L (SD ± 11 mg/L), i.e. approximately 7-fold and 
2-fold higher in comparison to a single dose and continuous standard dosing, 
respectively.
A few other protein kinase inhibitors have been investigated in a high-dose, 
pulsatile schedule. High-dose erlotinib administered at a dose of 2000 mg 
per week in NSCLC patients was well tolerated and resulted in a mean overall 
survival (OS) of 9.5 months [27]. Another phase II study investigated high-dose 
erlotinib 450 mg every three days or the EGFR-inhibitor gefitinib 1000 mg every 
four days in patients with known EGFR-mutations and disease progression after 
treatment with conventional dose erlotinib or gefitinib [28]. Treatment was well 
tolerated and resulted in a median PFS of 6 months in both groups and response 
rates of 15 and 21%, respectively. In addition, a phase I study escalating the 
HER2-inhibitor lapatinib in heavily pre-treated patients with HER2-positive 
breast cancer to 7000 mg on days 1-5 of repeating 14-day cycles showed an 
objective response rate in 15% of the patients [29]. We recently investigated 
the multikinase inhibitor sunitinib in a high-dose, pulsatile phase I study in more 
than 70 heavily pre-treated patients with advanced solid malignancies [13]. 
The study showed that a high-pulsatile schedule of 14 times the conventional 
dose of sunitinib was well tolerated and led to an 18-fold higher Cmax. In 
addition, the drug showed promising preliminary efficacy with clinical benefit 
in 63% of the patients, including a PFS of ≥ 5 months in 30% of the patients 
and is currently being investigated in two phase II trials (NCT03909724 and 
NCT03025893). Unfortunately, high-dose, pulsatile sorafenib exposure did not 
achieve sufficiently increased peak concentration levels, which were considered 
necessary for improved efficacy. With only ~3.5 times its conventional dose 
tolerated in a pulsatile schedule, a peak concentration of only 2 times the 
standard Cmax was attained in this study. Drug exposure is influenced by its 
absorption in the stomach which is dependent of factors such as diet and 
pH. The patients ingested sorafenib with a moderate fat meal and multiple 
divided doses of 200-400 mg every 2 hours, to maximize absorption. This 
resulted in increased exposure up to sorafenib doses of 2400 once per week, 
which is 3 times higher than the previously reported saturation > 800 mg 
sorafenib per day using the standard continuous schedule [15]. Regarding the 




sorafenib absorption, varying from no effects to 1/3 reduction of sorafenib 
absorption [17, 18]. We observed that an acidic beverage such as cola did not 
improve sorafenib exposure in patients using a PPI. Previously it was shown that 
erlotinib bioavailability did improve by cola intake in patients using omeprazole 
[20]. However, erlotinib is poorly soluble in water, while the maximal aqueous 
solubility of 0.4 mg/mL, occurs at pH ~2.0 [19]. Thus, the absolute differences 
in solubility for erlotinib dependent on stomach pH are much higher than for 
sorafenib, which ranges from 0.013 mg/100 mL at pH 4.5 to 0.034 mg/100 mL 
at pH 1.0 [17-19].
In this phase 1 study, dose escalation was performed in exposure escalation 
cohorts, instead of conventional dose escalation cohorts, because sorafenib 
exposure has large interpatient variability using a fixed dose [8]. Drug monitoring 
of sorafenib, with a maximum of 2 dose adjustments, resulted in a difference 
of 2% between observed and target AUC(0-12h) compared to 45% at the start 
of treatment using a fixed dose. Although this was only borderline significant 
(P = 0.06) in this small patient group, the feasibility of sorafenib drug monitoring 
to achieve a target exposure, supports this strategy to improve controlled drug 
exposure. Further research is necessary to investigate whether dose titration 
based on exposure will lead to improved efficacy.
Unfortunately, we observed considerable toxicity in this phase 1 study with 
high-dose, intermittent sorafenib. Grade 5 biliary tract perforation was observed 
in a patient treated at the target exposure level of 75-100 mg/L/h, and grade 
3 duodenal perforation and grade 5 multiorgan failure in 2 separate patients 
treated at target exposure level of 100-125 mg/L/h. We found that ≥ grade 3 
toxicity was associated with increased ingested sorafenib dose (doses ≥ 2800 
mg/week), but not with plasma sorafenib AUC(0-12h). Because sorafenib is a 
multikinase inhibitor, including inhibition of angiogenesis, perforation of the 
gastro-intestinal tract is a well-known side effect, but occurs at a low incidence 
in < 1% of the patients treated at the standard continuous schedule [30, 31]. We 
therefore took precautions to prevent perforations by excluding patients with 
previous radiotherapy of the thoracic/bowel region as other studies showed this 
was a risk factor for gastro-intestinal perforation in combination with VEGF-
inhibitors [13, 32, 33]. Several phase I studies have investigated the safety and 
pharmacokinetics of standard dose sorafenib and the most important DLTs 
were skin toxicity, diarrhea and fatigue [23]. However, this was the first study 
to investigate the safety and pharmacokinetics of sorafenib in a high-dose, 
pulsatile schedule, which showed a different DLT profile. The incidence of 
perforation was 13%. The frequency and type of serious toxicities (perforation 
and multiorgan failure) observed at only ~3.5 times the conventional sorafenib 
dose in a weekly schedule, were unexpected and reason for preliminary study 
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termination. This was in contrast to the example of high-dose, pulsatile 
sunitinib, which is also an anti-angiogenic drug and showed tolerability 
comparable to daily administration up to 14 times the conventional dose [13]. 
A possible explanation may be the enterohepatic circulation of sorafenib. 
This encompasses the hepatobiliary excretion of sorafenib and a second 
round of exposure of the intestinal tract to sorafenib with subsequent partial 
reabsorption. Enterohepatic circulation has been observed in animal models for 
sorafenib, but not for sunitinib, and is also an explanation for the biphasic plasma 
concentration time curve typical for sorafenib and observed in the current 
study [16, 34-37]. In addition, in this pulsatile weekly regimen, sorafenib doses 
were divided over consecutive 2-hourly dose administrations. For instance, a 
3600 mg dose was administered as 9 consecutive doses of 400 mg, which was 
done to circumvent the saturable absorption of sorafenib. As a result, local drug 
concentrations in the GI-tract were high during prolonged periods of time and 
may have caused local anti-angiogenic effects in the GI-tract, inducing DLT. 
The sorafenib dose administered is a better measure of local GI-tract sorafenib 
exposure as opposed to the observed plasma concentrations of sorafenib. This 
also explains why adverse events were not associated with sorafenib exposure, 
but rather with sorafenib dose. In contrast to the observed DLT in this study, 
we only observed mild diarrhea (< grade 3) in 27% of the patients. This may 
indicate that the anti-angiogenic effects of high-dose pulsatile sorafenib were 
more pronounced than other cytotoxic effects responsible for diarrhea, such 
as inhibition of the MAPK signaling pathway that can lead to increased chloride 
secretion by the normal GI-mucosa and subsequent secretory diarrhea [38, 
39]. While the pulsatile regimen was targeting high exposure (irrespective of 
dose), the study was discontinued early due to the occurrence of unexpected, 
serious DLT (despite relatively low plasma exposure). These results may help to 
guide the future selection of protein kinase inhibitors suitable for an alternative, 
pulsatile, high-dosing schedule.
In conclusion, we have shown the feasibility of drug monitoring to achieve 
exposure based treatment cohorts for high-dose, pulsatile sorafenib. 
Unfortunately, potentially effective high peak concentrations could not be 
reached due to early toxicity at already lower concentrations than anticipated. 
Dose escalation above the exposure cohort of 125-150 mg/L/h was impossible, 
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This thesis focused on the value of different positron emission tomography 
(PET) imaging techniques visualizing targets and targeted anticancer therapies 
for future treatment tailoring.
In chapter 1, a literature overview showed the possible applications of 
molecular imaging with PET for the improvement of personalized cancer care. 
In PET, a radiotracer consisting of a positron emitting radionuclide attached 
to the biologically active molecule of interest is administrated to the patient 
and its biodistribution throughout the body is detected by the PET-scan. 
Several approaches have been undertaken for direct visualization of the drug 
biodistribution in vivo, for example radiolabeled ligands have been developed 
for target/receptor identification and radiolabeled drugs have been developed 
to investigate intratumoral uptake. Although only a limited number of clinical 
studies with radiolabeled targeted anticancer drugs are available, the results 
indicate that PET imaging of targets and targeted therapies offers opportunities 
for response prediction, early response evaluation and optimization of dosing 
schedules.
Part I visualizing targets: hormone receptor imaging
Part I of this thesis concerned PET imaging of targets: estrogen receptor (ER) 
and androgen receptor (AR) imaging in patients with breast cancer. Correct 
identification of tumor receptor status is important for treatment decisions 
in breast cancer. About 75% of all breast cancers have ER expression, which 
means they can grow in response to the binding of estrogen and it is the main 
predictor of potential response to anti-estrogen therapies.1,2 Recently, also 
AR expression emerged as a possible target for therapy, whilst it is present 
in 70–80% of the patients with breast cancer.3 AR antagonists are currently 
under investigation in multiple breast cancer trials. A tumor biopsy is the 
gold standard to determine receptor expression. However, this is an invasive 
procedure, only gives information about a single lesion, is not always feasible 
in case of inaccessible tumor sites, and is subject to sampling errors.4-6 The 
imaging techniques 16α-[18F]fluoro-17β-estradiol ([18F]FES) PET and 16β- 
[18F]fluoro-5α-dihydrotestosterone ([18F]FDHT) PET have been developed to non-
invasively visualize the ER and AR status respectively, in tumor lesions within 
a patient. In this thesis essential steps were taken in the clinical application 
process of hormone receptor imaging.
In chapter 2, we evaluated whether [18F]FES and [18F]FDHT PET correlated 
with levels of ER and AR expression, respectively, in biopsies of corresponding 
metastases. In this prospective study, a total of 13 patients with metastatic 
breast cancer were analyzed. The amount of [18F]FES and [18F]FDHT uptake, 
respectively, correlated strongly with ER (R2 = 0.78, P = 0.01) and moderately 
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with AR expression levels (R2 = 0.47, P = 0.01) in representative tumor biopsies. 
For [18F]FES PET, the optimal maximum standardized uptake value (SUVmax) cut-
off for ER-positive lesions (more than 1% nuclear staining) was 1.54, resulting in 
a sensitivity and specificity of 100%. For [18F]FDHT, an optimal SUVmax cut-off of 
1.94 was found for AR-positivity (more than 10% nuclear staining), resulting in 
a sensitivity of 91% and specificity of 100%. There was substantial intrapatient 
heterogeneity in tracer uptake, with the majority of patients having both lesions 
with and without uptake of [18F]FES and [18F]FDHT, respectively. In addition, 
hormone receptor conversion in metastases, when compared with biopsies of 
the primary tumor, occurred in 23% of the patients. These results indicate that 
[18F]FES and [18F]FDHT PET have the potential to serve as a surrogate for tumor 
biopsies and have the advantage of being non-invasive techniques that can 
visualize heterogeneous receptor expression of different tumor lesions within 
a patient.
In chapter 3, the visual and quantitative interobserver variability of [18F]FES PET 
and [18F]FDHT PET interpretation were determined in patients with metastatic 
breast cancer. This is an important validation step in the clinical application 
of these new diagnostic tools. Here, we showed that visual and quantitative 
evaluation of [18F]FES PET was highly reproducible between independent 
observers at separate centers using different scanners and software. Visual 
positive and negative absolute agreement was > 80%, with a kappa of 0.67 
(95% CI 0.48-0.87). Intraclass correlation coefficients (ICC) for quantification 
of SUVmax, SUVpeak and SUVmean were 0.98 (95% CI 0.96-0.98), 0.97 (95% CI 
0.96-0.98) and 0.89 (95% CI 0.83-0.92). [18F]FDHT PET showed relatively low 
visual agreement (positive and negative absolute agreement of 49% and 74%, 
respectively and kappa = 0.23, 95% CI -0.04-0.49), presumably a result of 
the lower tumor to background ratios of [18F]FDHT in comparison to [18F]FES. 
However, there was good quantitative agreement between observers (ICCs ≥ 
0.75). This study demonstrated high interobserver agreement of [18F]FES PET 
assessments that support the use of this imaging technique in clinical practice, 
while for [18F]FDHT PET the lower visual agreement underscores the relevance 
of quantitative PET analysis in future breast cancer studies.
The role of [18F]FES and [18F]FDHT PET in addition to conventional diagnostic 
modalities in daily clinical practice needs to be defined further. The non-
invasive visualization of receptor status in different tumor lesions with PET 
offers a number of potential clinical advantages. In patients with metastatic 
breast cancer for example, it can help to establish a final diagnosis in case 
conventional diagnostics cannot, e.g. as a result of inaccessible biopsy sites or 




In addition, in patients with breast cancer amenable for curative treatment 
accurate staging is of great importance. Currently, the staging methods 
comprise of physical examination, mammography, ultrasound of the breast and 
axilla, magnetic resonance imaging (MRI) and, in case of stage IIB, III or recurrent 
disease also 2-[18F]-2-deoxy-D-glucose ([18F]FDG) PET/CT scanning to improve 
lymph node detection and to rule out the presence of distant metastases.7-9 
[18F]FDG PET detects lymph node involvement and distant metastases with 
a sensitivity of 63-100% and 98-100%, respectively.8,10 However, in case of 
biological factors such as low-grade breast cancer or lobular breast cancer, the 
detection accuracy of [18F]FDG PET decreases, leading to inadequate staging.11-13 
In these ER-positive breast cancer subtypes, [18F]FES PET may be of additional 
value to conventional staging.14 We are currently investigating the use of 
[18F]FES PET for staging patients with low grade, ER-positive locally advanced 
or recurrent breast cancer in comparison to [18F]FDG PET (NCT03726931).
Furthermore, in metastatic breast cancer PET imaging may help to determine 
the hormone receptor status of different tumor sites within one patient, which 
may guide treatment decisions. Discordant ER expression between the different 
breast cancer lesions within a patient has previously been described in 15 to 
40% of the patients, and was also observed in our studies.5,6 A single biopsy 
may therefore not be representative for the ER expression in other metastases 
throughout the body and may lead to suboptimal treatment choices for an 
individual patient. Hormone receptor imaging may help to select personalized, 
multimodality treatment strategies for heterogeneous tumor sites of breast 
cancer, such as endocrine therapy for [18F]FES positive lesions combined with 
a local modality such as radiotherapy for concurrent [18F]FES negative lesions. 
Recently, an exploratory study suggested that the extent of [18F]FES PET 
heterogeneity may potentially identify the subset of ER positive, metastatic 
breast cancer patients who will benefit from endocrine therapy combined with 
cyclin-dependent kinase inhibitors.15 The more heterogeneity in intrapatient 
[18F]FES uptake (i.e. more [18F]FES negative lesions), the shorter the progression-
free survival (PFS) and higher risk of progression during endocrine therapy 
alone.16 This is currently being investigated further in the SONImage study that 
aims to develop a [18F]FES/[18F]FDG PET prediction model based on the extent of 
heterogeneity to select patients for endocrine therapy alone or in combination 
with a cyclin-dependent kinase inhibitor (NCT04125277).
Hormone receptor imaging may also help to guide dosing strategies. Inadequate 
reduction of the [18F]FES PET signal (< 75%) by fulvestrant treatment, a selective 
ER downregulator (SERD), has shown to be associated with early progression.17 
Future studies should investigate the role of hormone receptor imaging in drug 
monitoring, for example to establish the effect of higher fulvestrant dosing 
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on patient outcome in the case of incomplete reduction of [18F]FES uptake 
after standard therapy. In addition, hormone receptor imaging has proven 
useful during drug development. For example, in patients with prostate cancer 
[18F]FDHT PET was used to determine the optimal dose of the AR blocker 
enzalutamide in a phase 1 trial.18 In phase I studies involving novel estrogen 
receptor antagonists, such as the oral SERD G1T48 (NCT03455270) and the 
selective estrogen receptor modulator (SERM) GDC0810, [18F]FES PET provided 
information about ER occupancy and helped to select the optimal dosage for 
phase II trials.19
Although the value of ER-blocking therapies for ER-positive breast cancer is well 
established, the exact role of AR and AR-blocking therapies in breast cancer is 
still subject of investigation. Between hormone receptors a level of promiscuous 
DNA binding occurs and practically every binding site of AR in the DNA of breast 
cancer is shared with the ER.20 Both AR agonists and antagonists have shown 
clinical efficacy in the treatment of breast cancer.21-24 Distinct signatures of ER 
and/or AR positivity may be indicative of treatment effects.25 Hormone receptor 
imaging with [18F]FDHT PET may help to guide for which patient with breast 
cancer AR-blocking therapies may be suitable and to visualize the effects of 
androgen blocking therapies in clinical trials (NCT02697032).
However, before clinical implementation of hormone receptor imaging can 
be finalized, some issues need to be addressed. We have shown that visual 
and quantitative [18F]FES uptake correlates well with ER expression levels in 
representative breast cancer biopsies. Although the study had a small sample 
size of 10 patients, these results have recently been confirmed in a larger 
study with 93 patients that showed an excellent positive predictive value of 
[18F]FES PET of 100% and a negative predicative value of 76.6% (CI 66.0-84.6%) 
compared to estrogen receptor status by immunohistochemical assay.26 
Of particular importance in the latter study is the very high specificity of 
[18F]FES PET, with no false-positives, as well as the good concordance with 
immunohistochemical ER assays (ρ = 0·83; p < 0·0001) endorsing it to be an 
alternative to tissue biopsies.26 Currently, in a prospective Dutch multicenter 
trial, the value of [18F]FES PET and [89Zr]trastuzumab PET is being investigated 
for the selection of first line treatment in patients with metastatic breast cancer 
and the optimal SUVmax cut-off point correlating with ER and HER2 positivity in 
tumor biopsies is validated further (NCT01957332).
In this thesis, we presented the first study investigating [18F]FDHT PET in patients 
with metastatic breast cancer. Larger confirmatory studies are necessary 
to validate the cut-off value for [18F]FDHT uptake corresponding with AR 




the physiological background uptake: for [18F]FES in the liver, gallbladder, 
intestine and bladder and for [18F]FDHT also in the blood pool. This hinders 
the evaluation of adjacent tumor lesions. A trial is in progress which examines 
the sensitivity of parametric [18F]FES PET imaging to distinguish background 
activity in healthy liver tissue from uptake in ER positive liver metastases using 
a compartmental approach to estimate the spatial distribution of the kinetic 
parameters governing tracer flow (NCT04150731).
A last issue to light out is that future widespread availability of these new 
imaging techniques in hospitals requires adequate tracer production and 
distribution within the half-life of the tracer (109.8 minutes), standardized 
scanning processes comparable to [18F]FDG PET, and finally training of nuclear 
physicians in the interpretation.27
Part II visualizing targeted anticancer therapies and effects: sorafenib 
imaging
Part II of this thesis focused on PET imaging of the targeted anti-cancer drug 
sorafenib. Sorafenib is an oral multikinase inhibitor with activity against multiple 
targets involved in the growth, angiogenesis and spread of cancer, such as 
C-RAF, B-RAF, mutant B-RAF, vascular endothelial growth factor receptors 1, 
2 and 3, platelet-derived growth factor receptor β, FMS-like tyrosine kinase 3, 
c-Kit protein and RET receptor tyrosine kinase.28 Sorafenib has been approved 
for treatment of locally advanced and metastatic hepatocellular carcinoma, 
renal cell carcinoma and iodine-refractory differentiated thyroid carcinoma 
at a standard fixed dose of 400 mg twice daily in a continuous schedule.29-31 
Recently, its indication has been extended to also include advanced or 
refractory desmoid tumors at a standard fixed dose of 400 mg once daily.32 
However, responses to sorafenib are variable resulting in clinical benefit for 
only a subgroup of patients, while all are exposed to potential toxicity.29-32 Most 
common side effects include gastrointestinal symptoms, fatigue, and (hand-
foot) skin reactions.29-32 Currently, no biomarkers are available to identify which 
patients are likely to benefit from sorafenib.
In chapter 4, we investigated whether [11C]sorafenib PET and [15O]H2O PET 
have the potential to act as predictive/early biomarkers of sorafenib efficacy. 
A response to sorafenib is thought to be directly related to drug concentrations 
achieved in tumor tissue, therefore the primary objective of this study was to 
assess whether microdose [11C]sorafenib PET at baseline or a change in uptake 
after 14 days of treatment (steady state), could predict sorafenib concentrations 
at therapeutic dosing as measured in corresponding tumor biopsies using 
liquid chromatography tandem mass spectrometry (LC-MS/MS) as a reference 
method.33-36 Secondary objectives included the association of [11C]sorafenib 
147
Summary, discussion and future perspectives
uptake, perfusion [15O]H2O PET and sorafenib concentrations after therapeutic 
dosing, with response. In this prospective exploratory study, 8 patients with 
advanced solid malignancies and an indication for sorafenib treatment were 
included. [11C]Sorafenib uptake, measured as the total distribution volume (VT), 
did not predict sorafenib concentrations in tumors during therapy as measured 
in corresponding tumor biopsies with LC-MS/MS. Although sorafenib plasma 
and tumor concentrations, measured with LC-MS/MS, were not associated with 
clinical outcome in this exploratory study, higher [11C]sorafenib accumulation 
in tumors at baseline (0.92 ± 0.61 versus 0.34 ± 0.08) and day 14 of treatment 
(0.37 ± 0.18 versus 0.13 ± 0.05) was associated with worse prognosis and was 
correlated with the perfusion of the tumor (rs = 0.671, P = 0.020). Interestingly, 
[15O]H2O PET demonstrated that patients with stable disease had a greater 
percentage decrease in tumor perfusion (56% ± 23%) after only 14 days of 
sorafenib treatment compared to patients with progressive disease (18% ± 
32%).
To the best of our knowledge, this was the first clinical study directly comparing 
uptake of a tracer with drug concentrations after therapeutic dosing measured 
with LC-MS/MS in corresponding tumor biopsies. For sorafenib, concentrations 
in tumors during treatment could not be predicted by microdose [11C]sorafenib 
PET studies. There are multiple factors that can help to explain these findings, 
such as intratumoral heterogeneity causing differences in outcome depending 
on the exact location of the tumor biopsy, partial saturation of drug transporting 
systems leading to differences in tumor accumulation between microdose and 
therapeutic dose, and slow drug-target binding kinetics after intra-tumor drug 
delivery for which 1 hour scanning time may have been too short to reflect drug-
target occupation after 14 days of continuous sorafenib treatment. In addition, 
the tracer signal of [11C]sorafenib is presumably complex as it binds to multiple 
pharmacological targets and the signal may be dominated by some targets, 
while other targets with less signal may lead to stronger antitumor effects. In 
contrast, there was preliminary evidence that early decrease in tumor perfusion 
as shown with [15O]H2O PET after only 2 weeks of treatment, may be associated 
with response to sorafenib treatment. This is in line with early perfusion 
reduction seen in patients with clinical benefit of other angiogenesis inhibitors, 
such as sunitinib and bevacizumab.37,38 The amount of decrease in tumor 
perfusion may have early predictive value and may guide treatment choices 
before effects on conventional CT can be evaluated. Given the potential benefit 
for patients, this finding warrants further investigation in larger clinical trials. 
In addition to PET, other promising techniques currently under investigation 
as predictive biomarkers for sorafenib response include molecular subtyping, 




For future PET-studies that aim to investigate a dose-response relationship 
between tracer uptake and anti-cancer efficacy, we suggest to start by 
selecting drug tracers with strong affinity for one or a limited number of 
targets and linear, dose proportional pharmacokinetics, so that the microdose 
represents the behavior of the therapeutic dose. For some small molecule 
protein kinase inhibitors, this has already proven successful. A study in ten 
patients with non-small cell lung cancer (NSCLC) investigated the uptake of the 
endothelial growth factor receptor (EGFR) inhibitor [11C]erlotinib in relation to 
EGFR mutations such as exon 19 deletion and exon 21 point mutations, which 
are positively correlated with the anti-tumor activity of erlotinib.45 Compared 
with wild type EGFR, these mutations resulted in a 2–3 fold higher tumor 
binding activity of [11C]erlotinib, p = 0.009, and tumor uptake of this tracer 
correlated well with treatment effects.45 In addition, [11C]afatinib PET has similar 
potential in patients with NSCLC, and showed significantly higher uptake in 
tumors harboring EGFR mutations in comparison to wild type tumours.46 Other 
clinical studies are underway, including [18F]dabrafenib PET in patients with 
BRAF-mutant metastatic melanoma (NCT02700763), [11C]osimertinib PET in 
patients with metastatic EGFR mutated NSCLC (NCT03463525) and recently a 
study investigated [11C]lapatinib PET which showed uptake in brain metastases 
in patients with HER2-positive breast cancer, but not in the normal brain, 
indicative of HER2 targeting across the blood brain barrier.47 In addition to small 
molecule kinase inhibitors, PET imaging with labeled monoclonal antibodies 
has made rapid progress. For example, [89Zr]trastuzumab PET showed to 
support clinical decision making when HER2 status could not be determined by 
standard work-up.48 In addition, [89Zr]rituximab PET in patients with diffuse large 
B cell lymphoma demonstrated a positive correlation between tumor uptake 
and CD20 expression in tumor biopsies.49 Finally, [89Zr]atezolizumab uptake in 
tumors appeared to be a strong predictor of response (including progression-
free and overall survival) to the anti-PD-L1 monoclonal antibody atezolizumab 
in patients with various solid malignancies.50
Chapter 5 was performed to evaluate an alternative dosing schedule of 
sorafenib. In chapter 4 we already showed that in several patients sorafenib 
accumulation in tumors was lower in comparison to plasma. There is growing 
evidence that tumor concentrations reached with the current therapeutic 
sorafenib schedule of 400 mg twice daily are too low, resulting in overall marginal 
clinical activity, and that higher sorafenib exposure may be necessary.51-53 In 
chapter 5, we performed a phase 1 study with high-dose, intermittent sorafenib. 
The aim was to reach the highest tolerable plasma sorafenib peak concentration 
supposed necessary for the highest intratumoral concentration to improve 
blockade of tumor kinase targets and increase sorafenib efficacy based on 
accumulating (pre)clinical literature.51,53-55 Dose escalation was performed 
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according to a novel concept, i.e. based on exposure escalating cohorts, instead 
of conventional dose escalating cohorts, because administration of a fixed dose 
has previously shown to result in large variability in sorafenib plasma area under 
the curve (AUC)(0–12 h) per patient.56 Drug monitoring was performed in weeks 
1-3 and doses were adjusted to achieve a predefined target plasma AUC(0-
12h). An important challenge for optimizing high-dose sorafenib administration 
is the amount of drug absorption in the gastrointestinal tract. Sorafenib 
absorption is saturable > 800 mg/day.57 To overcome saturation of absorption, 
we applied dose fractioning, a standardized moderate fat diet, and investigated 
the effect of cola on sorafenib bioavailability.57,58 A total of 17 patients with 
various advanced malignancies without standard treatment options were 
included. Once weekly, high-dose sorafenib exposure was escalated from a 
target AUC(0–12 h) of 25-50 mg/L/h up to 125–150 mg/L/h, achieving a twofold 
higher maximum plasma concentration (Cmax) compared to standard continuous 
dosing. Dissolving sorafenib in cola, instead of water, did not improve sorafenib 
exposure. Dose-limiting toxicity (DLT) was observed in three patients: at the 
target AUC(0-12h) level of 75-100 mg/L/h 1 out of 6 patients suffered from grade 
5 biliary tract perforation (3600 mg sorafenib) and at the target level of 125-150 
mg/L/h 2 out of 3 patients developed grade 3 duodenal perforation (2800 mg 
sorafenib) and grade 5 multiorgan failure (2800 mg sorafenib), respectively. 
Clinical benefit with stable disease as the best response was observed in 2 
patients. The mean difference between observed and target AUC(0–12 h) was 
45% (SD ± 56%) in week 1 using a fixed starting dose of sorafenib compared to 
2% (SD ± 32%) in week 3 as a result of drug monitoring (P = 0.06). The study 
showed the feasibility of drug monitoring to achieve a target sorafenib AUC(0-
12h). Unfortunately, potentially effective high peak concentrations could not 
be reached due to early toxicity of this sorafenib schedule at lower dosing 
than anticipated; from doses of 2800 mg per day and higher, i.e. 3.5 times the 
conventional dose.
In contrast, a phase I study with high-dose, intermittent sunitinib, another 
inhibitor of angiogenesis, showed tolerability comparable to daily administration 
up to 14 times the conventional dose and promising preliminary efficacy with 
clinical benefit in 63% of the patients, including a PFS of ≥ 5 months in 30% of 
the patients and is therefore currently being investigated in two phase II trials 
(NCT03909724 and NCT03025893).55 Possible explanations for this difference 
in tolerability between high-dose, pulsatile schedules of sorafenib and sunitinib 
may be the enterohepatic circulation of sorafenib, leading to a second round 
of exposure of the intestinal tract, and dose fractioning with multiple doses 
per day once a week, instead of one single dose per day once a week as was 
the case for sunitinib, resulting in high local sorafenib concentrations in the 




help select future targeted therapies suitable for alternative, pulsatile, high-
dosing schedules. Other protein kinase inhibitors have also been subject of 
investigation, including the EGFR inhibitors erlotinib and gefitinib. Erlotinib 
administered at a pulsatile, high-dose of 2000 mg per week in NSCLC patients, 
was well tolerated and resulted in a mean overall survival (OS) of 9.5 months.59 
Another phase II study investigated high-dose erlotinib 450 mg every 3 days 
or the EGFR inhibitor gefitinib 1000 mg every 4 days in patients with known 
EGFR mutations and disease progression after treatment with conventional 
dose erlotinib or gefitinib.60 Treatment was tolerated well and resulted in a 
median PFS of 6 months in both groups and response rates of 15 and 21%, 
respectively. Finally, a phase I study escalating the HER2 inhibitor lapatinib in 
heavily pre-treated patients with HER2-positive breast cancer to 7000 mg on 
days 1–5 of repeating 14-day cycles showed an objective response rate in 15% 
of the patients.61 In addition, a preclinical study has demonstrated improved 
anti-tumor efficacy, including prolonged T-cell activity, of high-dose pulsatile 
MEK-inhibitors.62 Further investigation of these alternative dosing strategies is 
necessary in an attempt to improve the activity of protein kinase inhibitors, 
preferably guided by techniques that can monitor the effects of these dose 
optimizing strategies, such as PET.
Conclusion
To conclude, PET imaging of targets and targeted anticancer therapies leads 
to better understanding of target expression in different tumor lesions within 
one patient and visualization of the tumor accumulation and effects of therapy. 
Although the development of each tracer has challenges, such as its target 
affinity, physiological background uptake and metabolism, concordance 
between tracer uptake and target expression/drug accumulation in tumors, 
physical half-life, scanning logistics, and reliable observer-independent 
evaluation, PET imaging has the potential to lead to progress in personalized 
treatment strategies, which includes dose optimizing strategies and treatment 
(combination) choices for an individual patient with cancer.
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Kanker is de belangrijkste doodsoorzaak na hart- en vaatziekten in Europa 
en heeft zeer grote impact op patiënten, hun dierbaren en de maatschappij: 
ieder jaar krijgen meer dan 3 miljoen patiënten deze diagnose en sterven 
1.7 miljoen mensen als gevolg hiervan. Er zijn de laatste jaren vele nieuwe 
antikankerbehandelingen ontwikkeld, zoals nieuwe zogenaamde doelgerichte 
therapieën (“targeted therapieën”), medicijnen die de groei en deling van 
kankercellen blokkeren doordat ze de werking tegengaan van specifieke 
moleculen (“targets”) die de kankercellen nodig hebben voor hun groei en 
overleving. Bij targeted therapieën wordt gebruik gemaakt van het verschil 
tussen normale lichaamscellen en kankercellen, waar deze targets bijvoorbeeld 
tot (over)expressie komen of in een gemuteerde vorm aanwezig zijn.
Hormoontherapie kan worden beschouwd als de oudste vorm van targeted 
therapie omdat het tegengaat dat een hormoon groei-impulsen kan 
geven aan een hormoonreceptor gedreven tumor, zoals bijvoorbeeld een 
oestrogeenreceptor-positieve borstkanker (mammacarcinoom). De ontdekking 
van nieuwe tumortargets heeft geleid tot de ontwikkeling van diverse 
andere targeted therapieën die bijvoorbeeld groeisignaalroutes blokkeren of 
bloedvatnieuwvorming (angiogenese) van tumoren tegengaan.
Slechts bij de helft van de in de praktijk toegepaste targeted therapieën zijn 
er testen beschikbaar om te voorspellen welke patiënten wel of niet zullen 
reageren op een antikankerbehandeling (predictieve biomarkers). Voorbeelden 
hiervan zijn HER2-receptor overexpressie of een PIC3CA mutatie die aanwezig 
moeten zijn bij patiënten met mammacarcinoom om een potentieel effect te 
kunnen verwachten van respectievelijk HER2-antilichamen of PI3Kα-remmers. 
Echter, ook als dergelijke predictieve biomarkers beschikbaar zijn, bestaan er 
beperkingen bij de toepasbaarheid voor de patiënt. Dergelijke testen worden 
namelijk vooral bepaald in tumorweefsel waarvoor invasieve biopten nodig 
zijn, iets wat niet altijd mogelijk of veilig is door de locatie van de tumor, noch 
patiëntvriendelijk. Soms kan er net naast de tumor, in normaal weefsel, worden 
geprikt (sample errors), waardoor de procedure opnieuw moet plaatsvinden. 
Daarbij kan de expressie van een biomarker veranderen in de loop der tijd 
en verschillen tussen de verschillende tumorlocaties binnen één patiënt. Als 
gevolg hiervan kan één enkel tumorbiopt inadequate informatie geven voor een 
persoonlijk behandelplan. Het is daarom van belang om nieuwe methoden te 
ontwikkelen die het effect van een antikankerbehandeling kunnen voorspellen.
Positron emissie tomografie (PET) is een onderzoek waarbij een radioactieve 
stof (tracer) kan worden afgebeeld in het lichaam. De manier waarop tumoren 
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en normale lichaamsweefsels de tracer opnemen kan hiermee zichtbaar 
worden gemaakt, gemeten en informatie geven over de stof. Deze techniek 
heeft als voordeel dat het in één keer informatie geeft over de verschillende 
tumorlocaties binnen één patiënt op een weinig belastende manier. PET 
imaging kan bijvoorbeeld inzicht geven over de mate van targetexpressie op/
in tumoren en de mate waarin een doelgerichte therapie die gekoppeld is aan 
een radioactieve stof de tumorlocaties in het lichaam bereikt. Dit zou kunnen 
helpen bij het voorspellen van de effecten van een targeted therapie bij een 
individuele patiënt.
Dit proefschrift beschrijft onderzoek naar de waarde van verschillende PET-
technieken om tumortargets en targeted therapieën af te kunnen beelden met 
als doel te beoordelen of deze technieken al dan niet in de toekomst gebruikt 
kunnen worden om de juiste antikankerbehandeling voor een individuele patiënt 
te selecteren.
In Hoofdstuk 1 wordt een introductie en overzicht gegeven van de ontwikkelingen 
op het gebied van PET imaging om antikankerbehandelingen te visualiseren en 
personaliseren. Er zijn tracers in ontwikkeling die tumortargets afbeelden, maar 
ook radioactief gelabelde targeted therapieën zoals proteïne/tyrosine kinase 
remmers (TKI-PET), of grote monoclonale antilichamen (immuno-PET). Hoewel 
er nu nog een beperkt aantal patiëntgebonden onderzoeken gepubliceerd zijn 
over dit onderwerp, tonen deze de mogelijkheden die geboden worden als 
potentiele predictieve biomarker, bij vroege evaluatie van behandeleffecten 
en om doseerstrategieën voor een individuele patiënt te kunnen optimaliseren.
Deel 1 Het visualiseren van tumortargets: hormoonreceptor imaging
Deel 1 van het proefschrift richt zich op PET imaging van tumortargets: de 
oestrogeen receptor (ER) en androgeen receptor (AR) bij patiënten met 
mammacarcinoom. Correcte identificatie van de hormoonreceptorexpressie 
van borstkanker is van belang voor behandelbeslissingen. Bij ongeveer 75% 
van de patiënten met mammacarcinoom is er sprake van ER-expressie. De 
tumorcellen groeien als oestrogeen aan deze receptor bindt en het is de 
belangrijkste voorspeller voor een potentiële respons op hormoontherapie. 
Recent is ook de AR onder de aandacht gekomen als een mogelijke target 
voor therapie bij mammacarcinoom, welke aanwezig is op 70-80% van de 
borstkankers. Verschillende studies onderzoeken op dit moment de waarde 
van AR-blokkerende medicijnen bij de behandeling van mammacarcinoom. 
Een tumor biopsie is de gouden standaard om hormoonreceptorexpressie 
te bepalen. De PET-technieken [18F]fluor-17β-oestradiol ([18F]FES) PET en 16β-
[18F]fluor-5α-dihydrotestosteron ([18F]FDHT) PET zijn ontwikkeld om op non-




patiënt te kunnen bepalen. Dit proefschrift levert een bijdrage aan de validatie 
van hormoonreceptor PET, wat nodig is voor toekomstige toepassing hiervan 
in de dagelijkse praktijk.
In Hoofdstuk 2 staat beschreven in hoeverre [18F]FES en [18F]FDHT PET opname 
overeenkomt met de mate van ER- en AR-expressie gemeten in een biopt 
van eenzelfde tumor laesie bij 13 patiënten met uitgezaaid (gemetastaseerd) 
mammacarcinoom. De mate van [18F]FES en [18F]FDHT opname (maximale 
Standardized Uptake Value, SUVmax) in tumoren, was respectievelijk sterk 
geassocieerd met ER-expressie (R2 = 0.78, P = 0.01) en redelijk geassocieerd 
met AR-expressie (R2 = 0.47, P = 0.01). De optimale [18F]FES afkapwaarde voor 
ER-expressie (gedefinieerd als > 1% kernaankleuring) was een SUVmax van 1.54, 
resulterend in een sensitiviteit en specificiteit van 100%. De optimale [18F]FDHT 
afkapwaarde voor AR-expressie (gedefinieerd als > 10% kernaankleuring) was 
een SUVmax van 1.94, resulterend in een sensitiviteit van 91% en specificiteit van 
100%. Er was heterogeniteit in traceropname tussen de tumorlaesies binnen 
een patiënt, waarbij het merendeel van de patiënten zowel tumorlaesies met 
als zonder traceropname van respectievelijk [18F]FES en [18F]FDHT hadden. 
Ook was er bij 23% van de patiënten receptorconversie aantoonbaar tussen 
biopten van metastasen vergeleken met de primaire tumor. Deze resultaten 
tonen aan dat [18F]FES en [18F]FDHT PET als een non-invasieve surrogaat zouden 
kunnen dienen van invasieve tumorbiopten om de receptorstatus te bepalen 
in de verschillende tumorlaesies binnen een patiënt met borstkanker. Grotere 
vervolgstudies zijn nodig om deze resultaten te bevestigen.
Hoofdstuk 3 beschrijft onderzoek naar de mate van visuele en kwantitatieve 
variabiliteit tussen beoordelaars van [18F]FES en [18F]FDHT PET scans bij 
patiënten met gemetastaseerd mammacarcinoom. Bij visuele beoordeling 
wordt er met het oog gekeken of tumorweefsel meer tracer opneemt dan de 
achtergrondaankleuring in normaal weefsel. Bij kwantitatieve beoordeling wordt 
de hoeveelheid traceropname in (tumor)weefsel daadwerkelijk gemeten en 
uitgedrukt als SUV: de gemeten radioactiviteit in de tumor gecorrigeerd voor 
de hoeveelheid geïnjecteerde radioactiviteit en het lichaamsgewicht. Hiervoor 
werden de volgende SUV-maten gebruikt: SUVmax (de voxel in de tumor met 
de hoogste waarde), SUVpeak (de gemiddelde waarde in een gebied van 1 cm
3 
rondom de heetste voxel van de tumor) en SUVmean met isocontour 50% (de 
gemiddelde waarde van alle voxels in de tumor waarbij de uptake ≥ 50% van 
de SUVmax is). We toonden aan dat er een hoge mate van reproduceerbaarheid 
is tussen onafhankelijke beoordelaars van [18F]FES PET scans in verschillende 
ziekenhuizen waar andere PET-scanners en analyse software wordt gebruikt. 
Het absolute aantal visueel positieve en negatieve consistente waarnemingen 
(positive/negative absolute interobserver agreement) tussen beoordelaars van 
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[18F]FES PET scans was > 80%. Cohen’s kappa (visuele interobserver agreement 
met correctie voor toevalsovereenstemming) was 0.67 (95% CI 0.48-0.87). 
Intraclass correlatiecoëfficiënten (ICC) voor de mate van overeenstemming 
tussen beoordelaars met betrekking tot de kwantificatie van SUVmax, SUVpeak and 
SUVmean waren 0.98 (95% CI 0.96-0.98), 0.97 (95% CI 0.96-0.98) en 0.89 (95% 
CI 0.83-0.92). Voor [18F]FDHT PET werd een relatief lage mate van consistentie 
tussen beoordelaars getoond met betrekking tot visuele waarnemingen. Het 
absolute aantal visuele positieve en negatieve consistente waarnemingen was 
respectievelijk 49% en 74%, waarbij Cohen’s kappa 0.23 was (95% CI -0.04-
0.49). Dit is waarschijnlijk het gevolg van de lagere tumor/achtergrond ratio 
voor de opname van [18F]FDHT ten opzichte van [18F]FES. Echter, er was goede 
overeenkomst tussen beoordelaars met betrekking tot de kwantificatie van 
[18F]FDHT opname (ICC ≥ 0.75). Dit benadrukt het belang van kwantitatieve 
[18F]FDHT beoordelingen bij toekomstig borstkankeronderzoek, terwijl voor 
[18F]FES PET zowel visuele als kwantitatieve beoordelingen reproduceerbaar zijn 
in de dagelijkse praktijk.
De rol van [18F]FES PET bij de behandeling van oestrogeenreceptor-positief 
mammacarcinoom wordt op dit moment onderzocht in verschillende (vervolg)
studies o.a. bij de stadiëring (bepaling van de uitgebreidheid) van borstkanker, bij 
het bepalen van de optimale dosering van nieuwe vormen van hormoontherapie 
en om vast te stellen of de mate van heterogeniteit tussen tumorlaesies binnen 
één patiënt met gemetastaseerde ziekte kan helpen bij keuzes voor het starten 
van endocriene monotherapie, danwel combinatietherapieën.
Deel 2 Het visualiseren van targeted therapieën en effecten: sorafenib 
imaging
Deel 2 van het proefschrift is gewijd aan het medicijn sorafenib. Sorafenib is 
een orale proteïne kinase remmer met activiteit tegen verschillende targets 
betrokken bij de groei, angiogenese en metastasering van kanker zoals de eiwitten 
C-RAF, B-RAF, gemuteerd B-RAF, vasculair endotheliale groeifactor receptoren 1, 
2 en 3, bloedplaatjes afgeleide groeifactor receptor β, FMS-like tyrosine kinase 
3, c-Kit en RET-receptor tyrosine kinase. Sorafenib is in Nederland goedgekeurd 
als behandeling van lokaal gevorderd en gemetastaseerd hepatocellulair 
carcinoom, niercelcarcinoom en gedifferentieerd schildkliercarcinoom dat 
refractair is voor radioactief jodium. Hierbij krijgen patiënten standaard een 
vaste dosering van 400 mg tweemaal per dag continue voorgeschreven. 
Echter, de respons op sorafenib is variabel waarbij slechts een deel van de 
behandelde patiënten daadwerkelijk baat heeft van het medicijn, terwijl alle 
patiënten worden blootgesteld aan mogelijke toxiciteit. De meest voorkomende 
bijwerkingen omvatten onder andere maag-darm klachten, vermoeidheid en 




beschikbaar om te voorspellen welke patiënten baat zullen hebben van een 
behandeling met sorafenib.
In Hoofdstuk 4 wordt onderzoek beschreven naar de waarde van [11C]sorafenib 
PET en [15O]H2O PET als respectievelijk predictieve en vroege biomarker van 
een respons op sorafenib. Voor een antitumor effect moet een adequate 
concentratie van het medicijn de tumor bereiken. Het primaire doel van de 
studie was om te onderzoeken in hoeverre een microdosis [11C]sorafenib 
dynamische PET scan vooraf en na 14 dagen behandeling met sorafenib, de 
concentratie in de tumor kon voorspellen tijdens therapie zoals werd gemeten in 
corresponderende tumorbiopten met zogenaamde vloeibare chromatografie in 
combinatie met tandem massaspectrometrie (LC-MS/MS). In deze prospectieve 
exploratieve studie werden 8 patiënten met verschillende gemetastaseerde 
tumoren geïncludeerd die in aanmerking kwamen voor een behandeling met 
sorafenib. De [11C]sorafenib opname in tumorweefsel vanuit het bloed, gemeten 
als het totale distributievolume (VT), was niet voorspellend (baseline, noch na 14 
dagen behandeling) voor de concentraties sorafenib gemeten in tumorbiopten 
met LC-MS/MS. Bij een minderheid van de patiënten kwam de [11C]sorafenib 
opname en de concentratie sorafenib in de tumor boven die van het plasma 
uit. In deze exploratieve studie waren de concentraties sorafenib die met 
LC-MS/MS in plasma en tumorweefsel werden gemeten ook niet voorspellend 
voor de respons op therapie. Echter, hogere [11C]sorafenib opname in tumoren 
werd gemeten bij patiënten met een slechtere uitkomst (VT voor patiënten 
met progressieve ziekte versus patiënten die klinisch baat hadden van de 
behandeling: baseline 0.92 ± 0.61 versus 0.34 ± 0.08 en na 14 behandeling 0.37 
± 0.18 versus 0.13 ± 0.05). De [11C]sorafenib VT was geassocieerd met de perfusie 
van de tumor (rs = 0.671, P = 0.020). Eerdere studies toonden een associatie 
tussen een hogere mate van tumorangiogenese en een slechtere prognose, 
wat een verklaring kan zijn voor deze bevindingen. Bij patiënten met stabiele 
ziekte op de CT-scan toonde [15O]H2O PET al na 14 dagen therapie een grotere 
percentuele daling in tumorperfusie (56% ± 23%) vergeleken met patiënten 
die progressieve ziekte hadden (18% ± 32%). Huidige responsevaluatie met 
conventionele CT-scans vindt na gemiddeld 12 weken behandeling plaats, 
het is dus van belang dat toekomstige studies de rol van [15O]H2O PET verder 
onderzoeken bij het vroegtijdig (na 2 weken) identificeren van patiënten die 
baat hebben van een behandeling met angiogeneseremmers zoals sorafenib.
In Hoofdstuk 5 wordt een alternatief doseringsschema van sorafenib 
onderzocht. In het vorige hoofdstuk toonden we dat bij de meerderheid van 
de patiënten de sorafenib concentratie in tumoren lager was vergeleken met 
de concentratie in plasma. Ook in eerder dierproefonderzoek is aangetoond 
dat sorafenib een duidelijk lagere tumoraccumulatie toont vergeleken met 
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andere angiogeneseremmers. Een hoge, intermitterende dosering sorafenib 
toonden in muizen een verbetering van de antikankereffecten vergeleken met 
conventionele continue dosering. In dit hoofdstuk wordt een fase I studie 
beschreven waarbij 17 patiënten tabletten sorafenib wekelijks intermitterend 
in een hoge dosering innamen. De hypothese was dat een hogere piekdosering 
zou kunnen resulteren in hogere tumorconcentraties sorafenib en dat dit de 
blokkade van tumor kinase targets en de effectiviteit van sorafenib zou kunnen 
verbeteren. Het hoofddoel was om de hoogst tolereerbare blootstelling aan 
wekelijks sorafenib vast te stellen. Dosisescalatie werd volgens een nieuw 
concept uitgevoerd: door middel van exposure-escalatie cohorten op geleide 
van een na te streven plasmaconcentratie (area under the curve, AUC (0-
12h)) in plaats van conventionele dosisescalatie cohorten. Eerder onderzoek 
toonde namelijk dat een vaste dosis sorafenib resulteert in een hoge mate 
van AUC(0-12h) variabiliteit tussen patiënten. Wij pasten drug monitoring toe 
in week 1 t/m 3 waarbij de doseringen werden aangepast per patiënt om de 
streef AUC(0-12h) van het cohort te bereiken. Een belangrijke uitdaging was 
de absorptie van sorafenib in het maagdarmkanaal. Sorafenib absorptie 
neemt namelijk sterk af bij doseringen > 800 mg per dag. Om de verminderde 
absorptie bij hogere doseringen te kunnen voorkomen werden de wekelijkse 
doseringen gesplitst in meerdere porties die dag (dosis fractionering), werd een 
gestandaardiseerd matig vet dieet gegeven om sorafenib opname te verbeteren 
en werd het effect van klassieke Coca Cola, een zure drank met een pH van 2.5, 
onderzocht op de biologische beschikbaarheid van sorafenib. Totaal werden 17 
patiënten geïncludeerd met diverse gemetastaseerde maligniteiten voor wie er 
geen reguliere behandelingen meer beschikbaar waren. Wekelijks, hoge dosis 
sorafenib exposure kon in stappen worden opgehoogd van streef AUC(0–12 h) 
25-50 mg/L/h tot maximaal 125–150 mg/L/h en dit resulteerde in een maximale 
plasmaconcentratie (Cmax) die tweemaal hoger was vergeleken met standaard 
continue dosering. De biologische beschikbaarheid van sorafenib verbeterde 
niet door dit op te lossen in cola in plaats van water. Dosis limiterende toxiciteit 
(DLT) werd geobserveerd bij 3 patiënten: in het cohort met streef AUC(0-12h) 
75-100 mg/L/h kreeg 1 van de 6 patiënten een graad 5 galwegperforatie (3600 
mg wekelijks sorafenib) en in het cohort met streef AUC(0-12h) 125-150 mg/L/h 
kregen 2 van de 3 patiënten respectievelijk een graad 3 duodenumperforatie 
(2800 mg wekelijks sorafenib) en graad 5 multiorgaanfalen (2800 mg wekelijks 
sorafenib. Stabiele ziekte was de beste behandelrespons in deze studie 
en werd geobserveerd bij 2 patiënten. Het gemiddelde verschil tussen de 
gemeten en nagestreefde AUC(0–12 h) was 45% (SD ± 56%) in week 1 met een 
vaste startdosering vergeleken met 2% (SD ± 32%) in week 3 als gevolg van 
drug monitoring (P = 0.06). De studie toont de uitvoerbaarheid aan van drug 
monitoring om een sorafenib AUC(0-12h) na te streven. Helaas konden er geen 




toxiciteit bij lagere doseringen sorafenib dan geanticipeerd: vanaf een wekelijkse 
doses van 2800 mg en hoger, dus slechts 3.5 maal de conventionele dagelijkse 
dosering sorafenib. Mogelijke verklaringen hiervoor zijn dosisfractionering en de 
enterohepatische kringloop van sorafenib, waarbij na opname en vervolgens 
uitscheiding door de galwegen, de darmen langere tijd worden blootgesteld aan 
sorafenib leidend tot DLT. Deze bevindingen kunnen helpen om toekomstige 
targeted therapieën te selecteren die wel/niet geschikt zijn voor onderzoek met 
alternatieve hoge, intermitterende doseringsschema’s.
Conclusie
PET imaging van targets en targeted antikankertherapieën leidt tot een beter 
inzicht in de targetexpressie van de verschillende tumorlaesies binnen één 
patiënt en maakt het mogelijk om behandelingen en behandeleffecten in het 
lichaam te visualiseren en kwantificeren. De ontwikkeling van iedere nieuwe 
PET tracer heeft diverse uitdagingen, zoals het vaststellen van de affiniteit van 
een tracer voor de target van interesse, de fysiologische achtergrondopname 
en het metabolisme van een tracer in het lichaam, concordantie tussen de 
microdose traceropname en de daadwerkelijke medicijnconcentratie in de 
tumor tijdens behandeling, de logistiek van productie tot aan distributie 
van een tracer rekening houdend met de halfwaardetijd door radioactief 
verval, gestandaardiseerde scanmethoden en betrouwbare, reproduceerbare 
beoordelingen van de scans. Maar, als deze uitdagingen zijn overwonnen kan 
PET imaging tot vooruitgang leiden in behandelstrategieën toegespitst op een 
individuele patiënt met kanker, dit omvat bijvoorbeeld de selectie van een 







Dit proefschrift is mogelijk geworden door de inzet van vele mensen. Hierbij wil 
ik eenieder bedanken voor alle hulp en betrokkenheid in de afgelopen jaren. Een 
aantal personen wil ik daarbij in het bijzonder bedanken.
Op de eerste plaats is mijn dank groot aan alle patiënten die, ondanks hun 
ernstige ziekte en alle onzekerheid die dit met zich meebrengt, aan het 
onderzoek hebben willen deelnemen. Zij ondergingen biopten, scans en 
ziekenhuisopnames voor de wetenschap. Zo vaak hoorde ik: ‘ook al heb ik er 
zelf niks aan, dan hebben jullie hopelijk wat kunnen leren voor de patiënten na 
mij’. Dit getuigt van grote onbaatzuchtigheid en moed. Graag had ik sommige 
uitkomsten van deze thesis anders gezien, grotere stappen voor u willen zetten, 
maar kanker is zo complex.
Natuurlijk wil ik ook mijn (co)promotoren bedanken. Prof. dr. H.M.W. Verheul, 
beste Henk, een hoogleraar die marathons rent in het weekend… Ik herinner 
me nog het eerste gesprek dat we hadden ingeroosterd om te bespreken dat 
ik graag translationeel oncologisch onderzoek wilde doen. Wat binnensmonds 
en voorzien van een lichte frons vertelde je mij dat dit niet gemakkelijk zou zijn 
naast de opleiding, dat hiervoor meerdere jaren moest worden uitgetrokken en 
dit ook in de vrije tijd de nodige investering zou vergen, en dat hier natuurlijk 
ook financiering voor geregeld zou moeten worden. Dankbaar ben ik dat ik de 
kans hiervoor gekregen heb, en de frons was terecht, want een promotietraject 
opzetten en uitvoeren naast een opleiding tot medisch oncoloog is geen 
sinecure, maar deze marathon is nu ten einde. Wat mij verder zal bijblijven is 
jouw manier van “contra-denken”: steevast de compleet tegenovergestelde 
invalshoek kiezen dan die van de onderzoeker. Dit houdt de discussie scherp 
en kan leiden tot verrassende resultaten.
Prof. dr. A.A. Lammertsma, beste Adriaan, zo veel kennis wat betreft 
kwantitatieve PET-studies om de kinetiek van tracers in de mens te bestuderen! 
Meer dan 500 wetenschappelijke artikelen dragen jouw naam als (co)auteur 
in de loop der jaren, maar toch was ook jij verbaasd over het gedrag van de 
tracer [11C]sorafenib. Jouw expertise, waarbij steeds nieuwe fysische analyses 
werden bedacht om deze tracer beter te kunnen doorgronden, zijn van groot 
belang geweest.
Prof. dr. E. Boven, beste Epie, bij jou is mijn eerste onderzoek ooit begonnen, 
een wetenschappelijke stage tijdens de studie geneeskunde. Een grande dame 
binnen de oncologie, direct, nauwgezet en gedreven. Je hebt de oncologie 
zien ontwikkelen en hier ook een belangrijke bijdrage aan geleverd (“al in 1985 
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publiceerden Tore Lindmo en ik een eerste artikel over het berekenen van de 
immunofractie na labelen van een monoclonaal antilichaam”), dank voor jouw 
interesse in dit onderzoek ook na het pensioen.
Dr. C.W. Menke-van der Houven van Oordt, beste Willemien, toen wij begonnen 
met dit onderzoek was PET imaging voor ons beiden nog relatief nieuwe materie. 
Je bijtte je erin vast en wist van de verschillende afdelingen en centra de juiste 
mensen samen te brengen. Daarbij wilde je van ieder dat de onderste steen 
boven kwam. Dat leidde bijvoorbeeld tot een uitgebreide lijst aan vragen in de 
kanttekening van mijn manuscripten. Dit alles heeft zijn vruchten afgeworpen, 
want inmiddels is er een lijst met mooie imaging publicaties tot stand gekomen 
binnen de afdeling medische oncologie en interessante vervolgonderzoeken 
door nieuwe promovendi zijn gaande. Ik herinner me nog jouw verjaardag tijdens 
ons laatste congres in Wenen, waarbij wij je als verrassing meenamen naar de 
staatsopera. Ondanks dat we maar een deel van het podium konden zien klonk 
“una furtiva lagrima” prachtig, een toepasselijke afsluiting van de SOPRANO 
studie. Veel dank!
Leden van de leescommissie, Prof. dr. J.M. Zijlstra-Baalbergen, Prof. dr. R.J. 
Bennink, Prof. dr. G.S. Sonke, Dr. W. Vogel, Dr. N. van Erp, Dr. I. Bahce, Dr. S. 
Oosting, Dr. N. Bijker, veel dank voor de aandacht waarmee u dit proefschrift 
heeft bestudeerd en de tijd die u genomen heeft voor het voeren van de 
oppositie.
Verder was dit proefschrift niet mogelijk geweest zonder de volgende personen.
Dr. M. Yaqub, beste Maqsood, jouw rol bij dit proefschrift was essentieel. Als 
de dynamische PET-onderzoeken gedaan zijn, begint het echte analytische 
werk namelijk pas. Achter de computer VOI’s tekenen en dan ‘modellen’, ‘fitten’ 
en kijken naar de uitkomsten zoals VT en delta K1. Een taal apart om klinisch 
relevante data te krijgen, veel dank ook voor jouw rol als tolk hierbij.
Prof. dr. O.S. Hoekstra, beste Otto, als nucleair geneeskundige met veel 
onderzoekservaring was jouw bijdrage van grote waarde. Een nuchtere blik, 
altijd pragmatisch en je voorziet ons in supersnelle mails van nuttige respons. 
Dank dat je me de PET-scans leerde beoordelen, hier heb ik in de dagelijkse 
praktijk nog heel veel profijt van.
Prof. dr. G.J. Peters, beste Frits, wij werkten al samen tijdens mijn allereerste 
fase-1-onderzoek bij de afdeling medische oncologie als geneeskundestudent. 
Nu dus ook een fijne samenwerking bij dit proefschrift, dank voor al het 




Dr. R. Honeywell en Dr. R. Schuit, beste Richard en Robert, beide de mannen 
van de sorafenib metingen in bloed, de ene van de ‘koude’ en de andere van de 
‘hete’ variant. De kleinste hoeveelheden werden door jullie zorgvuldig gemeten 
en het was daarom ook een lastige kwestie dat koud zich niet door heet liet 
voorspellen. Dank voor jullie input om dit beter te kunnen begrijpen.
Dr. A. Zandvliet, beste Anthe, dank voor jouw farmacologische bijdrage, je bent 
creatief en strategisch, precies wat nodig is om het maximale uit een studie te 
kunnen halen.
Oncologisch onderzoekers: Liesbeth, Suzanne, Maria, Madelon, Dennis, Robin, 
Elske, Esther, Joeri, Hanneke, Lisanne, Henk, Richard, Tineke, Mariette en 
Kathelijn, veel dank voor de fijne sfeer, interessante voordrachten en mooie 
discussies die zeer waardevol waren voor de voortgang van de onderzoeken.
Imagers uit het UMC Groningen, veel dank voor de fijne samenwerking tijdens 
het onderzoek met [18F]FES en [18F]FDHT PET. Dergelijke samenwerkingen zijn 
van groot belang om sneller vooruitgang te kunnen boeken binnen de oncologie.
Researchverpleegkundigen van de afdeling Medische Oncologie, Medisch 
Nucleair Werkers en verpleegkundigen van afdeling 4A, veel dank voor al jullie 
hulp bij het uitvoeren van deze onderzoeken, jullie altijd lieve bejegening en 
verzorging van de deelnemende patiënten en jullie interesse naar de resultaten.
Collega’s uit het VU medisch centrum, Antoni van Leeuwenhoek, College ter 
Beoordeling van Geneesmiddelen en Reinier de Graaf Gasthuis, veel dank voor 
jullie interesse in dit proefschrift. Addy, Annelie, Arjan en Marlies, wat heb ik 
het getroffen met jullie als collega-oncologen in het Reinier de Graaf Gasthuis!
Behalve de opgedane kennis, houd ik ook een aantal vrienden over aan dit 
proefschrift. Lieve Ludo’s (deze vreemde naam is te danken aan een concert 
van Ludovico Einaudi). Totaal 7 onderzoekers die op de te kleine kamer van 
3A17 al snel vriendschap sloten. Compleet verschillende karakters, met ieder 
zo zijn/haar eigen kracht (en eigenaardigheden) en bovenal doorzetters die 
hun einddoel weten te bereiken en tussendoor het gemoed hooghouden met 
veel humor. Dinja Kruger, powervrouw, direct, niet bang voor confrontaties, 
maar ook beschermend en dat gaat veel verder dan de toegewijde zorg voor 
de kamerplanten op kantoor. Sophie Gerritse, ongelooflijk sociaal, gedreven en 
nooit een tekort aan gesprekstof, wat een verdienste is, want met je vrolijke 
verhalen tover je een lach op de gezichten van al je toehoorders. Claudia 
Schuurhuizen: heeft flair, is ‘too blessed to ever be stressed’, en kan daarbij 
heel veel ballen tegelijk hooghouden in de lucht. Anne van der Werf, achter deze 
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vegetarische hipster schuilt een ware bèta-vrouw met een indrukwekkende 
wiskundeknobbel die met precisie werkt volgens planning. En dan de heren, mijn 
twee paranimfen en inmiddels beiden experts op het gebied van imaging binnen 
de oncologie. Erik van Helden, onze onderzoekprojecten liepen vrijwel parallel, 
en dat was een feest. We konden veel kennis uitwisselen, droomden over de 
resultaten, raakten dan weer ontnuchterd, en dan weer vierden we kleine 
overwinningen, want zo gaat dat met translationeel oncologisch onderzoek. 
Jouw positiviteit, humor, spontaniteit en verantwoordelijkheidsgevoel werken 
ontwapenend bij patiënten en collega’s. Cyrillo Brahm, je hebt evenzoveel humor 
en verantwoordelijkheidsgevoel en weet inmiddels heel veel over muizen. Je 
weet overigens ook heel veel over mensen en kunt hen feilloos aanvoelen, 
waarbij je hen probeert te geven wat ze nodig hebben. Patiënten en de mensen 
direct om je heen hebben het daarom ook altijd goed bij jou en dat alles doe je 
op je eigen bruisende wijze. Ik ben blij dat jullie mijn paranimfen zijn!
Lieve vrienden en families Bokelman, Droog, van Hattum, Huys, Kitzen, 
Mammatas, Rietveld en Semotok, veel dank voor jullie steun en interesse in 
dit proefschrift! Ευχαριστώ πολύ για την υποστήριξη και το ενδιαφέρον σας 
σε αυτή τη διατριβή! Ondanks dat sommigen van ons in verschillende landen 
verblijven, voelt het altijd dichtbij.
Liefste mama en Hans, jullie hebben er altijd alles aan gedaan zodat ik het 
goed zou hebben in het leven. Rekening houden met elkaar en met plezier hard 
werken waren vanzelfsprekend binnen onze familie. Lieve mama, jij werkte > 25 
jaar als verpleegkundige op de intensive care in het Antoni van Leeuwenhoek. 
Je bent uiterst zorgzaam, intelligent en we genieten groots van de kleine, mooie 
dingen in het leven tijdens het drinken van een kopje thee. Mijn vader kan dit 
proefschrift niet meer meemaken, maar had anders trots ‘το νέο μου κοστούμι’ 
aangetrokken. Hij genoot van de natuur, van het eiland Ikaria en de zee waarover 
hij als kapitein grote schepen van continent naar continent voer. Door mijn 
vaders verblijf in het buitenland en mijn moeders werk was het daarom fijn om 
altijd ondersteuning te hebben van mijn oma, opa en oom Hans. Zij werkten 
hard in familiebedrijf ‘Het Tapijthuis Droog’, mijn opa en oma zelfs tot na hun 80e 
levensjaar. In de weekenden ging ik vaak mee en studeerde bij opa op kantoor. 
Zij stimuleerden mij altijd liefdevol, vele mooie boeken en mijn eerste torso van 
het menselijk lichaam heb ik van hen gekregen. Hans, je bent mijn oom, ouder 
en maatje. Staat altijd voor mij klaar, zo creatief, eerlijk, beschermend en jij geeft 
mijn leven een betoverende glans. Ik houd zo veel van jullie!
Liefste Marco, jij hebt mij gevonden en daar ben ik iedere dag weer dankbaar 
voor. Vanaf de eerste dag dat ik je leerde kennen was ik onder de indruk van 




nonchalante lokken die vaak de oortjes gevuld met muziek of actualiteiten 
verstoppen brengen een lach op mijn gezicht. Ik ben zeer gelukkig dat ik aan 
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